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This	 study	 was	 conceived	 by	 all	 of	 the	 authors.	 My	 contribution	 involved	 the	 data	
collection	 and	 analysis	 of	 synapses	 by	 array	 tomography	 (Figures	 5	 and	 6).	 I	 also	
contributed	to	Figure	3	by	 increasing	the	n	for	the	neurite	curvature	experiments	and	
performed	 the	 western	 blots	 for	 Figure	 4.	 All	 other	 data	 was	 collected	 by	 the	 co-
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Alzheimer’s	 disease	 (AD)	 is	 characterized	 by	 the	 presence	 of	 aggregates	 of	
amyloid	beta	(Aβ)	in	senile	plaques	and	tau	in	neurofibrillary	tangles,	as	well	as	marked	
neuron	and	synapse	 loss.	Of	 these	pathological	changes,	synapse	 loss	correlates	most	
strongly	 with	 cognitive	 decline.	 Understanding	 the	 contributions	 of	 different	 risk	






APP/PS1	 mice	 were	 crossed	 with	 mice	 expressing	 full	 length	 wild	 type	 human	 tau	
(hTau).	 Expression	 of	 hTau	 in	 APP/PS1	 mice	 increased	 plaque	 size	 by~50%	 and	
increased	 plaque-associated	 dystrophic	 neurites.	 However,	 no	 increase	 in	 neurite	
curvature,	 neuron	 loss,	 or	 synapse	 loss	 was	 observed	 in	 the	 hTau	 APP/PS1	 animals	
compared	with	APP/PS1	alone.		
	
The	underlying	 cause	of	most	 cases	of	AD	 is	not	 known,	however	genetic	 risk	
factors	have	been	 identified,	 the	 strongest	of	which	 is	 the	APOE	e4	allele.	APOE	e4	 is	
associated	with	increased	risk	of	developing	AD	and	increased	rates	of	cognitive	decline	
compared	 to	 the	more	common	APOE	e3	allele.	The	 second	aim	of	 this	 thesis	was	 to	
detect	 differences	 in	 the	 AD	 synaptic	 proteome	 compared	 with	 controls	 and	 to	 also	
investigate	 the	effect	of	 an	APOE	e4	allele	on	 those	 changes.	Unbiased	 label	 free	 LC-
MS/MS	 based	 proteomics	 of	 synapses	 isolated	 from	 human	 AD	 and	 control	 post-
mortem	brains	of	known	APOE	genotypes	was	used.	Of	the	1043	proteins	detected	in	
20	 synaptic	 preparations	 17%	 (173)	 were	 found	 to	 differ	 significantly	 (p<0.05,	 fold	
change	>1.2)	in	AD	compared	with	control.	A	significant	sub-set	of	these	proteins	were	
affected	by	APOE	e4	 allele	 genotype.	One	of	 these	was	Clusterin	which	was	not	 only	
increased	 in	 the	 AD	 synapse	 but	 further	 increased	 in	 cases	 with	 an	 APOE	 e4	 allele.	





Aim	 three	 was	 to	 further	 investigate	 the	 involvement	 of	 Clusterin	 at	 the	
synapse	 and	 the	 interaction	 of	 ApoE	 with	 Clusterin	 using	 array	 tomography.	 Array	
tomography	 confirmed	 an	 increase	 in	 Clusterin	 co-localization	 with	 presynapses	 and	
postsynapses	in	AD	cases	compared	with	controls	and	found	a	further	increase	in	cases	
with	an	APOE	e4	allele.	Array	tomography	also	found	an	increase	in	synapses	which	co-




develop	 a	 novel	 human	 based	model	 of	 Aβ	mediated	 synapse	 loss.	 This	 model	 uses	
cortical	neurons	derived	from	induced	pluripotent	stem	cells	from	a	control	 individual	
that	are	challenged	with	Aβ	extracted	from	brains	from	AD	and	control	individuals.	This	
model	 shows	 a	 significant	 and	 concentration	 dependent	 reduction	 in	 the	 number	 of	
synapses	 in	 response	 Aβ	 from	AD	 brain	 but	 not	 to	 control	 brain	 extract	 or	 AD	 brain	
extract	immunodepleted	of	Aβ.	
	
The	work	presented	 in	 this	 thesis	has	 investigated	 two	novel	models	of	AD	 to	
assess	the	effect	of	known	toxic	proteins	in	AD	related	synapse	degeneration.	This	work	
also	shows	that	profound	protein	changes	occur	at	the	synapse	in	AD	and	that	many	of	
these	 are	 affected	 by	 APOE	 genotype.	 Many	 of	 these	 changes	 potentially	 cause	 or	






Alzheimer’s	 Disease	 (AD)	 is	 a	 neurodegenerative	 disease	 that	 is	 the	 most	
common	cause	of	dementia	in	older	people.	It	is	currently	one	of	the	leading	causes	of	
death	in	the	UK	and	current	treatments	only	cause	small	 improvement	in	some	of	the	
symptoms	of	disease	but	do	not	prevent	 the	progression	of	dementia.	Central	 to	 the	
loss	 of	 cognitive	 function	 in	 AD	 are	 the	 loss	 of	 synapses,	 the	 connections	 between	
neurons,	which	are	known	to	be	crucial	for	the	making,	losing,	and	keeping	of	memory.	








To	 further	 understand	 what	 effect	 these	 toxic	 proteins	 were	 having	 at	 the	
synapse,	 I	used	the	powerful	 technique	of	proteomics.	This	allowed	me	to	 investigate	
the	effects	 of	AD	on	 the	entire	protein	 contents	of	 synapses	 from	brains	donated	by	
individuals	 with	 and	 without	 AD.	 I	 found	 that	 many	 proteins	 in	 the	 synapse	 were	





The	greatest	genetic	 risk	 factor	 for	AD,	APOE	e4,	 increases	the	risk	of	AD	by	3	
times	 if	 inherited	 from	one	parent	and	12	 times	 if	 inherited	 from	both.	 The	effect	of	
APOE	e4	at	synapses	in	AD	is	not	yet	fully	understood.	Here	I	have	shown	that	APOE	e4	
affects	many	of	the	protein	changes	that	AD	has	on	the	synapse.	I	 investigated	one	of	
these,	Clusterin,	by	high	resolution	microscopy	and	found	that	 it	was	 increased	 in	the	
synapse	 of	 AD	 cases	 and	 was	 frequently	 found	 in	 the	 same	 synapses	 as	 Ab.	 This	
indicates	 that	 it	 plays	 a	 role	 in	 the	 effects	 of	 Ab	 on	 the	 synapse.	 However,	 it	 is	 still	
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5.3.4	 ApoE4	 is	associated	with	an	 increased	co-localization	of	Clusterin	with	presynapse	
and	postsynapse	in	AD	 150	
















































Figure	 4.13:	 Significant	 changes	 in	 the	NDC	 APOE4	 proteome	when	 compared	 to	 the	NDC	APOE3	
proteome.	 125	
Figure	 4.14:	 Changes	 in	 Cell	Morphology	Network	 in	 the	 AD	APOE4	 synapse	 compared	 to	 the	 AD	
APOE3	synapse.	 126	
Figure	 4.15:	 Significant	 changes	 in	 the	 AD	 APOE4	 proteome	 when	 compared	 to	 the	 AD	 APOE3	
proteome.	 127	

















































































































































































































































Dementia	 describes	 a	 state	 of	 progressive	 cognitive	 decline,	 which	 often	
manifests	 itself	 as	 memory	 loss,	 difficulty	 concentrating,	 and	 problems	 with	
visuospatial	 skills,	 among	 other	 signs	 and	 symptoms.	 Alzheimer’s	 disease	 (AD)	 is	
currently	 the	most	 common	 cause	 of	 dementia	which	 affects	 an	 estimated	 850,000	
people	 in	 the	 UK	 alone	 (Prince	 et	 al.,	 2015;	 Dementia	 Statistics	 Hub,	 2017)	 (Figure	
1.1A).	The	greatest	 risk	 factor	 for	AD	 is	age,	with	 the	 risk	of	developing	AD	doubling	
every	5	years	after	an	individual	turns	65.	This	is	especially	worrying	as	the	average	life	
expectancy	 of	 both	 the	 UK	 and	 the	 world	 is	 rising	 and	 it	 is	 predicted	 that	 if	 the	
incidence	of	AD	continues	to	rise	at	its	current	rate	the	number	of	affected	individuals	
in	 the	 UK	 will	 increase	 to	 1	 million	 by	 2025	 (Alzheimer’s	 Association	 2014)	 (Figure	
1.1C).	 	This	 is	compounded	by	the	fact	 that	there	are	currently	no	disease	modifying	
treatments	for	AD,	making	AD	the	only	condition	in	the	top	10	causes	of	death	in	the	
UK	 without	 a	 treatment	 to	 slow	 or	 prevent	 progression	 (Dementia	 Statistics	 Hub,	
2017).	The	current	financial	burden	of	dementia	in	the	UK	is	£26.3	billion	with	almost	
half	 of	 this	 cost	 provided	 by	 family	 and	 friends	 who	 also	 shoulder	 an	 enormous	
responsibility	 of	 care	 and	 the	 stress	 that	 goes	 along	 with	 it.	 Unfortunately,	 these	
numbers	 are	 only	 expected	 to	 increase,	 however	 treatment	 which	 could	 delay	 the	






















how	 these	 silver	 stained	 deposits	 appeared	 to	 correlate	 with	 neuron	 death.	 He	
commented	that	cells	with	only	one	or	two	fibrils	appeared	normal	but	cells	with	large	
“tangles”	 appeared	 to	 be	 dead	 or	 dying	 (Alzheimer	 et	 al.,	 1907).	 It	 is	 now	 well	
established	 that	NFTs	and	Aβ	plaques	appear	not	only	 in	 individuals	with	Alzheimer’s	
disease	but	also	 in	 the	brains	of	most	cognitively	normal	elderly	people,	however	 the	
degree	to	which	they	occur	is	often	much	less	(Spires-Jones	et	al.,	2017).			
	
The	brains	of	AD	patients	 also	 show	brain	atrophy	particularly	 in	 the	 cerebral	
cortex	and	the	hippocampus	due	to	neuron	 loss	that	 is,	 in	part,	associated	with	these	
misfolded	 proteins	 (Alzheimer	 et	 al.,	 1907;	 Perl,	 2010).	 More	 recently	 it	 has	 been	
shown	 that	 synapses	 are	 heavily	 affected	 in	 Alzheimer’s	 disease	 with	 some	 cases	
showing	a	loss	of	45%	of	synaptic	elements.	This	is	of	great	importance	as	it	is	the	loss	
of	synapses	that	provides	the	strongest	pathological	correlate	to	cognitive	ability,	with	
plaques	 exhibiting	 only	 a	 weak	 correlation	 and	 tangles	 and	 neuron	 loss	 a	 stronger	
correlation	(Masliah	et	al.,	1989;	Terry	et	al.,	1991).	Although	Alzheimer’s	disease	was	
first	described	110	years	 ago	 the	 complexity	of	both	 the	disease	and	 the	brain	mean	








the	 amyloid	 precursor	 protein	 (APP)	 is	 cleaved	 first	 by	 β-secretase	 and	 then	 by	 γ-
secretase	to	generate	an	internal	fragment	(APP	intracellular	domain)	and	a	small	~39-
43	amino	acid	long	molecule	(Ab),	which	oligomerizes	and	eventually	forms	aggregates	
of	 β-pleated	 sheets	 (Sun	 et	 al.,	 2015)	 (Figure	 1.2).	 Although	 all	 isoforms	 of	 Ab	 are	





due	 to	 its	 slightly	 longer	 hydrophobic	 carboxyl	 terminus	 (Burdick	 et	 al.,	 1992).	 It	 is	
predominantly	 Aβ42	 that	 accumulates	 into	 plaques	 in	 the	AD	brain	 and	 it	 is	 thought	
that	 other	 isoforms	 of	 Aβ	 including	 Aβ40	 may	 even	 be	 protective	 against	 AD	 by	
preventing	the	accumulation	of	Aβ42	(Kim	et	al.,	2007).	APP	can	also	be	cleaved	by	α-
secretase	which	 cleaves	 the	APP	molecule	 in	 the	middle	of	 the	Aβ	domain	and	 thus	
produces	non-amyloidogenic	fragments	(Gandy	et	al.,	1994).		Evidence	suggests	that	in	
development,	 APP	 plays	 an	 important	 role	 in	 neurite	 outgrowth	 and	 synapse	
formation	 and	 later	 in	 life	 it	 regulates	 synaptic	 function	 by	 regulating	 synaptic	
structure	 and	 acting	 as	 a	 cell	 adhesion	 molecule	 (Soldano	 and	 Hassan,	 2014;	
Montagna	et	al.,	2017)		
	
Aβ	 has	 been	 well	 studied	 throughout	 the	 history	 of	 Alzheimer’s	 research	 in	
particular	 due	 to	 its	 genetic	 link	 with	 the	 disease	 and	 its	 proposed	 place	 as	 the	
initiating	 factor	 of	 AD.	 Although	 mutations	 in	 both	 tau	 and	 Aβ	 are	 associated	 with	
dementia,	 tau	 related	 mutations	 have	 been	 found	 to	 cause	 rare	 familial	 forms	 of	
Frontotemporal	Dementia	(FTD),	while	Aβ	related	mutations	have	been	found	to	cause	
very	rare	forms	of	familial	AD	(fAD)	(Goedert	and	Jakes,	2005;	Sun	et	al.,	2015).	Most	
AD	 cases	 are	 sporadic	 (sAD),	 in	 that	 they	 occur	 in	 the	 absence	 of	 disease	 causing	
genetic	mutations,	 yet	 the	 rare	 genetic	 forms	 have	 the	 same	 signature	 plaques	 and	
tangles.	The	age	of	onset	of	fAD	is	often	less	than	60	years	of	age	placing	most	familial	
cases	 of	 AD	 in	 the	 bracket	 of	 Early	Onset	Alzheimer’s	Disease	 (EOAD).	 EOAD	 is	 very	








Figure	 1.2:	 Amyloid	 processing	 and	 the	 amyloid	 cascade	 hypothesis.	 APP	 is	 cleaved	 by	 β-
secretase	 and	!-secretase	 to	 form	 sAPPβ,	 Aβ,	 and	 an	APP	 intracellular	 domain	 (AICD).	 In	 the	
healthy	brain	Aβ40	 is	 the	most	 commonly	produced	 form	of	Aβ	but	Aβ42	 is	 also	produced.	Aβ	
aggregates	 into	oligomers	with	Aβ42	more	 likely	 to	 aggregate	 than	Aβ40.	 The	 amyloid	 cascade	
hypothesis	 is	 that	 these	 oligomers	 form	 fibrils	 and	 then	 plaques	 which	 cause	 the	 other	







Aβ	 related	 mutations	 almost	 all	 either	 increase	 the	 ratio	 of	 Aβ42:Aβ40	 or	 the	
total	 amount	 of	 Aβ	 present	 in	 the	 brain	 but	 they	 are	 found	 in	 number	 of	 different	
genes	 and	 thus	 affect	 the	 production	 of	 Aβ	 in	 different	 ways.	 Many	 of	 the	 fAD	
mutations	found	in	APP	promote	the	generation	of	Aβ	by	favouring	proteolysis	by	β	or	
γ	 secretases	 however	 there	 are	 also	 mutations	 internal	 to	 the	 Aβ	 sequence	 which	
increase	 the	propensity	of	Aβ	 to	aggregate	 (Tanzi,	 2012).	 Trisomy	21,	also	known	as	




cognitive	 decline	 even	 in	 the	 absence	 of	 AD	 (Jonsson	 et	 al.,	 2012).	 There	 are	 also	
mutations	 that	 have	 been	 found	 in	 the	 presenilin	 proteins	 1	 and	 2	 (PS1,	 PS2).	 The	
presenilin	proteins	act	as	the	catalytic	component	of	γ-secretase,	and	mutations	in	the	
presenilins	 increase	 the	 production	 of	 Aβ42	 (Bertram	 and	 Tanzi,	 2008).	 As	 fAD	




However,	 in	 recent	 years	 the	 evidence	 for	 the	 amyloid	 cascade	 hypothesis	 has	
been	 questioned.	 Despite	 senile	 or	 neuritic	 plaques	 being	 one	 of	 the	 most	
characteristic	 hallmarks	 of	 Alzheimers	 Disease,	 the	 number	 of	 plaques	 correlates	
poorly	with	the	speed	and	severity	of	cognitive	decline	(Giannakopoulos	et	al.,	2003).	
Indeed	a	growing	cohort	of	 individuals	with	a	 large	number	of	plaque	deposits	post-
mortem	 but	 no	 cognitive	 deficit	 in	 life	 are	 evidence	 against	 the	 amyloid	 cascade	
hypothesis	 (Perez-Nievas	 et	 al.,	 2013).	 	 The	 failure	 of	 a	 number	 of	 high	 cost,	 high	
profile	 drug	 trials	 which	 targeted	 and	 reduced	 Aβ	 and	 Aβ	 plaque	 deposition	 in	 the	
brain	have	similarly	called	into	question	the	validity	of	the	amyloid	cascade	hypothesis	
(Small	and	Duff,	2008).	These	 trials	also	call	 into	question	 the	usefulness	of	many	of	
the	current	AD	animal	models	 in	which	these	drugs	worked	very	well.	Proponents	of	
the	 amyloid	 hypothesis	 will	 pertinently	 point	 out	 that	 it	 is	 possible	 that	 these	
therapeutics	 were	 administered	 too	 late	 in	 the	 course	 of	 the	 disease	 to	 have	 any	
therapeutic	 benefit	 or	 did	 not	 effectively	 engage	 their	 intended	 targets	 at	 the	
7	
	
concentrations	 administered,	 and	 clinical	 trials	 are	 currently	 underway	 to	 assess	 the	
validity	 of	 this	 statement	 (Karran	 et	 al.,	 2011).	 It	 is	 also	 worth	 noting	 that,	 more	
recently	 it	 has	 been	 postulated	 that	 the	main	 target	 of	 therapeutics	 should	 be	 the	




It	 is	 obvious	 however	 that	 AD	 is	 more	 complicated	 than	 the	 amyloid	 cascade	
hypothesis	can	effectively	display.	That	despite	over	20	years	of	Aβ	directed	research	
no	 effective	 therapeutics	 have	 been	 found	 is	 evidence	 that	 researchers	 are	 only	
beginning	 to	 understand	 certain	 elements	 of	 this	 heterogeneous	 and	 multifaceted	







as	dementia	 causing	mutations	 in	 tau	cause	FTD,	although	genetic	 risk	 factors	 for	AD	
have	been	found	in	tau	(Coppola	et	al.,	2012;	Pastor	et	al.,	2015).	However,	NFTs	made	




neuron	 loss.	Much	 like	with	Aβ,	 there	 is	now	a	growing	base	of	evidence	 that	argues	
that	it	is	the	soluble	oligomeric	forms	of	tau	that	are	toxic	to	the	neurons	and	synapses	
rather	 than	NFTs	 themselves	 (Kopeikina	et	al.,	2012).	 It	 is	proposed	by	some	that	 the	
phosphorylation	and	aggregation	of	tau	is	downstream	of	Aβ	aggregation	while	others	







Tau	 pathology	 and	 the	 deposition	 of	NFTs	 follows	 a	 very	 defined	 path	 through	
the	brain.	In	1991	Braak	and	Braak	described	the	extent	of	tangle	deposition	using	six	
stages	 which	 define	 the	 extent	 and	 location	 of	 NFTs	 (Braak	 and	 Braak,	 1991).	 The	
early	stages	describe	a	brain	with	some	tangles	found	in	the	transentorhinal	(stage	I)	
and	 entorhinal	 cortex	 (EC)	 (stage	 II).	Most	 individuals	 to	 reach	 50	 years	 of	 age	will	
have	 some	 tangles	 in	 these	 two	 areas	making	most	 elderly	 people	 at	 least	 stage	 I.	
Stages	 III	 and	 IV	 see	 tangle	 deposition	 in	 limbic	 areas	 of	 the	 brain	 including	 the	
hippocampus	as	well	as	an	increase	in	the	deposition	of	tangles	in	the	transentorhinal	
and	entorhinal	cortex.	Often	times	individuals	with	a	Braak	stage	III	or	IV	will	present	
with	Mild	 Cognitive	 Impairment	 (MCI)	 or	 even	mild	AD	 in	 life.	 	 Stages	V	 and	VI	 are	
considered,	neuropathologically,	to	be	full	AD	when	Ab	plaques	are	also	present.	They	




In	 the	 1960s	 it	 was	 discovered	 that	 the	 NFTs	 discovered	 by	 Alzheimer	 in	 1907	
were	 made	 up	 of	 abnormal	 filaments	 termed	 paired	 helical	 filaments	 and	 straight	

























assembly	 and	 function	 in	 the	1970s	 (Weingarten	et	 al.,	 1975).	 Investigations	 into	 the	
sequence	and	structure	of	Tau	lead	to	the	discovery	of	6	isoforms	of	the	protein	which	





In	 combination	 with	 3R	 and	 4R	 a	 tau	 molecule	 has	 2,	 1	 or	 0	 N-terminal	 inserts	
generating	 the	6	different	 isoforms	of	 tau	 (Ballatore	et	al.,	2007)	 (Figure	1.3A).	Tau	 is	
most	prominently	expressed	during	foetal	development	when	predominantly	3R	tau	is	
expressed	however	the	adult	brain	expresses	all	six	isoforms	of	tau	with	the	ratio	of	3R	




In	 the	healthy	brain	Tau	 is	expressed	most	abundantly	 in	 the	axons	of	 central	
nervous	 system	 where	 it	 helps	 to	 bind	 and	 stabilize	 the	 microtubules.	 Tau	 is	 not	
required	 for	 microtubule	 development	 or	 function	 and	 tau	 knockout	 mice	 develop	
normally	with	no	neurodegeneration,	although	these	mice	do	show	slight	muscle	and	
balance	weakness	at	advanced	ages	(Ke	et	al.,	2012).	However,	these	mice	also	show	an	
increased	 expression	 of	 other	microtubule	 associated	 proteins	 indicating	 that	 several	
proteins	play	a	role	in	microtubule	development	and	stabilization	and	that	these	other	
microtubule	 associated	 proteins	 can	 compensate	 for	 the	 loss	 of	 tau.	 Tau	 has	 several	









of	 phosphate	 bound	 to	 tau.	 	 The	 largest	 isoform	 of	 tau	 (4R/2N)	 has	 85	 potential	
phosphorylation	sites	over	40	of	which	are	phosphorylated	in	AD	(Figure	1.3B)	(Iqbal	et	
al.,	 2016;	 Šimić	et	 al.,	 2016).	 The	main	 sites	 of	 phosphorylation	 on	 tau	 are	 serine	 or	
threonine	 residues	 followed	 by	 a	 proline.	 Proline-directed	 protein	 kinases	 such	 as	




Not	 only	 does	 this	 hyperphosphorylation	 cause	 tau	 to	 dissociate	 from	microtubules,	
potentially	 interrupting	axonal	 transport,	 but	 it	 also	 increases	 the	pool	of	 soluble	 tau	
free	 in	 the	 cytosol	 to	misfold	 and	aggregate	 into	 tangles	 (Ballatore	et	 al.,	 2007).	 This	
likely	 causes	 a	 toxic	 gain	 of	 function	 as	 soluble	 tau	 misfolds,	 mislocalizes,	 and	








































Alzheimer	also	noted	 in	1907	 that	 the	glial	 cells	of	his	patient	appeared	 to	differ	







cells	 become	 activated,	 has	 been	 suggested	 to	 have	 a	 causal	 role	 in	 the	 synaptic	
degeneration	associated	with	AD	(Heneka	et	al.,	2015).		
	




also	 support	 tissue	 maintenance	 by	 secreting	 neurotrophic	 factors	 (Heneka	 et	 al.,	





by	 phagocytosis	 (Tarasoff-Conway	 et	 al.,	 2015).	 Microglia	 use	 multiple	 cell-surface	
receptors	 to	bind	 to	Aβ	and	after	binding,	become	activated;	 this	 is	 thought	 to	begin	
the	inflammatory	process	that	occurs	in	AD.	Activated	microglia	are	particularly	found	
around	 Ab	 plaques	 however	 once	 Ab	 is	 aggregated	 into	 plaques	 it	 is	 unable	 to	
enzymatically	destroyed.	This	leads	to	aberrant	activation	of	microglia	and	an	increase	
in	 pro-inflammatory	 pathways	which	 cause	 other	microglia	 and	 glial	 cells	 to	 become	
activated	 (Malm	 et	 al.,	 2015).	 This	 continuous	 activation	 of	 microglia	 in	 AD	 can	 be	
neurotoxic	having	negative	effects	both	on	neurons	and	synapses.	In	this	way	microglia	
are	 not	 only	 failing	 to	 clear	 the	 amyloid	 load	 but	 also	 producing	 neuroinflammatory	
molecules	which	 themselves	can	be	harmful	 to	 the	surrounding	 tissue	 (Guillot-Sestier	
and	Town,	2013).	
	
Another	 major	 glial	 cell	 type	 that	 plays	 a	 role	 in	 AD	 pathogenesis	 are	 the	
astrocytes.	 Astrocytes	 play	 an	 important	 role	 in	 the	 homeostatic	 control	 of	 the	 brain	




the	 blood	 brain	 barrier	 (Osborn	 et	 al.,	 2016).	 Astrocytes	 also	 play	 a	 major	 role	 in	
clearing	 soluble	 Aβ	 which	 is	 mediated	 through	 Apolipoprotein	 E	 (ApoE)	 one	 of	 the	














exquisitely	 intricate	 and	 complex	 arrangements	 to	 make	 us	 the	 people	 we	 are;	
responsible	for	our	thought,	senses,	movement,	emotion,	and	memories.	To	allow	the	
human	 brain	 and	 body	 to	 perform	 these	 many	 complex	 and	 incredibly	 varied	 tasks	
neurons	need	to	be	able	to	coordinate	with	other	cells,	most	especially	other	neurons.		
This	communication	occurs	at	synapses,	the	specialized	connections	that	allow	neurons	
to	 exchange	 information	 in	 a	 way	 that	 is	 rapid,	 controlled,	 and	 highly	 plastic.	 The	
plasticity	 of	 synapses,	 their	 ability	 to	 grow	 stronger	 when	 frequently	 used	 or	 grow	
weaker	when	unnecessary	was	proposed	over	100	years	ago	by	the	pioneer	of	modern	
neuroscience	 Ramon	 Y	 Cajal	 (Cajal,	 1894).	 	 Even	 before	 physical	 evidence	 supporting	
the	existence	of	synapses	was	available	Ramon	Y	Cajal	proposed	that	the	connections	
between	neurons	and	 the	strength	of	 those	connections	could	be	 the	mechanism	 for	
memory	 formation,	 rather	 than	an	 increase	 in	 the	number	of	neurons.	Over	50	years	
later	Hebb	built	on	this	knowledge	by	suggesting	that	neurons	which	fired	at	the	same	
time	 were	 more	 likely	 to	 become	 more	 strongly	 connected	 and	 in	 1973	 this	










Synapses	 are	 the	 critical	 connection	 point	 between	 neurons.	 Most	 of	 the	
synapses	 in	 the	 human	 brain	 are	 chemical	 synapses	meaning	 that	 a	 signal	 is	 passed	
from	 the	 presynaptic	 region	 of	 one	 neuron	 to	 the	 postsynaptic	 region	 of	 another	
through	 extracellular	 chemical	 messengers	 known	 as	 neurotransmitters,	 which	 are	








Chemical	 synapses	 can	be	 either	 inhibitory	 or	 excitatory	 and	 these	 inputs	 are	
summed	within	the	postsynaptic	cell	which	can	have	up	to	10,000	different	presynaptic	
inputs.	 The	 vast	majority	 of	 excitatory	 synapses	 in	 the	 CNS	 use	 the	 neurotransmitter	
glutamate,	 while	 g-aminobutyric	 acid	 (GABA)	 and	 glycine	 are	 the	 main	
neurotransmitters	 of	 inhibitory	 synapses	 in	 the	 CNS	 although	 there	 are	 other	




fire	 whereas	 neurotransmitter	 binding	 to	 inhibitory	 postsynaptic	 receptors		
hyperpolarize	 the	membrane	making	 a	 cell	 less	 likely	 to	 fire	 (Kandel	et	 al.,	 2012).	 As	
well	as	differences	in	neurotransmitters	inhibitory	and	excitatory	synapses	tend	to	have	
different	morphologies	with	excitatory	 synapses	having	 rounder	 synaptic	 vesicles	 and	
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large	 electron	 dense	 regions	 at	 the	 action	 zone	 and	 post	 synaptic	 density	 (PSD)	 and	
inhibitory	 synapses	 having	 oval	 like	 vesicles	 with	 less	 dense	 active	 zones	 and	 PSDs	
(Klemann	and	Roubos,	2011).	However,	morphology	does	not	correlate	perfectly	with	






At	 chemical	 synapses,	 neurotransmitters	 are	 packaged	 into	 vesicles	 that	 are	
released	 from	 specialised	 swellings	 of	 the	 axon	 called	 the	 presynaptic	 bouton	 or	
terminal.	 Thus,	many	 of	 the	 proteins	 in	 the	 presynaptic	 terminal	 are	 involved	 in	 the	
trafficking,	packaging,	release,	and	recycling	of	neurotransmitters.	Many	of	the	proteins	
that	 decorate	 synaptic	 vesicles	 aid	 in	 the	 function	 and	 control	 of	 vesicles	 in	
neurotransmitter	 release.	 For	 example:	 Synapsins,	 Vesicular	 glutamate	 transporter	
(VGLUT),	 and	 synaptophysin	 are	 all	 required	 for	 the	 functioning	 of	 glutamatergic	
synapses.	Antibodies	against	 these	proteins	are	often	used	experimentally	 to	 indicate	
the	 presence	 of	 excitatory	 presynaptic	 terminals.	 Synapsin	 proteins	 are	 involved	 in	
binding	a	pool	of	synaptic	vesicles	to	the	actin	cytoskeleton	and	making	them	available	
for	 release	 when	 required	 in	 a	 Ca2+	 dependent	 manner	 (Cesca	 et	 al.,	 2010).	 VGLUT	
transports	 glutamate	 from	 the	 cytoplasm	 into	 vesicles	 and	 these	 proteins	 in	 part	
regulate	 the	 amount	 of	 neurotransmitter	 present	 within	 each	 vesicle	 (Wilson	 et	 al.,	
2005).	Synaptophysin	is	not	only	involved	in	the	transport	of	synaptic	vesicle	precursors	
down	 the	 axon	 through	 its	 interaction	 with	 axon	 transport	 proteins	 but	 it	 is	 also	













are	 held	 in	 readiness	 at	 the	 active	 zone	 by	members	 of	 the	 Soluble	NSF	 Attachment	
Protein	 Receptor	 (SNARE)	 protein	 complex	 (Han	 et	 al.,	 2017).	 The	 SNARE	 protein	
complex	 is	made	 up	 of	 synaptobrevin	 (also	 called	 VAMP-1/-2)	which	 is	 bound	 to	 the	
vesicle	 membrane,	 and	 syntaxin	 and	 SNAP-25	 which	 are	 bound	 to	 the	 plasma	
membrane	 (Trimble	 et	 al.,	 1988;	 Oyler	 et	 al.,	 1989;	 Bennett	 et	 al.,	 1992).	 Synaptic	
vesicles	 and	 their	 cargo	 are	 	 released	 in	 a	 Ca2+	 dependent	 manner	 which	 is	 often	 a	
result	 of	 a	 propagating	 action	 potential	 reaching	 the	 presynaptic	 terminal,	 although	
spontaneous	 release	of	vesicles	does	also	occur	 (Südhof,	2012;	 Li	and	Kavalali,	2017).	
An	action	potential	traveling	down	the	axon	causes	voltage	gated	Ca2+	channels	within	
the	 presynapse	 to	 open	 triggering	 fusing	 of	 the	 vesicle	 and	 plasma	membranes	 and	
release	of	neurotransmitter	 into	the	synaptic	cleft	(Tokumaru	et	al.,	2001;	Basu	et	al.,	
2005;	Pang	et	al.,	2006;	Kümmel	et	al.,	2011;	Han	et	al.,	2017).		Ca2+	has	a	very	localized	
area	 of	 action	 as	 free	 Ca2+	 ions	 are	 rapidly	 buffered	 by	 a	 wide	 array	 of	 Ca2+	 binding	
proteins	 including	 calbindin,	 calcineurin	 and	 calmodulin.	 	 Ca2+	 is	 also	 removed	 by	 a	
Na+/Ca2+	 exchanger	 proteins,	 or	 pumped	 into	 the	 endoplasmic	 reticulum	 or	
mitochondria	 in	 an	ATP	 dependent	manner	 (Scott,	 2007).	 As	 such	 voltage	 gated	 Ca2+	





synaptotagmin	 family,	 particularly	 synaptotagmin	 1.	 Indeed	 deletion	 of	 this	 protein	
results	in	loss	of	fast	calcium	triggered	exocytosis	and	an	increase	in	asynchronous	and	
spontaneous	release	(Südhof,	2013).	Synaptotagmins	are	phospholipid	binding	proteins	
that	 bind	 to	 the	 SNARE	protein	 complex	 and	upon	binding	 to	Ca2+	 trigger	membrane	
fusion	 (Sudhof,	 2012;	Rizo	 and	Xu,	 2015).	 Complexin	 1,	 from	 the	 complexin	 family	 of	
proteins,	 also	 regulates	 the	 exocytosis	 of	 vesicles	 in	 response	 to	 Ca2+	 influx,	 likely	
through	 an	 interaction	 with	 synaptotagmin	 as	 complexin	 itself	 does	 not	 bind	 Ca2+.	













usage.	 Clathrin-independent	ultra	 fast	 endocytosis	 and	 kiss	 and	 run	endocytosis	 both	
take	 less	 than	 a	 second	 while	 clathrin	 mediated	 endocytosis	 and	 activity-dependent	




the	best	studied	although	 less	 is	known	about	endocytosis	than	exocytosis	 in	general.	
Like	 exocytosis,	 many	 of	 the	 regulatory	 elements	 of	 endocytosis	 act	 through	 Ca2+.	
Calcinuerin,	for	example,	is	a	calcium	dependent	phosphatase	that	affects	endocytosis	
by	 dephosphorylating	 dynamin	 which	 is	 responsible	 for	 pinching	 off	 new	 vesicles	
(Cousin	and	Robinson,	2001).	The	calpain	family	of	proteases	also	regulate	endocytosis	
in	a	calcium	dependent	manner	both	by	 interacting	directly	with	endocytic	machinery	
and	 also	 through	 GSK3β	 and	 calcineurin	 (Wang	 and	 Zhang,	 2017).	 These	 regulatory	






As	 well	 as	 the	 proteins	 directly	 involved	 in	 vesicle	 release	 a	 large	 number	 of	
proteins	go	 into	 supporting	vesicle	 release.	The	 large	 scaffolding	proteins	piccolo	and	




Mukherjee	 et	 al.,	 2010).	 RIM	 proteins	 and	 RIM	 binding	 proteins	 are	 also	 important	
scaffolding	 proteins	 and	 are	 involved	 in	 the	 tethering	 of	 Ca2+	 channels	 to	 the	 active	
zone,	ensuring	that	these	channels	cause	vesicle	release	(Sudhof,	2012).	RIM	proteins	
also	bind	Munc13	which	is	crucial	for	vesicle	priming	by	modifying	syntaxin	to	allow	it	
to	 form	 SNARE	 protein	 complexes	 (Stevens	 et	 al.,	 2005;	 Gerber	 et	 al.,	 2008).	 These	







Neurotransmitters	 released	 from	 the	 presynapse	mostly	 bind	 to	 receptors	 on	
the	 postsynapse	 however	 presynaptic	 terminals	 also	 have	 neurotransmitter	 binding	
proteins.	 These	 receptors	 are	 important	 for	 LTP	 and	 long	 term	 depression	 (LTD)	 and	
have	 a	 number	 of	 effects	 such	 as	 	 increasing	 or	 decreasing	 the	 amount	 of	
neurotransmitter	 released	 from	 the	 presynaptic	 terminal	 (Schlicker	 and	 Feuerstein,	
2017).	Receptors	on	the	presynapse	also	bind	to	signalling	molecules	released	from	the	
postsynaptic	terminal.	For	example,	endocannabionoids	released	from	the	postsynapse	
in	 during	 LTD	 act	 on	 cannabinoid	 receptors	 at	 the	 presynaptic	 terminal	 to	 cause	
inhibition	 of	 voltage-gated	 Ca2+	 channels.	 This	 effects	 both	 sort-term	 and	 long-term	
synaptic	strength	and	acts	at	both	excitatory	and	inhibitory	synapses	(Chevaleyre	et	al.,	
2006;	 Branco	 and	 Staras,	 2009).	 Calcium	 signalling	 within	 the	 presynapse	 also	 has	 a	





Ca2+	 influx	 leading	 to	plasticity	 (de	 Jong	and	Verhage,	2009).	 	A	number	of	 	G-protein	
coupled	 receptors	 (GPCRs)	 are	 also	 found	 at	 the	 presynapse	 and	 are	 involved	 in		
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Figure	 1.4:	 Basic	 schematic	 of	 an	 excitatory	 glutamatergic	 synapse.	Diagram	highlighting	 a	 select	
few	of	the	proteins	found	in	the	synaptic	cleft,	presynaptic,	postsynaptic,	and	astrocytic	components	
of	the	synapse.	Neurexin	and	neuroligin	stabilize	the	synaptic	cleft	and	hold	the	presynaptic	active	
zone	 opposite	 the	 post	 synaptic	 density.	Members	 of	 the	 SNARE	protein	 complex	 (synaptobrevin,	
syntaxin	and	SNAP-25)	cause	the	release	of	vesicles	upon	Ca2+	 influx	through	Ca2+	channels	due	to	
synaptotagmin	and	complexin.	Neurotransmitter	binds	to	AMPAR	and	NMDAR	to	allow	the	influx	of	
Na+	 and	 Ca2+	 into	 the	 postsynaptic	 terminal	which	 is	 stabilized	 by	multiple	 proteins.	 Activation	 of	
mGluRs	causes	down-stream	signalling	cascades	through	activation	of	g-proteins.	Dynamin	controls	










for	efficient	 transfer	of	 signals	 through	the	synaptic	cleft.	Some	receptors	on	 the	PSD	
cause	 the	 direct	 influx	 of	 ions	 (ionotropic)	 while	 others	 work	 through	 downstream	
signalling	cascades	to	cause	changes	in	protein	homeostasis	(metabotropic).	Excitatory	
neurotransmitters	 cause	 ion	 channels	 that	 have	 a	 depolarizing	 effect	 on	 neurons	 to	
open,	 making	 it	 more	 likely	 to	 propagate	 an	 action	 potential;	 while	 inhibitory	
neurotransmitters	 cause	 an	 influx	 of	 hyperpolarizing	 ions	making	 an	 action	 potential	







Glutamate	 binds	 to	 ionotropic	 receptors	 (iGluR)	 which	 are	 found	 primarily	 at	
excitatory	 postsynapses	 however	 the	 mechanism	 of	 action	 depends	 on	 the	 type	 of	
receptor	 it	binds	to.	There	are	three	main	types	of	 ionotropic	glutamate	receptors;	α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic	 acid	 receptor	 (AMPARs),	 kainate	
receptors	and	N-methyl-D-aspartate	receptor	(NMDARs)	all	of	which	are	formed	of	four	
subunits.	 The	 different	 iGluRs	 have	 different	mechanisms	 of	 action	 and	 the	 different	
subunits	 and	 thus	 the	 iGluR	 they	make	 up	 are	 unique	 in	 their	 functional	 properties,	
making	 for	a	huge	variety	of	glutamate	 receptors.	The	 iGluR	subtypes	and	assembled	
receptors	can	differ	from	one	synapse	to	another	and	vary	according	to	developmental	
stage,	 activity	 of	 the	 synapse,	 brain	 area,	 and	 disease	 (Smart	 and	 Paoletti,	 2012).	






presynaptically	 and	 postsynaptically	 and	 serve	 a	 crucial	 role	 in	 the	 regulation	 of	
presynaptic	 LTP.	 Glutamate	 binding	 to	 kainate	 receptors	 on	 the	 presynaptic	 terminal	





of	 receptor	 activation	 (Frerking	 et	 al.,	 1998;	 Rodríguez-Moreno	 and	 Lerma,	 1998;	
Rodríguez-Moreno	 and	 Sihra,	 2011).	 Independent	 of	 their	 ionic	 function,	 kainate	
receptors	 also	 act	 through	 GPCRs,	 however	 this	 is	 likely	 through	 interactions	 with	




Na+	 and	 K+	 which	 depolarizes	 the	 postsynaptic	 terminal.	 In	 this	 way	 activation	 of	
AMPARs	 directly	 increases	 the	 likelihood	 of	 postsynaptic	 cell	 firing.	 Changes	 in	 the	
number	of	AMPAR	at	the	PSD	is	one	of	the	major	ways	in	which	the	efficacy	of	synaptic	
transmission	is		altered	(Chater	and	Goda,	2014).	The	number	of	AMPARs	at	a	particular	
PSD	 correlates	 well	 with	 spine	 size	 and	 synaptic	 strength	 and	 changes	 in	 AMPAR	
number	are	regulated	by	a	number	of	different	proteins.	Some	of	these	proteins,	such	
as	 TARPs	 and	 cornichons,	 are	 responsible	 for	 trafficking	 AMPAR	 from	 the	 ER	 to	 the	
synapse	although	local	translation	of	AMPAR	at	the	synapse	has	been	shown	to	occur,	
and	 this	 causes	an	 increase	 in	 the	number	of	AMPARs	available	 for	 insertion	 into	 the	
membrane	 (Tang	 and	 Schuman,	 2002).	 Other	 proteins	 are	 involved	 in	 altering	 the	
number	of	AMPARs	embedded	 in	 the	membrane	at	 the	PSD.	Many	of	 these	proteins	
are	controlled	by	Ca2+	either	directly	or	indirectly	through	Ca2+	binding	proteins.	In	the	






Unlike	 AMPARs	 and	 kainate	 receptors	 which	 require	 only	 glutamate	 for	






LTP	 and	 LTD	with	 strong,	 quick	 Ca2+	 influx	 causing	 LTP	 and	 low,	 sustained	Ca2+	 influx	
causing	LTD.	Low	levels	of	Ca2+	engages	high	affinity	Ca2+	molecules	such	as	calcineurin.	
Activation	 of	 these	 molecules	 leads	 to	 downstream	 signalling	 events	 such	 as	 the	
dephosphorylation	of	GluA1,	which	results	in	the	removal	of	AMPARs	from	the	synaptic	
membrane	 and	 leads	 to	 LTD	 (Jurado	et	 al.,	 2010).	 Rapid	 increase	 in	 intracellular	 Ca2+	
concentrations	 leads	 to	 activation	 of	 molecules	 such	 as	 CaMKII	 which	 leads	 to	 LTP	
(Sanhueza	 and	 Lisman,	 2013).	 CaMKII	 is	 a	 protein	 kinase	 that	 when	 bound	 to	 Ca2+	
phosphorylates	target	proteins	such	as	GluA1.	CaMKII	can	bind	to	the	GluN2B	subunit	
of	 NMDARs	which	 causes	 it	 to	 be	 in	 close	 contact	 to	 the	 site	 of	 Ca2+	 influx	 and	 this	
interaction	 has	 been	 shown	 to	 be	 important	 for	 LTP	 (Sanhueza	 and	 Lisman,	 2013).	
Although	the	phosphorylation	of	GluA1	and	other	PSD	proteins	is	important	for	LTP	or	
LTD	 it	 is	not	crucial,	 indicating	that	other	processes	are	also	at	play	and	NMDARs	and	




postsynaptic	membranes.	 These	GPCRs	are	part	of	 the	C	 class	of	GPCRs.	 This	 class	of	
GPCRs	 form	 obligatory	 dimers	 and	 have	 large	 venus	 flytrap	 and	 amino	 terminal	
domains	 which	 have	 been	 shown	 to	 bind	 allosteric	 modifiers	 and	 Ca2+	 (Jiang	 et	 al.,	
2010;	Willard	and	Koochekpour,	2013;	Hanlon	and	Andrew,	2015).	These	GPCRs	affect	
synaptic	 strength	 and	 size	 through	 a	 number	 of	 second	 messengers	 including	 PLC,	
cAMP,	and	adenylyl	cyclase	(Mukherjee	and	Manahan-Vaughan,	2013).	There	are	three	
groups	 of	 mGluRs	 and	 all	 mGluRs	 have	 been	 found	 both	 presynaptically	 and	
postsynaptically.	 Group	 1	 receptors	 are	 predominantly	 found	 postsynaptically	 and	
Groups	 2	 and	 3	 receptors	 are	 predominantly	 found	 presynaptically.	 Even	 within	 the	
same	 group	 these	 different	 mGluRs	 have	 very	 different	 functions.	 For	 example,	
although	 both	 group	 1	mGluRs,	mGlu1	 is	 involved	 in	 the	 induction	 of	 persistent	 LTP	
while	mGlu5	is	mainly	involved	in	the	protein	synthesis	and	maintenance	of	LTP	as	well	
as	 being	 incredibly	 important	 for	 LTD	 (Mukherjee	 and	 Manahan-Vaughan,	 2013).	
mGlu1	 functions	 by	 increasing	 the	 intracellular	 Ca2+	 levels	 both	 through	 interactions	
with	 NMDARs	 and	 also	 through	 second	 messengers	 which	 release	 Ca2+	 from	
intracellular	 stores.	Group	 2	 and	 3	mGluRs	 are	 critically	 required	 for	 LTD	 (Mukherjee	
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and	 Manahan-Vaughan,	 2013).	 These	 receptors	 have	 been	 shown	 to	 inhibit	 Ca2+	
channels	 to	 prevent	 transmitter	 release	 from	 both	 glutamatergic	 and	 GABAergic	





The	 PSD	 contains	 a	 large	 number	 of	 proteins	 that	make	 up	 a	 scaffolding	 that	
hold	 receptors	 in	place	and	disruptions	 to	 this	 scaffolding	are	detrimental	 to	synaptic	
function	 (Bayés	 and	 Grant,	 2009).	 A	 core	 component	 of	 the	 PSD	 is	 PSD95	 which	 is	
closely	 related	 to	 PSD93,	 SAP102,	 and	 SAP97	 all	 of	 which	 are	 present	 at	 the	 PSD	
although	 to	 a	 lesser	 degree	 than	 PSD95	 (Gao	 et	 al.,	 2013).	 These	 proteins	 are	 all	
responsible	for	binding	to	both	AMPARs	and	NMDARs	at	the	postsynaptic	membrane.	
Although	these	proteins	are	structurally	similar	they	have	different	affinities	for	specific	
molecules	 and	 neurotransmitter	 receptors	 and	 thus	 the	 scaffolding	 protein	
composition	of	the	PSD	is	integral	to	its	function.	For	example,	SAP97	interacts	directly	
with	 the	 AMPAR	 subunit	 GluR1,	 while	 PSD95	 only	 interacts	 with	 AMPARs	 through	
transmembrane	 AMPAR	 regulatory	 proteins,	 for	 example	 stargazin,	 in	 a	 process	 that	
crucial	 for	 LTP	 (Opazo	 et	 al.,	 2012).	 SAP102	 preferentially	 interacts	 with	 NR2A-
containing	 NMDARs	 while	 PSD95	 preferentially	 interacts	 with	 NR2B	 containing	
NMDARs	(Gao	et	al.,	2013).	Other	postsynaptic	scaffolding	proteins	 include	the	Shank	
family	 and	 the	Homer	 family.	Homer1	 and	 Shank	 3	 are	 particularly	 important	 due	 to	
their	 interaction	 with	 mGluRs	 and	 knock	 down	 of	 either	 protein	 results	 in	 reduced	
mGlu5	 dependent	 LTD	 and	 LTP	 (Gao	 et	 al.,	 2013).	 Actin	 also	 plays	 a	major	 role	 as	 a	










is	 gephyrin	 and	 post-translational	 modifications	 of	 this	 protein,	 specifically		
phosphorylation,	 are	 crucial	 to	 strengthing	 and	 weakening	 of	 inhibitory	 synapses	
(Zacchi	et	 al.,	 2014).	Gephyrin	 stabilizes	GABAA	 receptors	 (GABAAR)	 at	 the	 PSD	which	
are	fast	acting	ligand	gated	Cl-	ion	channels	found	at	the	inhibitory	postsynapse	(Kandel	
et	al.,	2012).	This	causes	the	membrane	potential	 to	drop	to	 -70mV	from	its	normal	 -
65mV	increasing	the	amount	of	positive	ion	influx	required	to	cause	an	action	potential.	
GABAARs	 are	 heteropentamers	 and	 there	 are	 many	 GABAAR	 subunits	 which	 all	 have	
slightly	 different	 effects	 similar	 to	 the	 iGluRs	 discussed	 earlier	 (Vithlani	 et	 al.,	 2011).	
GABAB	receptors	(GABABR)	are	the	main	GABAergic	receptors	of	the	inhibitory	synapse	
and	 these	 are	 coupled	 to	 G	 proteins	 which	 influence	 synaptic	 transmission	 through	
second	messengers	at	both	the	presynapse	and	the	postsynapse	(Kandel	et	al.,	2012).	
These	 receptors	also	have	different	mechanisms	of	action	depending	on	 the	 subunits	
that	make	them	up	and	the	localization	of	the	receptor.	At	the	presynapse	for	example,	
GABABR	 activation	 can	 cause	 the	 inhibition	 of	 Ca2+	 influx	 causing	 less	 vesicle	 release.	
The	activation	of	GABABRs	can	also	affect	the	actions	of	nearby	NMDARs	affecting	the	





The	primary	symptom	of	AD	is	progressive	memory	 loss	and	thus	 it	 is	perhaps	
not	 surprising	 that	 synapses	 and	 indeed	 synaptic	 dysfunction	 and	 dysregulation	 are	
important	 in	 the	 disease.	 Of	 all	 the	 neuropathological	 hallmarks	 of	 AD	 synaptic	 loss	
correlates	best	with	the	cognitive	impairment	that	is	the	phenotype	of	AD	(DeKosky	et	
al.,	 1990,	1996).	Plaques	and	 tangles	are	often	 found	 in	aged	 individuals	without	any	
cognitive	 symptoms,	 indicating	 that	 they	 in	 themselves	 are	 not	 sufficient	 to	 cause	
disease	 however	 the	 soluble	 oligomeric	 forms	 of	 Aβ	 and	 tau	 play	 a	 role	 in	 synaptic	
degeneration	and	the	accompanying	memory	loss	(Spires-Jones	and	Hyman,	2014).		
	




human	 brain	 synaptic	 loss	 was	 greatest	 in	 the	 core	 and	 halo	 of	 dense	 core	 plaques,	
areas	 with	 high	 oligomeric	 Ab	 levels.	 Synaptic	 density	 then	 returns	 to	 control	 levels	
greater	than	30μm	from	the	plaque	where	the	number	of	synapses	associating	with	Ab	






studied	by	a	variety	of	experimental	procedures	and	 it	 is	 likely	 that	many	 if	not	all	of	
these	 play	 a	 role	 in	 the	 human	 disease.	 It	 is	 important	 to	 note	 that	 many	 of	 these	
experiments	both	in	vitro	and	in	vivo	involve	overexpression	or	high	concentrations	of	





impairs	 LTP	 and	 facilitates	 LTD	 (Walsh	 et	 al.,	 2002).	 Aβ	 is	 proposed	 to	 affect	 LTP	





















been	 shown	 to	 interact	 with	 the	 cellular	 prion	 protein	 (PrPc)	 to	 cause	 aberrant	
activation	 of	 Fyn	 kinase.	 This	 kinase	 then	 goes	 on	 to	 phosphorylate	mGluR5	 protein	
increasing	LTD	and	impairing	LTP	(Renner	et	al.,	2010;	Hamilton	et	al.,	2014;	Xia	et	al.,	
2016).	Ab	has	also	been	shown	to	bind	acetylcholine	receptors	specifically	α7-nicotinic	













The	 mechanisms	 by	 which	 tau	 affects	 synapse	 loss	 are	 much	 less	 well	
established	although	mouse	models	show	that	knocking	out	tau	prevents	some	of	the	
detrimental	effects	of	Aβ	on	cognition	and	seizure	susceptibility	(Roberson	et	al.,	2007).		
Mouse	models	of	 tauopathy	 indicate	that	tau	pathology	 is	sufficient	to	cause	synapse	
and	 neuron	 loss	 although	 in	 contrast	 to	 Aβ,	 Ca2+	 dysregulation	 is	 not	 involved	
(Kopeikina	et	al.,	2013).	Pathogenic	forms	of	tau	are	found	to	be	localized	to	both	the	
pre-	 and	 postsynaptic	 terminals	 and	 similar	 to	 Aβ	 evidence	 suggests	 that	 it	 is	 the	
oligomeric	 species	 of	 these	 proteins	 that	 have	 a	 direct	 effect	 on	 synaptic	 function	
(Rocher	 et	 al.,	 2010;	 Crimins	 et	 al.,	 2013).	 Studies	 in	 fly	 and	 rat	 neurons	 show	 that	
pathogenic	 tau	 disrupts	 presynaptic	 vesicle	mobility	 thus	 lowering	 neurotransmission	
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Given	 the	 role	 of	 tau	 as	 a	microtubule	 transporter	 synapse	 dysfunction	 could	
result	from	an	impairment	of	transport	down	the	axon	(Stoothoff	et	al.,	2009;	Kanaan	
et	 al.,	 2011;	 Kopeikina	 et	 al.,	 2011).	 Indeed,	 tau	 overexpression	 in	 vitro	 leads	 to	
impairment	of	transport.	This	effect	of	tau	could	be	due	to	an	increase	toxicity	as	some	
groups	 show	 that	knocking	out	mouse	 tau	does	not	affect	 cognition.	However	others	
have	shown	a	small	effect	 in	cognition	 in	older	age	groups	 including	plasticity	deficits	
(Roberson	et	al.,	2007;	Ahmed	et	al.,	2014;	Ma	et	al.,	2014).	This	loss	of	transport	has	
been	 shown	 to	 affect,	 among	 other	 things,	mitochondria	 that	 are	 needed	 for	 energy	
demanding	 synapses	 to	 function	 (Kopeikina	 et	 al.,	 2011).	 Synapses	 are	 extremely	
dependent	 on	 mitochondria,	 not	 only	 for	 ATP	 production	 but	 also	 for	 their	 calcium	
buffering	capabilities.	Studies	have	shown	that	mitochondria	trafficked	to	the	synapse	
show	a	different	proteomic	 signature	 from	 those	which	are	 found	non-synaptically	 in	
neurons	 (Völgyi	 et	 al.,	 2015).	 However	 synaptic	 mitochondria	 appear	 to	 be	 more	
susceptible	 to	 Ca2+	 dysregulation	 and	 oxidative	 phosphorylation	 as	 well	 as	 Aβ	







LTP	 and	 LTD	 through	 the	 release	 of	 small	 signalling	molecules	 (Vincent	 et	 al.,	 2010).	
Astrocytes	are	also	 important	 in	the	uptake	of	glutamine	and	GABA	from	the	synaptic	
cleft	 which	 contributes	 to	 the	 termination	 of	 signal	 (Chung	 et	 al.,	 2015).	 Aβ	 causes	
dysregulation	 of	 calcium	 signalling	 in	 astrocytes	 impairing	 not	 only	 their	 ability	 to	
modulate	LTP	but	also	 impairing	control	of	 the	neurovascular	unit	 (Kuchibhotla	et	al.,	




risk	 factor	 for	AD	and	 likely	reduces	the	flow	of	oxygen	to	the	brain	 further	 impairing	
the	mitochondria	(Dickstein	et	al.,	2010).	
	
Microglia	 also	 play	 a	 role	 both	 in	 normal	 synaptic	 function	 and	 in	 AD.	 In	 the	
healthy	 brain	microglia	 support	 neurons	 both	 by	 clearing	 extracellular	 debris	 and	 by	
releasing	extracellular	growth	factors	such	as	brain-derived	neurotrophic	factor	(Ueno	
et	 al.,	 2013;	 Southam	 et	 al.,	 2016).	 In	 AD	 mouse	 models,	 microglia	 appear	 to	 be	
responsible	for	synapse	loss	in	a	Complement	C1q,	C3	dependent	manner	(Hong	et	al.,	
2016;	 Shi	 et	 al.,	 2017).	 Although	 this	 removal	 of	 synapses	 occurs	 normally	 in	
development,	over-activation	of	 this	 system	 in	disease	 is	detrimental	 to	 the	 synapses	
(Paolicelli	 et	 al.,	 2011;	 Hong	 et	 al.,	 2016;	 Shi	 et	 al.,	 2017).	 Although	 microglia	 and	
astrocytes	are	clearly	 important	 in	the	disease	pathogenesis,	 in	vitro	work	shows	that	
they	 are	 not	 a	 requirement	 for	 synaptic	 dysfunction	 and	 loss	 in	 the	 presence	 of	
pathogenic	proteins.			
	
Synapses	 also	 contribute	 to	 the	 spread	 of	 disease	 throughout	 the	 brain.	 Tau	
pathology	 in	 particular	 follows	 a	 very	 well-defined	 spreading	 pattern,	 which	 follows	
pathways	of	neurons	which	are	synaptically	connected.	This	finding	led	groups	to	look	
at	whether	synaptic	connections	were	 involved	 in	the	spread	of	pathological	 forms	of	




of	 this	 tau	pathology	 (Pooler	et	al.,	 2015).	Cell	 culture	 studies	hint	at	 the	mechanism	
behind	 this	 as	Aβ	 is	 known	 to	 increase	 local	 synaptic	 activity	 and	 increased	neuronal	
activity	stimulates	tau	release	from	neurons	 (Renner	et	al.,	2010;	Pooler	et	al.,	2013).	




Synaptic	 degeneration	 is	 undoubtedly	 important	 to	 AD	 pathogenesis	 and	












Epidemiological	 studies	 indicate	 that	 many	 factors	 are	 associated	 with	 an	
increase	the	risk	of	developing	LOAD	including	education,	physical	 inactivity,	diabetes,	
cardiovascular	health,	and	genetics.	Many	of	these	factors	particularly	those	related	to	
cardiovascular	health	are	 important	 in	midlife	 and	predispose	 individuals	 to	 cognitive	
decline	even	 in	 the	absence	of	AD.	 Indeed,	distinguishing	between	vascular	dementia	
and	 AD	 clinically	 is	 sometimes	 difficult	 due	 to	 the	 overlapping	 and	 heterogeneous	
factors	at	play	(Imtiaz	et	al.,	2014).	High	blood	pressure	and	hypertension	in	midlife,	in	
particular,	 are	 associated	with	 an	 increased	 risk	 of	 AD.	However	 physical	 activity	 can	
help	 mitigate	 this	 risk	 and	 a	 recent	 study	 has	 shown	 that	 physical	 activity	 can	 even	
reduce	 the	 progression	 of	 AD	 (Kivipelto	 et	 al.,	 2001,	 2013;	 Stephen	 et	 al.,	 2017).	
Cardiovascular	health	affects	the	amount	of	oxygen	that	can	be	delivered	to	the	brain	

















cells	 in	AD	 (Jonsson	et	al.,	 2013).	Gender	 is	 also	an	 important	 risk	 factor	 for	AD	with	
women	having	a	higher	incidence	of	AD	(Pike,	2017)	(Figure	1.1C).	The	reasons	behind	



















protective	 (Corder	 et	 al.,	 1994).	 	 The	 possession	 of	 two	 copies	 of	APOE	 e4	 has	 been	
shown	to	not	only	 increase	the	chance	of	getting	AD	by	12	fold	that	of	a	person	with	
two	copies	of	APOE	e3,	but	also	lower	the	average	age	of	clinical	onset	to	68	years	of	
age.	 One	 copy	 of	 APOE	 e4	 increases	 the	 chance	 of	 AD	 by	 3	 times	 and	 lowers	 the	
average	 age	 of	 onset	 to	 76	 years	 of	 age	 from	 an	 average	 age	 of	 onset	 of	 84	 for	 an	
individual	 with	 two	 copies	 of	 APOE	 e3	 (Corder	 et	 al.,	 1993).	 Although	 mentioned	 in	
association	with	AD	most	frequently,	ApoE	has	also	been	linked	to	Parkinsons	Disease	
(Li	et	al.,	2004),	FTD	(Agosta	et	al.,	2009)	and	other	neurological	diseases	(reviewed	in	
Huynh	 et	 al.	 2017)	 as	 well	 as	 linked	 to	 lower	 cognition	 in	 non-demented	 aged	
individuals	(Deary	et	al.,	2004).	The	pathways	by	which	ApoE	impacts	the	development	
of	 AD	 have	 been	 widely	 studied	 both	 in	 vitro	 and	 in	 vivo	 however	 the	 exact	
mechanisms	 have	 yet	 to	 be	 uncovered.	 It	 is	 clear	 however	 that	 the	 effects	 of	 this	







2012).	 Apolipoproteins	 bind	 lipids	 allowing	 them	 to	 be	 soluble	 in	 water	 and	






delivery	of	 cholesterol	by	ApoE	 is	 important	 for	neurons	and	has	also	been	shown	 to	
have	 a	 function	 in	 synaptogenesis	 (Mauch	 et	 al.,	 2001;	 Dietschy	 and	 Turley,	 2004).	
Apoe	 knock	 out	 mice	 develop	 normally	 indicating	 that	 the	 presence	 of	 ApoE	 is	 not	
necessary	for	either	development	or	survival	and	no	overt	cognitive	defects	have	been	














The	 different	APOE	 alleles	 are	 all	 fairly	 common	 in	 the	 population.	 The	most	
common	allele	found	in	the	population	is	the	APOE	e3	allele	which	has	a	frequency	of	
79%	 while	 APOE	 e4	 and	 APOE	 e2	 have	 frequencies	 of	 14%	 and	 7%	 respectively	
(AlzGene,	 2017).	 ApoE2	 and	 ApoE4	 differ	 from	 ApoE3	 by	 a	 single	 amino	 acid	
substitution	each,	and	thus	differ	from	one	another	by	two	amino	acids,	although	rarer	
polymorphisms	 within	 these	 3	 isoforms	 have	 been	 found	 (Nickerson,	 2000).	 ApoE2	
contains	the	amino	acid	cysteine	at	positions	112	and	158	while	ApoE	3	has	a	cysteine	
at	 position	 112	 and	 an	 arginine	 at	 position	 158	 and	 ApoE	 4	 has	 an	 arginine	 at	 both	
position	112	and	158	(Holtzman	et	al.,	2012)	(Figure	1.6A).	The	different	ApoE	isoforms	
also	 found	 in	different	concentrations	 in	 the	cerebrospinal	 fluid	 fluid	 (CSF)	with	APOE	
e2/2	individuals	having	the	greatest	amount	of	measurable	ApoE	in	the	CSF	and	APOE	
e4/4	 individuals	 the	 lowest	 (Riddell	 et	 al.,	 2008).	 This	 is	 likely	 due	 to	 the	 structural	
differences	 between	 the	 isoforms	with	 ApoE4	 being	 the	most	 unstable	 and	 thus	 the	






Figure	 1.6:	 Basic	 schematic	 of	 the	 mechanisms	 of	 ApoE	 signalling	 through	 receptors.	 The	






ApoE3	 and	 is	more	 efficient	 at	 endocytosis	 and	 degradation	 of	 the	 ApoE-Aβ	 complexes	 than	
LDLR.	ApoER2	binds	both	ApoE3	and	ApoE4	 causing	endocytosis,	 however	ApoER2	 returns	 to	









terminal	 region	 to	 be	 close	 to	 the	N-terminal	 region,	 in	ApoE3	 and	ApoE2,	 Arg112	 is	
Cys112	which	does	not	allow	for	this	Arg61-Glu225	 interaction	causing	the	C-terminal	




around	 the	brain	 and	body	 (Zhong	and	Weisgraber,	 2009).	 In	particular,	ApoE4	binds	
preferentially	 to	 lower	density	 lipoproteins	 (LDL)	while	ApoE3	and	ApoE2	bind	higher	
density	lipoproteins	(HDL)(Weisgraber,	1990).		
	
In	 comparison	 to	 the	 plasma	 where	 ApoE	 associates	 mainly	 with	 very	 low-
density	 lipoprotein	 (VLDL)	particles	ApoE	secreted	 in	 the	brain	 is	mainly	 found	 in	HDL	
particles	 (Zhao	et	al.,	2017).	Due	to	the	role	of	the	blood	brain	barrier,	ApoE	made	 in	
the	CNS	remains	 in	the	CNS	and	there	 is	very	 little	or	no	infiltration	of	ApoE	from	the	











(Holtzman	 et	 al.,	 2012).	 Among	 the	 ApoE	 binding	 receptors	 are	 the	 low-density	
lipoprotein	 receptor	 family	 (LDLR),	 ApoE	 receptor	 2	 (ApoER2),	 very	 low-density	
lipoprotein	 receptors	 (VLDLRs),	 and	 lipoprotein	 receptor-related	 protein	 1	 (LRP1).	
These	proteins	all	have	short	cytoplasmic	C-terminal	domains	with	a	 tetra-amino	acid	





and	 the	 lipid	moieties	 it	 is	 carrying.	 It	 could	 be	 argued	 that	many	 of	 the	 differences	
between	the	ApoE	isoforms	are	due	to	their	different	interactions	with	ApoE	receptors.		
	
Many	 of	 the	 ApoE	 receptors	 play	 an	 important	 role	 in	 receptor-mediated	
endocytosis	of	 lipoprotein	particles.	These	receptors	are	 important	 for	bringing	 in	 the	
cholesterol	 and	 lipids	 that	 allow	 for	 the	 maintenance	 of	 the	 lipid	 bilayer	 that	 is	
important	 to	 cell	 function	 and	 survival.	 LRP1	 in	 particular	 is	 crucially	 important	 for	
cholesterol	 transport	 and	 although	 ApoE	 deficiency	 does	 not	 lead	 to	 cholesterol	
deficiency	in	the	brain,	LRP1	deficiency	does	(Liu	et	al.,	2007).	This	indicates	that	there	
are	ApoE	independent	mechanisms	of	cholesterol	transport	in	the	brain.	LDLR	and	LRP1	
are	 also	 known	 to	 influence	 ApoE	 levels	 through	 endocytosis	 and	 then	 either	
subsequent	 lysosome	 degradation	 or	 recycling	 of	 ApoE	 through	 recycling	 vesicles	
(Figure	 1.6B).	 Removal	 of	 either	 LDLR	 or	 LRP1	 from	 a	 mouse	 model	 containing	
humanized	ApoE	 increases	 the	amount	of	ApoE	 in	 the	brain	 (Fryer	et	al.,	2005;	Liu	et	
al.,	 2007).	 The	 different	 specificities	 for	 these	 receptors	 that	 the	 isoforms	 of	 ApoE	
display	may	be	the	reason	for	the	higher	levels	of	abundance	of	ApoE2	in	the	brain	as	






and	 synapse	 development	 and	morphology	 as	well	 as	 being	 a	 neuroprotective	 agent	
(reviewed	 in	Holtzman	2012).	 In	 later	 life	 it	 has	 been	 shown	 to	 naturally	 decrease	 in	
abundance.	Although	ApoE	and	Reelin	do	not	bind	 the	 same	 site	on	 these	 receptors,	
ApoE	 binding	 to	 ApoER2	 causes	 it	 to	 be	 endocytosed	 and	 thus	 not	 available	 to	 bind	
Reelin	(Chen	et	al.,	2010).	While	endocytosed	ApoE3	is	recycled	quickly	and	efficiently,	









ApoE	 and	 the	ApoE	 receptors	play	 an	 important	 role	 at	 the	 synapse.	ApoE,	 is	
the	 main	 transporter	 of	 cholesterol	 in	 the	 brain	 and	 cholesterol	 is	 important	 for	




reduced	 branching,	 shorter	 dendrites,	 less	 spines,	 and	 reduced	 synaptic	 transmission	
when	 compared	 with	 those	 expressing	 humanized	 ApoE3	 (Wang	 et	 al.,	 2005).	





















Much	of	 the	work	 looking	at	ApoE	 in	AD	 investigates	 its	 relationship	with	Aβ.	
Early	post	mortem	work	found	a	positive	correlation	between	APOE	e4	allele	dose	and	
Aβ	 plaque	 density	 in	 individuals	 with	 AD	 (Rebeck	 et	 al.,	 1993).	 In	 vivo	 imaging	 in	
humans	 has	 shown	 that	 fibrillar	 Ab	 can	 be	 detected	 in	 individuals	 with	 an	 APOE	 e4	
allele	 20	 years	 earlier	 than	APOE3/3	 individuals	 (Reiman	 et	 al.,	 2004;	 Fleisher	 et	 al.,	
2013).	This	build	up	of	detectable	Aβ	in	the	brain	occurs	well	before	the	onset	of	clinical	
symptoms	and	 is	often	accompanied	by	a	decrease	 in	Aβ42	 in	the	CSF	(Sunderland	et	
al.,	2004;	Morris	et	al.,	2010).	A	wide	range	of	studies	 indicate	that	ApoE4	affects	the	




to	 an	 increase	 in	 production	 of	 Aβ.	 The	 ApoE	 receptor	 LRP1	 and	 the	 closely	 related	
LRP1B	 have	 been	 implicated	 in	 potential	 effects	 of	 ApoE	 on	 Aβ	 synthesis.	 The	
production	 of	 Aβ	 occurs	 when	 APP	 is	 endocyosed	 and	 brought	 into	 contact	 with	 b-
secretase	and	thus	an	increase	in	APP	endocytosis	likely	increases	Aβ	production.	LRP1	
causes	 an	 increase	 in	 the	 rate	 of	 APP	 endocytosis	 while	 LRP1B	 potentially	 causes	 a	
decrease	 in	 Aβ	 by	 preventing	 APP	 endocytosis	 (Ulery	 et	 al.,	 2000;	 Cam	 et	 al.,	 2004,	
2005).	 A	 recent	 study	 has	 also	 indicated	 that	 ApoE	 can	 cause	 a	 signalling	 cascade	
through	ERK1/2	which	causes	an	increase	in	APP	production	(Huang	et	al.,	2017).	This	
study	found	that	ApoE4	up-regulates	this	signalling	cascade	more	than	ApoE3	and	thus	




culture	 with	 astrocytes	 this	 phenomenon	 ceases	 to	 exist	 (Huang	 et	 al.,	 2017).	









than	 those	 expressing	 humanized	ApoE3	 thus	 highlighting	 the	 importance	of	ApoE	 in	
regulating	Aβ	levels	(Castellano	et	al.,	2011).	Although	neurons	cannot	clear	or	degrade	
Ab,	 astrocytes	 and	 microglia	 can	 (Cole	 and	 Ard,	 2000;	 Wyss-Coray	 et	 al.,	 2003;	
Mandrekar	et	al.,	2009).	Astrocytes	clear	Ab	mainly	through	Blood	Brain	Barrier	(BBB)	
but	 also	 through	 internal	 degradation.	 The	 internalization	 of	 Ab	 by	 astrocytes	 is	
dependent	on	ApoE	and	 is	prevented	 in	ApoE-KO	astrocytes	 (Koistinaho	et	al.,	2004).	
The	ApoE	 receptors	 LRP1	and	LDLR	both	contribute	 to	 the	 internalization	of	Ab-ApoE	
complexes	although	at	different	rates,	with	LRP1	being	the	quicker	of	 the	two	(Figure	
1.6B).	However	Aβ-ApoE4	complexes	are	preferentially	cleared	by	LDLR	which	results	in	
a	 slower	 rate	 of	 clearance	 of	 these	 molecules	 compared	 with	 Aβ-ApoE3	 complexes	
which	are	cleared	through	the	faster	LRP1	(Deane	et	al.,	2008).	However	not	all	Aβ	 is	
cleared	through	the	BBB.	Microglia	also	phagocytose	Aβ	in	an	ApoE	dependent	fashion	
in	 a	 process	 that	 is	 dependent	 on	 ApoE	 isoform	 and	 both	 microglia	 and	 astrocytes	




receptors	 could	 end	 up	 being	 detrimental	 if	 they	 also	 increase	 the	 amount	 of	 Ab	
internalized	by	neurons	(Billings	et	al.,	2005).		
	
Intriguingly	although	ApoE	KO	 increases	 the	 rate	of	Aβ	clearance	 into	 the	CSF	
Apoe	KO	from	fAD	mice	show	increased	Aβ	deposition	(DeMattos	et	al.,	2004)	in	some	
models	 of	 AD	 (Bales	 et	 al.,	 1997).	 Knocking	 out	 the	 closely	 related	 ApoJ	 (also	 called	
Clusterin)	increases	Aβ	deposition	further	(DeMattos	et	al.,	2004).	This	shows	ApoE	and	
Clusterin	 have	profound	effects	 on	Aβ	 in	 terms	of	 its	 aggregation	 into	oligomers	 and	











ApoE	 also	has	 effects	 on	 the	 localization	of	Aβ	deposition.	 For	 example,	mice	
which	 express	 humanized	 ApoE4	 have	 an	 increased	 amount	 of	 cerebral	 amyloid	
angiopathy	 compared	 with	 mice	 which	 express	 ApoE3	 or	 mouse	 ApoE	 (Fryer	 et	 al.,	
2005).	ApoE4	individuals	also	contain	more	Aβ	at	the	synapse	(Koffie	et	al.,	2012).	This	
increase	in	Aβ	is	accompanied	by	an	increase	in	ApoE	which	may	be	the	result	of	ApoE	











showed	 that	 while	 a	 copy	 of	 the	 “protective”	 ApoE2	 did	 reduce	 the	 number	 of	 Aβ	
plaques	in	individuals	with	AD	there	was	no	effect	on	the	number	of	NFTs	in	this	cohort	
(Tiraboschi	et	 al.,	 2004).	 This	 could	 indicate	 that	while	 ApoE2	 does	 have	 a	 beneficial	
role	in	regards	to	Aβ	pathology	only	ApoE4	affects	both	Aβ	and	tau.		
	
One	 reason	 for	 this	 could	 be	 that	 the	 main	 effect	 of	 ApoE	 on	 tau	 is	 likely	




ApoE	 independent	manner	 (Vázquez-Higuera	 et	 al.,	 2009).	 As	 for	 ApoER2	 and	 VLDR,	
ApoE2	 and	ApoE3	have	 very	 similar	 receptor	 binding	properties	with	 these	 receptors	




by	ApoE4	 leads	 to	 reduced	phosphorylation	of	GSK3β	and	 thus	hyperphosphorylation	












which	 presents	methodological	 challenges	 to	 investigating	 the	 effect	 of	 AD	 on	 these	
structures.	 Therefore,	 to	 further	 understand	 this	 disease	 requires	 the	 study	 of	 both	





The	 discovery	 of	 green	 fluorescent	 protein	 and	 the	 resulting	 development	 of	
fluorescently	 tagged	 antibodies	 has	 dramatically	 increased	 our	 understanding	 of	
biological	 systems	 by	 allowing	 for	 the	 identification	 of	 more	 than	 two	 proteins	 in	
biological	 samples	 (Micheva	 and	 Smith,	 2007).	 However	 fluorescent	 light	microscopy	
has	 a	 number	 of	 limitations	 not	 least	 of	 which	 is	 that	 the	 axial	 resolution	 of	 the	 z	
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direction	 is	 about	 800nm	 depending	 on	 the	 wavelength	 used	 (Pawley	 and	 Pawley,	
2006).	 This	means	 that	 for	 very	 small	 structures	 such	as	 synapses	 co-localization	of	 a	
protein	marker	with	a	synapse	could	indicate	either	that	said	protein	is	in	the	synapse	
or	merely	near	the	synapse.	To	overcome	this	problem	Micheva	and	Smith	developed	






thick	 ribbons	 of	 serial	 sections.	 These	 ribbons	 can	 be	 stained	 using	 standard	
fluorescently	tagged	antibodies	and	imaged	using	a	fluorescent	light	microscope.	Image	
processing	 then	 allows	 for	 a	 3D	 visualization	 of	 the	 imaged	 tissue	 with	 a	 z	 axis	
resolution	of	70nm.	This	allows	for	synaptic	co-localization	to	be	assessed	with	greater	
confidence	than	standard	light	microscopy.	Array	tomography	has	already	been	put	to	






on	 a	 large	 scale	 and	 in	 an	 unbiased	manner.	 The	 technical	 capabilities	 of	 proteomic	
systems	have	advanced	greatly	 in	recent	years	 to	allow	for	not	only	 the	 identification	
but	 also	 the	 quantification	 of	 proteins	 to	 a	 high	 degree	 of	 accuracy	 and	 sensitivity	
(Bantscheff	et	al.,	2012).	Proteomic	systems	have	been	put	to	good	use	exploring	the	
changing	 protein	 landscape	 of	 different	 diseases	 in	 an	 unbiased	 method.	 This	 has	




full	 of	 a	 mix	 of	 proteins	 is	 digested	 by	 a	 protease,	 normally	 trypsin,	 which	 is	 then	
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separated	 by	 reverse-phase	 liquid	 chromatography	 (LC)	 and	 then	 analysed	 by	 mass	
spectrometers.	The	mass	spectrometers	can	detect	the	mass	to	charge	ratio,	intensity,	
and	sequence	 information	for	each	peptide	which	are	then	searched	 in	a	database	to	
identify	 the	 proteins	 present	 in	 the	 sample.	 For	 samples	 where	 a	 known	 amount	 of	
analyte	 is	 added	 prior	 to	 analysis	 (also	 called	 labelled	 proteomics)	 the	 protein	
quantification	can	be	absolute	but	 in	cases	of	 label	free	proteomics	the	quantification	
of	proteins	is	relative	to	other	proteins	detected	by	the	system.	Although	shotgun	label	












be	 valuable	 to	 the	discovery	of	 biomarkers	which	 are	particularly	 important	 in	AD	as	
cognitive	 tests	have	 low	accuracy	and	dynamic	 range	 thus	preventing	 investigation	of	
subtle	 changes	 in	 cognitive	 function	 (Fiandaca	 et	 al.,	 2014).	 Clinical	 trials	 for	 disease	
modifying	treatments	in	AD	have	thus	far	failed	and	one	explanation	is	that	treatments	
are	 applied	 after	 the	 onset	 of	 clinical	 systems	which	may	 be	 too	 late	 in	 the	 disease	
course.	Biomarkers	which	allow	for	the	 identification	of	preclinical	AD	and	MCI	would	
allow	 for	 trials	 to	 occur	 in	 these	 individuals	 allowing	 drug	 companies	 to	 test	 drugs	
which	prevent	the	onset	of	AD.	
	
Explorative	 proteomics	 in	 post-mortem	 human	 brain	 has	 shed	 light	 on	 the	
pathological	 protein	 changes	 that	 occur	 in	 disease	 and	 lead	 to	 neurodegeneration.	
However	 so	 far	 proteomic	 studies	 have	 failed	 to	 reach	 a	 consensus	 on	 the	 protein	
43	
	
changes	 that	 are	 linked	with	 AD.	 This	 is	 no	 doubt	 due	 in	 part	 to	 technical	 problems	
particularly	 with	 2D	 electrophoresis	 and	 inherent	 variability	 between	 individuals	 and	
cohorts	but	are	also	likely	due	to	the	variety	of	brain	areas	and	sample	processing	used	
(Brinkmalm	 et	 al.,	 2015).	 A	 list	 of	 proteomics	 studies	 undertaken	 in	 post-mortem	
human	 brain	 is	 presented	 in	 Table	 1.1.	 However	 even	 with	 advances	 in	 proteomic	
techniques	 and	 careful	 sample	 processing	 of	 the	 same	 brain	 area	 different	 labs	
continue	to	report	largely	different	protein	sets	(Andreev	et	al.,	2012;	Musunuri	et	al.,	
2013;	 Moya-Alvarado	 et	 al.,	 2016).	 There	 are	 several	 possible	 reasons	 for	 this	
continued	variability,	the	first	being	that	the	brain	 is	a	very	complex	tissue	with	many	
cell	 types	 that	 are	 differently	 affected	 by	 AD.	 The	 second	 is	 that	 AD	 is	 a	 very	
heterogeneous	 disease	 with	 many	 comorbidities	 and	 variability	 between	 individuals	




One	mechanism	of	 reducing	variability	 in	proteomics	 studies	 is	 to	 remove	 the	
effect	of	genetic	variability	and	post-mortem	interval	differences	and	for	that	animal	or	
cell	models	are	needed.	These	models	can	be	very	powerful	 in	 looking	at	the	changes	
that	 occur	 in	 the	 progression	 of	 a	 disease	 or	 at	 the	 response	 of	 proteins	 to	 a	 single	
insult,	 such	 as	 Aβ,	 Tau	 hyperphosphorylation,	 or	 oxidative	 stress.	 However,	 it	 is	
important	to	highlight	that	to	date	no	mouse	model	has	fully	recapitulated	the	disease	
and	the	failed	clinical	trials	discussed	earlier	have	been	successful	in	mouse	models	and	































































































































































































































































































































Given	 the	 prominent	 role	 of	 synapses	 in	 the	 brain	 knowing	 their	 constituent	
elements	 is	 beneficial	 to	 understanding	 brain	 function	 both	 in	 health	 and	 disease.	
Proteomics	 of	 synapses	 biochemically	 isolated	 from	 brain	 tissue	 has	 been	 used	 to	
reveal	over	2,000	proteins	and	has	also	been	used	in	a	number	of	diseases	(Bayés	and	
Grant,	 2009).	 The	 first	 step	 in	 synaptic	proteomics	 is	biochemically	 isolating	 synapses	
from	 tissue	 and	 there	 are	 a	 number	 of	 different	methods	 by	which	 scientists	 do	 this	
which	are	aptly	reviewed	in	table	1	of	Dieterich	and	Kreutz	2016	(Dieterich	and	Kreutz,	
2016).	 The	majority	 of	 synaptic	 proteomic	 studies	 so	 far	 have	 taken	place	 in	 isolated	
PSDs	although	others	investigate	the	presynapse,	spine	head,	and	astrocytic	end	feet	in	








in	 one	 synapse	 could	 be	 offset	 by	 another.	 To	 begin	 to	 understand	 synaptic	 protein	
differences	 in	 greater	 depth	 scientists	 are	 now	 using	 new	 proteomics	 techniques	 to	
look	 at	 the	 post-translational	 modifications	 that	 these	 proteins	 can	 undergo	 in	 an	
attempt	 to	 understand	 the	 physiological	 role	 of	 these	 proteins	 in	 a	 static	 “snapshot”	
image	(Trinidad	et	al.,	2012).	This	is	of	course	still	only	an	attempt	at	understanding	the	
role	of	these	proteins	in	different	conditions	and	need	to	be	followed	up	with	studies	of	
a	 few	 proteins	 of	 interest	 in	 systems	 that	 allow	 greater	 depth	 of	 understanding.	 As	
always	 investigation	of	a	system	balances	depth	and	width	of	understanding	although	












aspects	 of	 AD.	 As	 AD	 is	 a	 heterogeneous	 disease	 with	 many	 features	 it	 is	 perhaps	
unsurprising	 that	many	 animal	models,	 127	 at	 time	 of	writing,	 have	 been	 developed	
over	 the	 years	 to	 answer	 a	 variety	 of	 questions	 (Alzforum,	 2017).	 It	 is	 important	 to	
point	out,	even	though	it	has	already	been	highlighted	in	this	introduction,	that	none	of	
these	animal	models	fully	recapitulate	the	disease.	This	however	does	not	negate	their	
usefulness	 in	 providing	 information	 about	 disease	 onset,	 progression	 and	 pathology.	
Indeed,	 the	 ability	 to	 test	 the	 effects	 and	 interactions	 of	 proteins,	 networks,	 and	







lines,	 are	becoming	more	 common	 (Hiroki,	 2017).	Mice	which	express	 these	mutated	
fAD	genes	have	a	build	up	of	Ab	pathology	that	looks	remarkably	similar	to	that	seen	in	
humans.	There	are	a	number	of	different	AD	causing	mutations	that	have	been	found	in	
both	 APP	 and	 PS1	 and	 many	 of	 these	 have	 been	 introduced	 into	 animal	 models	 to	
create	 animals	 with	 different	 disease	 progressions	 and	 timelines	 (Lamb	 et	 al.,	 1997;	
Oakley	et	al.,	2006;	Alzforum,	2017).Most	of	the	animals	harboring	fAD	mutations	have	
amyloid	plaques,	and	behavioural	deficits	with	some	neuron	and	synapse	loss.	However	
while	 some	 tau	 pathology	 such	 as	 hyperphosphorylation	 and	 neuritic	 dystrophies	 is	





In	 an	 effort	 to	 recapitulate	 both	 the	 plaque	 and	 the	 tangle	 pathology	 of	 AD,	
mouse	 models	 which	 contained	 fAD	 mutations	 alongside	 tau	 mutations	 were	
developed	(Oddo	et	al.,	2003).	However	the	mutations	in	tau	that	cause	the	formation	
of	 tangles	 in	mouse	models	 are	 found	not	 in	AD	 individuals	but	 individuals	with	FTD.	
These	mouse	models	have	helped	answer	some	of	the	questions	about	the	interactions	
of	tau	and	Aβ	in	AD.	For	example	the	triple	transgenic	mouse	line	which	over	expresses	
mutated	 APP,	 PS1,	 and	 tau	 show	 Aβ	 pathology	 prior	 to	 the	 onset	 of	 tau	 pathology	
(Oddo	et	al.,	2003).	However	when	APP/PS1	mice	are	crossed	with	mice	which	do	not	
produce	endogenous	tau	there	 is	 rescue	not	of	 the	Aβ	pathology	but	of	 the	cognitive	
impairment	 that	 accompanies	 it	 (Roberson	 et	 al.,	 2007).	 This	 suggests	 that	 while	 Aβ	
pathology	 precedes	 tau	 pathology,	 tau	 is	 necessary	 for	 the	 cognitive	 effect	 of	 Aβ	 on	
mice.	 The	 interactions	 of	 these	 two	 proteins	 in	 regulating	 the	 spread	 of	 pathogenic	
proteins	has	also	been	studied	and	here	labs	have	shown	than	Aβ	increases	the	speed	
of	 tau	 spread	 and	 toxicity	 (Pooler	et	 al.,	 2015).	 Although	 this	would	 indicate	 that	 Aβ	
pathology	precedes	tau	pathology	which	then	causes	disease,	both	tau	pathology	and	
Aβ	 pathology	 cause	 cognitive	 deficits	 in	 the	 absence	 of	 overt	 pathology	 of	 the	 other	





Cell	 culture	 systems	allow	 for	 the	 study	of	different	protein	 interactions	 in	an	
easily	 modifiable	 system.	 Cell	 culture	 systems	 also	 offer	 a	 unique	 opportunity	 to	
investigate	the	role	of	different	cell	types	on	the	different	aspects	of	AD.	Much	of	the	
work	looking	at	AD	in	cell	culture	systems	thus	far	has	been	done	using	rodent	primary	
cultures	 either	 from	 AD	 models	 or	 by	 adding	 exogenous	 Aβ	 or	 tau	 to	 cells	 from	 a	
control	 mouse.	 This	 work	 which	 has	 been	 performed	 by	 a	 number	 of	 labs	 over	 a	
number	 of	 years	 has	 been	 instrumental	 in	 highlighting	 the	 spread	 of	 pathogenic	
proteins	from	one	cell	to	another,	the	effects	of	Aβ	on	neurons	and	the	importance	of	
astrocytes	 in	 AD	 pathology	 (Frost	 et	 al.,	 2009;	 Garwood	 et	 al.,	 2011;	 Kayed	 and	




human	 cells	 thus	 increasing	 the	 translational	 value	 of	 the	 system	 (Takahashi	 et	 al.,	
2007).	Yagi	et	al.	created	the	first	stem	cells	from	familial	AD	patients	in	2011	and	since	
then	many	AD	 related	 lines	 have	 been	 created	 from	patients	 harbouring	 a	 variety	 of	




lines	 containing	 a	mutation	 in	 APP	 to	 show	 that	 this	mutation	 confers	 protection	 by	







cells,	 and	 the	 fact	 that	 cells	 are	 missing	 a	 major	 phenotype	 of	 the	 disease,	 protein	
aggregates.	 However	 advances	 are	 being	 made	 towards	 ameliorating	 some	 of	 these	
limitations.	 Firstly	 co-culture	 systems	 and	 organoid	 technology	 are	 becoming	 more	
popular.	Co-culture	systems	allow	 for	different	cell	 types	 to	be	cultured	 together	and	




As	 well	 as	 allowing	 for	 a	 greater	 understanding	 of	 these	 non-neuronal	 cells	 in	 AD,	
increasing	 the	 speed	 of	 neuronal	 development	 is	 very	 useful	 in	 a	 disease	 that	 is	
primarily	a	disease	of	aging.	Human	 iPSC	neurons	 take	 longer	 to	develop	 than	mouse	
primary	neurons	and	this	 is	a	disadvantage	 in	AD	research	particularly	 in	 the	study	of	
tau	 which	 is	 developmentally	 regulated	 (Goedert	 et	 al.,	 1989;	 Sposito	 et	 al.,	 2015).	
Neurons	 derived	 from	 iPSCs	 show	 a	 phenotype	 similar	 to	 that	 of	 a	 neuron	 in	 the	
developing	 embryo	 when	 only	 0N3R	 tau	 is	 produced.	 This	 prevents	 scientists	 from	














et	 al.,	 2014).	 This	 culture	 system	 also	 shows	 faster	 maturation	 of	 neurons	 when	
compared	 to	 conventional	 2D	 although	 no	 model	 system	 to	 date	 has	 produced	 tau	
tangles	 in	 the	 absence	of	 tau	mutations,	 potentially	 due	 to	 how	 long	 tangles	 take	 to	
form.	No	model	is	perfect,	however	all	have	their	place	in	answering	specific	questions	
about	 AD,	 and	 when	 used	 in	 combination	 both	 with	 other	 models	 and	 with	 post	
mortem	 tissue	 derived	 from	 patients	 and	 controls	 then	 we	 get	 ever	 closer	 to	 the	






causes	of	 synapse	dysfunction	 in	AD	are	still	not	well	understood.	Although	 it	 is	clear	
that	the	major	pathological	proteins	of	AD,	Aβ	and	tau,	are	important,	it	is	unclear	how	
these	proteins	 interact	with	each	other	and	other	risk	 factors	 for	AD	to	cause	protein	
changes	in	the	synapse	leading	to	synaptic	dysfunction.	Using	novel	mouse	and	cellular	
models	 of	 AD	 combined	with	 proteomics	 and	high-resolution	 imaging	 of	 human	post	



















of	 Clusterin,	 Aβ	 and	 ApoE	 using	 the	 high	 resolution	 imaging	 technique	 Array	



















All	 animal	 experiments	 conformed	 to	 national	 and	 institutional	 guidelines	









	 under	 the	 control	 of	 the	 PrP	 promoter,	 were	 crossed	 with	
rTg21221	mice	 (Hoover	 et	 al.,	 2010)	 which	 overexpress	 wild-type	 human	 tau	 (hTau)	




Micheva	 and	 Smith	 2007	 (Micheva	 and	 Smith,	 2007)	 were	made	 from	 the	 cortex	 of	
both	 these	 APP/PS1/hTau	 mice	 (n=5)	 and	 APP/PS1	 (n=3)	 littermates.	 This	 was	














into	 hard	 resin	which	 is	 then	 sectioned	 into	 70µm	 thick	 ribbons	 of	 serial	 sections.	 These	 are	







Tissue	 from	 the	 BA41/42	 area	 of	 the	 cortex	 was	 embedded	 as	 described	 in	
described	in	Kay	et	al.	2013	(Kay	et	al.,	2013).	In	brief	fresh	post-mortem	samples	were	
cut	 into	 small	 cortical	 blocks	 and	 fixed	 in	 4%	 paraformaldehyde.	 Samples	 were	 then	
dehydrated	 in	ascending	concentrations	of	ethanol	and	then	 incubated	with	LR	white	







0.1%	 fish	 skin	 gelatin	 and	 0.01%	 chromium	 potassium	 sulphate	 and	 allowed	 to	 dry.	
Cortical	 blocks	 from	 the	mice	 and	blocks	 containing	 BA41/42	 from	 the	 humans	were	
sectioned	onto	these	cover	slips	using	a	Jumbo	Histo	Diamond	Knife	(Diatome,	Hatfield,	
PA)	 and	 an	 EM	 UC7	 ultracut	 microtome	 (Leica	 Microsystems,	 Cambridge,	 UK).	







5	 minutes	 at	 room	 temperature.	 This	 was	 then	 removed	 and	 with	 no	 delay	 was	
replaced	with	 array	 tomography	 block	 buffer	 (0.1%	 fish	 skin	 gelatin,	 0.05%	 tween	 in	
TBS).	 Ribbons	 were	 incubated	 in	 block	 buffer	 for	 45	 minutes	 at	 room	 temperature	
before	 being	 replaced	 by	 primary	 antibody	 mix.	 Primary	 antibodies	 were	 diluted	 in	
array	 tomography	 block	 and	 ribbons	were	 incubated	 in	 primary	 antibody	 solution	 at	







tomography	block	 for	5	minutes	at	 room	 temperature	 in	 the	dark.	 The	DAPI	 solution	






Coolsnap	digital	 camera	 and	 the	AxioImager	 software	with	 array	 tomography	macros	
(Carl	 Zeiss	 Ltd.,	 Cambridge,	 UK).	 First	 a	 tilescan	 of	 the	 DAPI	 channel	 for	 the	 entire	
ribbon	was	obtained	at	a	10x	magnification.	Then	using	 the	AxioImager	 software	one	
nucleus	 was	 chosen	 and	 was	 indicated	 on	 two	 adjacent	 sections.	 For	 ribbons	 which	
contained	plaques	the	nucleus	selected	was	chosen	such	that	the	plaque	was	visible	in	
the	 image	 stack,	 for	 ribbons	were	 no	 plaque	was	 present	 the	 selection	was	 random.	
Once	the	nuclei	were	selected	a	63x	objective	was	used	to	obtain	a	single	image	in	the	
same	location	in	every	slice	of	the	ribbon.	This	process	is	graphically	explained	in	Figure	
2.1	 and	 the	 linked	 video	 (http://dx.doi.org/10.7488/ds/297).	 Two	 image	 stacks	 were	
obtained	per	ribbon.		
	
Ribbons	were	 then	 stripped	 of	 antibodies	 using	 stripping	 buffer	 (0.2M	NaOH,	
0.02%	SDS	in	dH2O)	for	15-20	minutes	with	gentle	shaking.	Ribbons	were	then	washed	
once	 in	 1x	 TBS	 for	 10	minutes	 and	 once	 in	 dH2O	 for	 5	minutes	with	 gentle	 shaking.	
Ribbons	 were	 then	 allowed	 to	 dry	 on	 a	 slide	 heater	 and	 stored	 for	 no	more	 than	 2	




Image	 stacks	were	 aligned	 using	 the	 DAPI	 channel	with	 the	 Image	 J	 program	
(Fiji)	 and	 the	mutistackreg	macro	 (Thevenaz	 et	 al.,	 1998).	 10µm	 x	 10µm	 crops	were	
selected	 from	 image	 stacks	 within	 the	 neuropil	 avoiding	 cell	 bodies,	 blood	 vessels,	
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used	 on	 all	 samples	 used	 in	 western	 blotting	 and	 proteomics	 to	 determine	 protein	
amount.	 Samples	were	 run	 along	 side	 a	 Bovine	 Serum	 Albumen	 standard	 curve	 that	
consisted	of	samples	at	2mg/ml,	1.5mg/ml,	1mg/ml,	0.75mg/ml,	0.5mg/ml,	0.25mg/ml	
and	0.125mg/ml.	Samples	were	diluted	1:5,	1:10,	or	1:25	with	diH2O	to	be	brought	into	










protein.	 The	 appropriate	 volume	 of	 protein	 sample	 was	 added	 to	 7μl	 of	 2x	 laemmli	
(Sigma-Aldrich,	St	Louis,	MO)	and	the	total	volume	was	brought	up	to	14μl	with	diH2O.	




12%	 Bis-Tris	 precast	 polyacrylamide	 15	 well	 gels	 (Invitrogen)	 using	 a	 25µL	 Hamilton	
Syringe.	 The	 proteins	 were	 then	 separated	 by	 weight	 using	 sodium	 dodecyl	 sulfate	
polyacrylamide	gel	electrophoresis	(SDS-PAGE)	for	2	hours	at	100V.	The	gels	were	run	
in	 an	 XCell	 SureLock™	 Mini-Cells	 (Invitrogen,	 Carlsbad,	 CA)	 NuPAGE	 using	
morpholineethanesulfonic	acid	SDS	running	buffer	(Invitrogen,	Carlsbad,	CA).		
	
Proteins	 were	 electro-transferred	 onto	 nitrocellulose	 membrane	 (Bio-Rad,	
Watford,	UK)	at	30V	for	1.5	hours	using	the	XCell	 II™	Blot	Module	system	(Invitrogen,	
Carlsbad,	 CA)	 in	 tris-glycine	 transfer	 buffer	 (25mM	 Tris,	 192mM	 Glycine,	 10%	
Methanol).	 Membranes	 were	 incubated	 in	 blocking	 buffer	 (10ml	 Odyssey	 blocking	
buffer	 (Li-Cor	 Biosciences,	 Lincoln,	 NE)	 diluted	 1:1	 with	 Phosphate	 Buffered	 Saline	
(PBS)(Sigma-Aldrich,	 St	 Louis,	 MO)	 for	 1	 hour	 to	 reduce	 background	 staining.	
Membranes	 were	 then	 incubated	 with	 primary	 antibodies	 diluted	 in	 blocking	 buffer	
with	added	0.1%	Tween-20	over	night	at	room	temperature	while	shaking.		
	
Primary	 antibodies	were	 removed	 and	 saved	 for	 reuse	 and	membranes	were	











DNA	 mini	 kit	 (Qiagen,	 Hilden,	 Germany)	 which	 was	 used	 as	 per	 the	 manufacturers	
instructions,	thus	all	buffers,	collection	tubes,	and	the	column	were	provided	by	Qiagen	
unless	 otherwise	 stated.	 To	 do	 this	 25mg	 of	 tissue	was	 cut	 up	 into	 small	 pieces	 and	
added	 to	 a	 1.5ml	 microcentrifuge	 tube	 and	 180µl	 of	 Buffer	 ATL	 was	 added	 to	 each	
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samples	 which	 was	 vortexed	 and	 then	 added	 to	 a	 QIAamp	Mini	 spin	 column	 placed	
inside	the	provided	2ml	collection	tube.	The	samples	were	then	centrifuged	at	6,000G	




500µl	 of	 Buffer	 AW2	was	 then	 added	 to	 the	 column	which	 was	 then	 centrifuged	 at	
17,000G	 for	 5	minutes.	 The	 column	was	 then	 placed	 into	 a	 clean	 and	 labelled	 1.5ml	
microcentrifuge	 tube	 and	 the	 collection	 tube	 and	 filtrate	 were	 discarded.	 200µl	 of	
Buffer	 AE	was	 then	 added	 to	 the	 column	 and	 incubated	 at	 room	 temperature	 for	 at	
least	1	minute.	The	column	(and	microcentrifuge	tube)	was	then	centrifuged	at	6,000G	





set	 up	 in	 20µl	 per	 reaction	which	 contained	1µM	of	primer	 and	10%	DMSO.	 For	 this	
10µl	of	2x	Master	mix	(Promega,	Madison,	WI)	was	combined	with	1µl	of	primer	stock	
(20µM	 forward	 primer,	 20µM	 reverse	 primer),	 2µl	 of	DMSO	 (Sigma-Aldrich,	 St	 Louis,	
MO),	 6µl	 ddH2O	 and	 1µl	 of	 isolated	 DNA.	 The	 forward	 primer	 was	












reaction	 tube	 along	 with	 DNA	 extracted	 from	 the	 cerebellum	 of	 human	 cases.	 PCR	 is	 run	
through	the	cycle	depicted	in	A	and	the	product	is	cut	using	the	HhaI	restriction	endonuclease	







The	 product	 from	 PCR	 was	 then	 digested	 using	 the	 restriction	 endonuclease	
HhaI	 (New	 England	 Biolabs,	 Ipswich,	 MA).	 For	 this	 0.5µl	 of	 enzyme,	 2.5µl	 of	 10x	
CutSmart	buffer	(New	England	Biolabs,	 Ipswich,	MA)	and	2µl	of	ddH2O	were	added	to	
each	PCR	reaction	tube	to	give	a	total	volume	of	25µl.	The	final	volume	contains	50	mM	
Potassium	 Acetate,	 20	mM	 Tris-acetate,	 10	mM	Magnesium	Acetate,	 and	 100	 μg/ml	





containing	 0.4%	 orange	 G,	 0.03%	 bromophenol	 blue,	 0.03%	 xylene	 cyanol	 FF,	 15%	
Ficoll®	 400,	 10mM	Tris-HCl	 (pH	 7.5)	 and	 50mM	EDTA	 (pH	 8.0)	was	 added	 to	 the	 the	
reaction	 tube.	 14µl	 of	 this	mixture	was	 then	 loaded	 onto	 precast	 15	well	Novex	 TBE	
20%	gel	 (Thermo	Fisher	 Scientific,	Waltham,	MA)	using	a	25µL	Hamilton	 Syringe.	 The	
DNA	were	 then	separated	by	 size	using	electrophoresis	 for	2	hours	at	200V.	The	gels	

















To	assess	 the	amount	of	Ab	 in	 the	human	brain	extract	 the	Ab42	(292-64501,	
Wako,	Neuss,	Germany)	and	Ab40	(294-64701,	Wako,	Neuss,	Germany)	kits	were	used	
according	 to	 the	 manufacturers	 instructions.	 The	 protocol	 is	 the	 same	 for	 both	 the	
Ab42	and	Ab40	kits	and	all	reagents	were	provided	by	Wako	unless	otherwise	stated.	
Solutions	 for	 a	 standard	 curve	 were	 made	 using	 the	 provided	 100pmol/L	 Ab40	 and	
Ab42	and	the	provided	standard	diluent.	The	standard	curve	contained	100,	50,	25,	10,	
5,	 2.5,	 and	 1	 (pmol/L)	 and	 all	 solutions	 were	 run	 in	 duplicate	 on	 the	 provided	
microplate.	 Brain	 extracts	were	diluted	1:20	using	 the	provided	 standard	diluent	 and	
were	run	in	triplicate.	100µl	of	standard	curve,	brain	extract	or	standard	diluent	(used	




incubated	 with	 100µl	 of	 HRP-conjugated	 Antibody	 at	 4°C	 for	 2	 hours	 with	 gentle	
shaking	 and	 a	 plate	 seal.	 The	 plate	 was	 washed	 again	 5	 times	 using	 200µl	 1x	 wash	

















900G	 for	 10	 minutes.	 The	 supernatant	 was	 removed	 and	 saved	 and	 the	 pellet	 was	
resuspended	 in	 300μl	 Buffer	 C	 and	 centrifuged	 at	 900G	 for	 10	 minutes.	 The	





Figure	2.3:	 Two	methods	of	 isolating	 synaptic	 fractions.	Synapses	were	 isolated	using	 serial	




The	 supernatant	was	divided	 into	 two	 fractions,	 one	 for	western	blotting	 and	
one	 for	 electron	 microscopy.	 Both	 fractions	 were	 centrifuged	 for	 20	 minutes	 at	
20,000G	 to	 yield	 the	 synaptosome	 pellet.	 The	 supernatant	 was	 removed	 and	 snap	
frozen	on	dry	ice.	The	synaptosome	pellet	for	western	blotting	was	resuspended	in	400	
μl	of	Buffer	B	(50	mmol/L	Tris	[pH	7.5],	1.5%	SDS,	and	2	mmol/L	DTT)	and	boiled	for	5	








This	 protocol	 is	 depicted	 in	 Figure	 2.3B.	 Synaptoneurosomes	 and	 crude	
homogenate	were	prepared	according	to	Tai	et	al.	(Tai	et	al.,	2012).	About	two	hundred	
milligrams	 of	 fresh-frozen	 human	 brain	 tissue	 was	 homogenized	 in	 a	 glass	 dounce	
homogenizer	with	1	mL	ice-cold	buffer	A	(25	mmol/L	HEPES	pH	7.5,	120	mmol/L	NaCl,	5	
mmol/L	KCl,	1	mmol/L	MgCl2,	and	2	mmol/L	CaCl2),	supplemented	with	2	mmol/L	DTT,	
protease	 inhibitors	 (cOmplete	 mini,	 roche,	 Basel	 Switzerland),	 and	 phosphatase	
inhibitors	(Millipore,	Billerica,	MA).	The	homogenate	was	passed	through	2	layers	of	80-





through	 a	 5-μm	 Durapor	 membrane	 filter	 (Millipore,	 Billerica,	 MA)	 to	 remove	 large	
organelles	 and	 nuclei.	 The	 Filtrate	 was	 centrifuged	 at	 1,000G	 for	 10	 minutes.	 The	
supernatant	 containing	 cytoplasmic	 proteins	 was	 removed,	 and	 the	 pellet	 was	
resuspended	in	200μl	buffer	A.	If	needed	the	resuspended	pellet	was	divided	into	three	
microcentrifuge	 tubes,	 one	 for	 electron	microscopy	 (EM),	 one	 for	western	 blots,	 and	
one	 for	 proteomics	 and	 all	 were	 centrifuged	 again	 at	 1,000G	 for	 5	 minutes.	 The	
supernatant	 was	 discarded	 and	 the	 synaptoneurosome	 pellets	 for	 western	 blot	 and	
proteomics	were	snap	frozen	on	dry	ice	and	then	transferred	to	-80°C.		
	
The	 pellet	 for	 electron	 microscopy	 was	 placed	 in	 200μl	 of	 EM	 buffer	 (4%	
Paraformaldehyde,	2.5	%	Gluteraldehyde	in	0.1M	Phosphate	Buffer).	After	48	hours	in	
EM	buffer	the	EM	pellet	was	transferred	to	0.1M	Phosphate	Buffer	(PB)	and	kept	at	4°C	
ready	 for	 EM	 embedding.	 	 The	 synaptoneurosome	 pellet	 for	 western	 blotting	 was	








Pellets	 to	be	embedded	 for	EM	were	centrifuged	at	10,000G	 for	2	minutes	 to	
compact	the	pellet	further.	Pellets	were	then	washed	twice	in	0.1M	PB	for	10	minutes	
before	being	incubated	for	30	minutes	in	1%	osmium	tetroxide	in	0.1M	PB	in	the	dark	




an	 ascending	 concentration	 of	 ethanol	 (95%,	 100%,	 100%)	 before	 being	 incubated	 in	





EM	 blocks	 were	 cut	 into	 70nm	 sections	 with	 a	 Leica	 Ultracut	 microtome	 (as	
described	for	array	tomography)	and	mounted	onto	formvar/carbon	coated	EM	grids.		
These	were	 	 imaged	on	a	 JOEL	TEM	 in	 the	Philly	Dake	Electron	microscopy	Center	at	





Synaptoneurosome	 pellets	 were	 stored	 at	 -80°C	 until	 ready	 for	 extraction.	
100µl	 of	 extraction	 buffer	 (100nM	 Tris-HCL	 pH7.6,	 4%	 (w/v)	 SDS)	 with	 protease	
inhibitors	 (cOmplete	 mini,	 roche,	 Basel,	 Switzerland)	 was	 then	 added	 to	 each	 tube	
containing	the	prep.	The	prep	was	then	mixed	by	pipetting	up	and	down	and	was	then	











Raw	 data	 from	 the	 LC/MS-MS	 was	 imported	 into	 Progenesis	 QI	 (Nonlinear	
Dynamics,	 Newcastle	 upon	 Tyne,	 UK).	 Data	 were	 aligned	 and	 peptides	 were	 filtered	
(power	 >0.7,	 p<0.05).	 Data	 sets	 were	 exported	 from	 Progenesis	 for	 subsequent	
identification	 of	 peptides	 sequences	 (94,569	 peptides)	 using	 Mascot	 Search	 Engine	
(Matrix	 Science,	 Boston,	MA).	Mascot	 -generated	 data	was	 imported	 into	 Progenesis	
for	protein	expression	comparison.	Quantification	of	protein	expression	was	only	done	
on	proteins	identified	by	two	or	more	unique	peptides.	Using	these	requirements	1,043	
proteins	 were	 detected	 across	 all	 samples.	 Proteins	 were	 considered	 significantly	
different	in	abundance	if	p<0.05	and	fold	change	was	>1.2.	p	values	were	calculated	by	






(Qiagen,	Hilden,	Germany)	 software	with	 the	help	of	 the	Wishart	 group	at	 the	Roslin	
Institute.	All	proteins	which	met	significance	cut	offs	(p	<	0.05,	fold	changes	>	1.2)	for	
each	 observation	 (control	 v	 AD,	 control	 APOE3	 v	 control	 APOE4,	 AD	 APOE3	 v	 AD	
APOE4)	were	uploaded	 into	 IPA.	Analysis	was	 set	 so	 that	 all	 experimentally	observed	
direct	 and	 indirect	 relationships	 from	 all	 data	 sources	 were	 assessed.	 These	
relationships	were	allowed	to	have	been	observed	in	all	species	and	cell	lines.	Network	






Database	 for	 Annotation,	 Visualization	 and	 Integrated	 Discovery	 (DAVID)	 was	
used	to	assess	enrichment	of	GO	terms	and	functionally	related	gene	groups	(Huang	et	
al.,	2009).	All	proteins	which	met	significance	cut	offs	(p	<	0.05,	fold	changes	>	1.2)	for	









Artificial	 cerebrospinal	 fluid	 (aCSF)	 (124mM	 NaCl,	 2.8mM	 KCl,	 1.25mM	
NaH2PO4,	25.9mM	NaHCO3)	was	made	fresh	on	day	1	of	the	protocol,	filtered	through	a	
0.2µm	filter,	and	kept	at	4°C	until	needed.	Protease	 inhibitors	 (cOmplete	mini,	 roche,	
Basel,	Switzerland)	were	added	fresh	to	10ml	of	aCSF	and	which	was	then	kept	on	ice.	
0.2g	of	brain	was	defrosted	and	homogenized	 in	1ml	of	aCSF	with	protease	 inhibitors	















pipette	 to	ensure	 the	buffer	does	not	 leak.	 The	aCSF	was	 then	discarded	and	 the	Ab	
extract	was	added	and	the	lid	secured.	The	cassette	was	placed	in	a	1L	bucket	of	aCSF	





	 Case	Number	 Diagnosis	 Sex	 ApoE	Genotype	 MRC	BBN	
AD	Pool	1	 52/12	 AD	 M	 3/4	 9505	
28/13	 AD	 F	 3/4	 15259	
19/14	 AD	 M	 4/4	 20995	
18/13	 AD	 F	 3/4	 15810	
Control	Pool	1	 14/13	 NDC	 F	 3/3	 14395	
46/13	 NDC	 M	 3/3	 18407	
35/14	 NDC	 F	 3/4	 22629	
Control	ApoE3	Pool	 34/15	 NDC	 M	 3/3	 26308	
10/15	 NDC	 F	 3/3	 24780	
38/13	 NDC	 M	 3/3	 18391	
Control	ApoE4	Pool	 46/13	 NDC	 M	 3/4	 18407	
11/15	 NDC	 M	 3/4	 24781	
54/13	 NDC	 F	 4/4	 19687	
AD	ApoE3	Pool	 02/14	 AD	 F	 3/3	 19994	
45/13	 AD	 F	 3/3	 19600	
35/13	 AD	 F	 3/3	 18798	
AD	ApoE4	Pool	 46/14	 AD	 F	 4/4	 24360	
38/14	 AD	 F	 3/4	 23394	
21/13	 AD	 F	 3/4	 15811	
28/13	 AD	 F	 3/4	 15259	
AD	Pool	2	 988	 AD	 F	 4/4	 -	
1028	 AD	 F	 3/3	 -	
970	 AD	 F	 3/4	 -	
AD	Pool	3	 1003	 AD	 F	 3/3	 -	
1636	 AD	 M	 3/3	 -	







for	 110	minutes	 at	 4C.	 Samples	were	 then	 dialyzed	 to	 remove	 small	molecules.	 Some	of	 the	




To	 ensure	 that	 Ab	 is	 the	 toxic	 element	 in	 AD	 brain	 homogenate,	 some	 brain	
homogenate	was	immunodepleted	of	Ab	using	4G8	an	antibody	against	Ab.	To	ensure	











San	 Diego,	 CA).	 For	 MID,	 PrA	 beads	 and	 8µl	 of	 pre-immune	 mouse	 serum	 (Sigma-
Aldrich,	St	Louis,	MO)	were	added	to	the	extract.	All	tubes	were	then	incubated	for	24	
hours	 at	 4°C	with	 constant	mixing.	 Tubes	 were	 then	 centrifuged	 at	 6,000	 rpm	 for	 5	
minutes.	The	supernatant	was	then	removed	and	placed	in	a	new	tube	along	with	30µl	
fresh	PrA	beads	and	either	4G8	or	sera	as	appropriate.	Tubes	were	then	incubated	for	
24	 hours	 at	 4°C	 with	 constant	 mixing.	 This	 occurred	 for	 three	 round	 of	
immunodepletion	at	which	point	the	supernatant	was	incubated	with	50µl	of	PrA	beads	
only	for	4	hours	at	4°C	with	constant	mixing.	After	a	final	centrifugation	at	6,000	rpm	
for	 5	minutes,	 the	 supernatant	was	 removed	 and	 aliquots	were	pooled	 as	 ID	 or	MID	





All	 reagents	 for	 growing	 and	 maintaining	 cells	 were	 purchased	 from	 Life	
Technologies	 (Carlsbad,CA)	 unless	 otherwise	 stated.	 Neuronal	 precursor	 cells	 (NPC)	
were	derived	from	induced	pluripotent	stem	cells	(iPSC)	made	from	a	control	individual	
by	 Dr.	 Karen	 Burr	 in	 the	 Chandran	 lab	 as	 previously	 described	 (Bilican	 et	 al.,	 2014).	
NPCs	 were	 maintained	 at	 high	 density	 in	 NPC	 media	 (DMEM/F12,	 1%	 PSF,	 1%	
Glutamax,	1%	N2,	0.1%	B27,	and	10	ng/mL	FGF2	 (PeproTech,	 London,	UK))	 and	were	
passaged	 1:2	 once	 a	 week	 using	 Acutase	 (Sigma-Aldrich,	 St	 Louis,	 MO).	 Cells	 were	













laminar	 flow	 hood	 for	 25	minutes.	 The	 coverslips	were	 the	 incubated	with	 a	 coating	
solution	 (0.01mg/ml	 Laminin	 (Sigma-Aldrich,	 St	 Louis,	 MO),	 0.02mg/ml	 Fibronectin	
(Sigma-Aldrich,	St	Louis,	MO),	1:10	matrigel	(BD	Biosciences,	Oxford,	UK)	in	DMEM/F12)	
overnight	at	4°C.	This	coating	was	then	removed	immediately	prior	to	cell	plate	down.	














To	 knock	 down	 the	 expression	 of	 Clusterin	 siRNA	 (sc-43688,	 Santa	 Cruz	
Biotechnology,	 Dallas,	 TX)	 was	 used	 and	 control	 siRNA-A	 (sc-370007,	 Santa	 Cruz	
Biotechnology,	Dallas,	TX)	was	used	as	control.	For	each	well,	3µl	of	siRNA	was	mixed	
with	 34µl	 of	 transfection	 media	 (sc-36868,	 Santa	 Cruz	 Biotechnology,	 Dallas,	 TX).	
Separately,	 2.5µl	 of	 transfection	 reagent	 (sc-29528,	 Santa	Cruz	Biotechnology,	Dallas,	
TX)	was	mixed	with	34.5	µl	of	transfection	media.	The	siRNA	mixture	was	then	added	to	





7.5	 week	 old	 neurons	 were	 removed	 from	 the	 incubator	 and	 the	media	 was	




fresh	 BDNF/GDNF	 media	 or	 human	 derived	 Ab	 in	 BDNF/GDNF	 media	 for	 48	 hours	














Fixed	 cells	were	washed	 3	 times	with	 PBS	 and	 then	 permeabilized	with	 0.5%	
triton	in	PBS	for	20	minutes	at	room	temperature.	Cells	were	then	washed	three	times	
for	5	mintues	with	PBS.	Cells	were	then	blocked	for	2	hours	at	room	temperature	with	
gentle	 shaking	 in	 5%	 normal	 goat	 serum	 and	 5%	 normal	 donkey	 serum	 in	 PBS.	 Cells	
were	 then	 incubated	with	 primary	 antibodies	which	were	 diluted	 in	 1%	 normal	 goat	
serum	 in	 PBS	 at	 4°C	over	 night	with	 gentle	 shaking.	 Primary	 antibodies	 and	dilutions	
used	 were	 1:1000	 guinea	 pig	 anti-MAP2	 (188	 004	 synaptic	 systems,	 Goettingen,	





Cells	 were	 then	 washed	 3	 times	 with	 PBS	 before	 being	 incubated	 with	
secondary	 antibodies	 diluted	 in	 1%	 normal	 goat	 serum	 in	 PBS	 for	 2	 hours	 at	 room	
temperature	 in	 the	 dark	with	 gentle	 shaking.	 Secondaries	 used	were	 goat	 anti-rabbit	




for	10	minutes	at	 room	temperature	 in	 the	dark	with	gentle	shaking.	Cells	were	 then	
washed	 3	 times	 with	 PBS	 and	 cover	 slips	 were	 removed	 from	 the	 culture	 plate	 and	
mounted	 using	 Immunomount	 (Thermo	 Fisher	 Scientific,	 Waltham,	 MA)	 onto	
microscope	slides.		
	
Cells	 were	 imaged	 using	 a	 Leica	 DM6	 CS	 upright	 microscope	 with	 a	 TCS	 SP8	
confocal	platform.	5-10	z-stacks	per	coverslip	were	obtained	at	63x	using	a	250µm	step.	





image	 using	 the	 maximum	 intensity	 of	 each	 pixel	 using	 custom	 image	 J	 macros	
(appendix	4).	Background	subtraction	was	 then	performed	 in	 image	J	using	a	30	pixel	
rolling	 ball	 and	 then	 images	 were	 processed	 using	 custom	 cell	 profiler	 pipelines	
(Carpenter	et	al.,	2006;	Nieland	et	al.,	2014)(appendix	4).	CellProfiler	was	used	to	select	
MAP2	 positive	 dendrites	 but	 exclude	 cell	 bodies.	 The	 pipeline	 then	when	 on	 to	 find	
synaptic	 puncta	 which	 co-localized	 with	 MAP2	 using	 a	 local	 maxima	 and	 primary	
characteristic	 selection	 of	 the	 synaptic	 channels.	 The	 output	 of	 this	 was	 an	 excel	
spreadsheet	where	the	number	of	synaptic	puncta	per	dendrite	and	the	 length	of	the	
dendrite	were	outputs.	Excel	was	then	used	to	calculate	the	number	of	synaptic	puncta	





Different	 plate	 downs	 had	 slightly	 different	 cell	 densities	 and	 thus	 slightly	












The	 vast	 majority	 of	 AD	 cases	 have	 no	 known	 genetic	 cause,	 however	 the	
discovery	 that	mutations	 in	 the	 proteins	 responsible	 for	 Ab	 production,	 namely	 APP,	
PS1,	 and	 PS2,	 are	 responsible	 for	 rare	 genetic	 AD	 gave	 rise	 to	 the	 Ab	 cascade	
hypothesis.	 This	 hypothesis	 posits	 that	 Ab	 is	 responsible	 for	 the	 initiation	 of	 disease	
and	 that	 all	 other	 pathologies	 including	 the	 glial,	 neuronal,	 and	 tau	 related	
neuropathological	hallmarks	 follow	on	 from	Ab	deposition	 (Hardy	and	Higgins,	1992).	
The	Ab	hypothesis	is	well	supported	by	genetic	evidence	as	sporadic	cases	of	AD	have	
the	 same	 neuropathological	 hallmarks	 as	 familial	 forms	 of	 the	 disease	 and	 it	 is	 this	
hypothesis	that	many	of	our	animal	models	of	AD	are	based	on,	with	mutated	human	
APP,	PS1,	or	both	knocked	into	various	mouse	lines.	However,	these	mouse	models	do	
not	 recapitulate	 all	 of	 the	 pathological	 features	 of	 AD	 especially	 the	NFTs	 associated	
with	tau	or	the	gross	neuron	loss	seen	in	AD.	Mutations	in	tau	that	cause	NFTs	in	mice	
are	causative	of	FTD	in	humans	rather	than	AD	and	yet	NFTs	correlate	better	with	the	
cognitive	 decline	 seen	 in	 AD	 cases	 (Hutton,	 2000;	 Ingelsson	 et	 al.,	 2004).	 However	
neither	 tau	nor	Ab	 pathology	 correlate	as	well	with	 cognitive	decline	as	 synaptic	 loss	
although	 mouse	 lines	 expressing	 either	 fAD	 mutations	 or	 tau	 mutations	 both	 show	
synapse	 loss	 (Koffie	et	al.,	 2009;	 Lasagna-Reeves	et	al.,	 2011).	 These	 two	pathologies	









There	 is	 strong	 evidence	 that	 tau	 is	 necessary	 for	 Ab	 mediated	 synapse	 loss	 and	
memory	 deficits	 and	 reducing	 tau	 in	 an	 fAD	mouse	model	 protects	 against	 synaptic	
pathology	and	 cognitive	 impairment(Roberson	et	al.,	 2007).	 Equally	 there	 is	 evidence	
that	 Ab	 pathology	 affects	 tau	 distribution	 and	 pathology	 in	 both	 humans	 and	 mice	
(Pooler	 et	 al.,	 2015;	 Sepulcre	 et	 al.,	 2016).	 This	 novel	model	was	 used	 to	 assess	 the	
impact	of	wild	 type	human	 tau	on	Ab	pathology	and	 the	effect	of	Ab	on	non-mutant	
tau.	
	
	This	 chapter	 is	 made	 up	 of	 a	 published	 paper	 (Jackson	 et	 al.,	 2016)	 and	my	
contribution	involved	the	data	collection	and	analysis	of	synapses	by	array	tomography	
(Figures	 5	 and	 6).	 I	 also	 contributed	 to	 Figure	 3	 by	 increasing	 the	 n	 for	 the	 neurite	
curvature	experiments	and	performed	the	western	blots	for	Figure	4.	All	other	data	was	

























in	 the	paper	 tau	 is	known	to	be	necessary	 for	much	of	 the	Ab	pathology	 found	 in	AD	
models	 and	 thus	 is	 it	 surprising	 that	 an	 increase	 in	 tau	 would	 not	 have	 an	 effect	
(Roberson	et	al.,	2007,	2011;	Shipton	et	al.,	2011).	This	 lack	of	exacerbation	could	be	
due	 in	 part	 to	 a	 ceiling	 effect	 of	 mouse	 tau	 where	 by	 the	 amount	 of	 tau	 found	
endogenously	in	the	mouse	is	sufficient	to	cause	neuron	and	synapse	loss.	It	is	possible	
that	while	 tau	 is	necessary	 for	Ab	mediated	 synapse	 loss	an	 increase	 in	 tau	does	not	
affect	 the	 number	 of	 Ab	 oligomers	 present	 at	 the	 synapse,	 potentially	 because	 any	
extra	oligomers	made	are	 sequestered	 into	dense	 core	and	 reasonably	 inert	plaques,	
hence	 the	 increase	 in	 ThioS+	 plaque	 size.	 The	 lack	 of	 tangles	 or	 increased	 tau	
hyperphosphorylation	seen	in	this	model	indicates	that	even	in	the	presence	of	human	
tau	the	effect	of	Ab	on	tau	in	a	mouse	is	different	from	that	seen	in	a	human	(Bilousova	





4 Investigating	 the	 proteomics	 of	 synapses	 in	




Of	the	main	pathological	 features	of	AD,	synapse	 loss	 is	 the	greatest	correlate	
of	the	clinical	cognitive	decline	that	is	the	phenotype	of	the	disease	(Terry	et	al.,	1991;	
Koffie	et	 al.,	 2011).	 It	 is	 this	 loss	 of	 synapses	 that	 is	 thought	 to	 underlie	most	 of	 the	
memory	 deficits	 that	 occur	 in	 AD.	Much	 effort	 has	 gone	 into	 looking	 at	 the	 protein	
changes	 that	accompany	AD	 in	 the	brain	 in	general	but	 thus	 far	 study	of	 the	synapse	




of	AD	on	 synaptic	 dysfunction	 and	degradation	 is	 needed.	 Chapter	 3	 also	highlighted	












(Schiepers	 et	 al.,	 2012).	 The	 effects	 of	APOE	 genotype	 on	 the	 synaptic	 proteome	 of	




























Target	 Host	 Dilution	 Catalogue	number	
PSD95	 Rabbit	 1:1000	 D27E11	
Synapsin	 Rabbit	 1:10000	 AB1543	
Beta-actin	 Mouse	 1:1000	 ab8226	
Histone	H3	 Rabbit	 1:1000	 ab1791	
Synaptophysin	 Mouse	 1:5000	 ab8049	
NMDAR2B	 Mouse	 1:500	 610416	
GAPDH	 Mouse	 1:1000	 ab8245	
GAPDH	 Rabbit	 1:1000	 ab9485	
Flotillin	1	 Rabbit	 1:1000	 A303-422A	
LRP1	 Rabbit	 1:1000	 Bs-2677R	
Clusterin	 Rabbit	 1:1000	 Sc-8354	






Synaptoneurosome	 prepared	 by	 both	 the	 filtration	 and	 the	 centrifugation	





is	 quicker	 which	 reduces	 enzymatic	 degradation	 of	 the	 synaptic	 proteins.	 EM	 also	
showed	that	the	filtration	method	resulted	in	higher	preservation	of	both	the	pre	and	
the	 postsynaptic	 densities	 as	 opposed	 to	 the	 centrifugation	 method	 which	 showed	
greater	 presynaptic	 isolation	 (Figure	 4.2B).	 This	 was	 expected,	 as	 the	 centrifugation	
method	 is	 a	 synaptosome	 preparation	 which	 are	 known	 to	 be	 preferentially	
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Figure	4.2:	A	comparison	of	 two	methods	of	 isolating	 the	synaptic	 fraction.	A)	The	purity	of	
the	 synaptic	 fraction	 (pellet,	 P)	 was	 compared	 to	 the	 crude	 homogenate	 (H)	 using	 western	
blotting	 and	EM.	 	Both	methods	 show	exclusion	of	nuclear	material	 (histone)	 from	 the	pellet	
and	 enrichment	 of	 the	 pre-synaptic	 proteins	 (synapsin)	 and	 post-synaptic	 proteins	 (PSD95).	
Beta-actin	was	using	as	a	 loading	control.	B)	EM	images	of	the	synaptoneurosome	preps	from	








were	 probed	 for	 PSD95,	 synaptophysin,	 histone	 and	 GAPDH	 which	 was	 used	 as	 a	 loading	
control.	 (B)	A	 graphical	 representation	of	 PSD95	and	Synaptophysin	normalized	 to	GAPDH.	 In	







Protein	 degradation	 was	 assessed	 using	 the	 “HUSPIR”	 ratio	 or	 degradation	
index	 (Bayés	et	 al.,	 2014).	 To	 find	 this	 value,	 synaptoneurosmes	 run	on	western	 blot	
were	probed	using	an	antibody	against	NMDAR2B	which	recognizes	two	bands,	the	full	
length	 protein	 at	 170	 kDa	 and	 a	 degradation	 product	 at	 150kDa	 (Figure	 4.4).	 This	
degradation	product	only	occurs	post-mortem	as	it	is	not	found	in	autopsy	tissue	thus	
comparing	 these	 two	 bands	 is	 a	 good	 indication	 of	 post	 mortem	 synaptic	 protein	
degradation.	 The	 degradation	 index	 was	 found	 to	 significantly	 correlate	 to	 the	 RNA	
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integrity	 number	 (p=0.009,	 R
2








Figure	4.4:	A	 sample	degradation	blot	and	graphical	 representation	of	 the	HUSPIR	 ratio.	 (A)	
Each	synaptoneurosome	prep	was	probed	for	NMDAR2B.	Boxes	indicate	what	was	taken	to	be	
band	1	at	~170kDa	and	band	2	at	~150kDa.	(B)	A	graphical	representation	of	the	Band	1/Band	2	
ratio	 from	 this	blot	 indicating	 the	 spread	of	 ratios	and	 thus	 the	varied	extent	of	degradation.	
Sample	 SD038/13	was	 considered	 to	 be	 below	 the	 cut	 off	 value	 of	 1	 and	was	 therefore	 not	
included	in	proteomics.	
	
Protein	 degradation	 was	 assessed	 using	 the	 degradation	 index,	 7	 out	 of	 35	










Table	 4.2:	 Human	 cases	 from	 the	 Edinburgh	 sudden	 brain	 bank	
prepared	for	proteomics.		
	 Condition	 Case	No	 MRC	
BBN	
Gender	 Age	 PMI	 pH	 RIN	 Degradation	
index	
	 NDC	 SD042/14	 24219	 Male	 63	 76	 5.9	 3.5	 0.187	
	 AD	 SD050/12	 9503	 Male	 61	 38	 	 4.1	 0.459	
	 AD	 SD039/13	 19602	 Male	 86	 21	 6	 4.1	 0.607	
	 AD	 SD015/13	 15813	 Male	 92	 25	 6.3	 4.5	 0.608	
	 AD	 SD052/12	 9505	 Male	 81	 34	 	 3.5	 0.740	
	 AD	 SD032/14	 22626	 Female	 81	 60	 6.5	 3.4	 0.858	
	 NDC	 SD038/13	 18391	 Male	 58	 49	 5.9	 4.9	 0.874	
	 AD	 SD019/14	 20995	 Male	 60	 86	 5.9	 4.2	 1.043	
*	 AD	 SD003/13	 10591	 Male	 86	 76	 	 5.8	 1.400	
*	 AD	 SD026/13	 15258	 Male	 65	 80	 6.1	 3.9	 1.410	
	 NDC	 SD022/14	 22612	 Male	 61	 70	 6.1	 4.6	 1.617	
	 AD	 SD038/14	 23394	 Female	 88	 59	 6.3	 5.2	 1.712	
	 AD	 SD018/13	 15810	 Female	 73	 96	 6.2	 4.3	 1.870	
*	 AD	 SD028/13	 15259	 Female	 87	 28	 6.1	 3.2	 2.030	
*	 AD	 SD056/14	 24527	 Male	 81	 74	 6.1	 6.3	 2.047	
*	 AD	 SD055/14	 24526	 Male	 79	 65	 6.05	 5.7	 2.176	
	 NDC	 SD035/14	 22629	 Female	 59	 53	 6.3	 5.6	 2.191	
	 NDC	 SD029/13	 15809	 Male	 58	 90	 5.9	 5.1	 2.194	
	 NDC	 SD006/14	 20593	 Male	 60	 52	 6	 5.6	 2.302	
	 NDC	 SD046/13	 18407	 Male	 62	 41	 6.1	 4.5	 2.335	
*	 AD	 SD062/13	 19595	 Male	 87	 58	 6.5	 4.5	 2.466	
*	 NDC	 SD007/14	 20120	 Male	 53	 97	 6.4	 4.9	 3.007	
*	 AD	 SD002/14	 19994	 Female	 87	 89	 5.9	 5	 3.375	
*	 NDC	 SD003/14	 20122	 Male	 59	 74	 6.1	 6.1	 3.591	
	 NDC	 SD023/13	 15221	 Male	 53	 114	 6.1	 5.4	 3.753	
*	 NDC	 SD032/13	 16425	 Male	 61	 99	 6.2	 5.8	 3.944	
*	 NDC	 SD016/11	 2555	 Male	 74	 66	 6.3	 5	 4.041	
	 NDC	 SD036/12	 4174	 Male	 75	 78	 6.43	 5.1	 4.554	
*	 NDC	 SD014/13	 14395	 Female	 74	 41	 6.3	 5.6	 4.881	
*	 AD	 SD021/13	 15811	 Female	 81	 41	 6.3	 3.8	 5.104	








Table	 4.3:	 Individual	 and	 pooled	 samples	 that	 were	 sent	 for	
Proteomics	
	 Non-Demented	Controls	 AD	






SD051/14	 SD016/11	 SD029/14	 SD021/13	
SD014/13	 SD032/13	 SD062/13	 SD055/14	
SD003/14	 SD007/14	 SD056/14	 SD028/13	




	 SD035/14	 SD02/14	 SD003/13	
	 SD006/14	 	 SD019/14	
	 SD029/13	 	 SD038/14	
Number	of	total	
samples	in	that	group	
4	 7	 5	 7	
Average	age	of	group	 61.75	 59.71	 84.4	 79.42	







and	 biological	 annotation	 of	 large	 lists	 of	 genes	 (Huang	et	 al.,	 2008,	 2009).	 DAVID	 is	
particularly	 powerful	 at	 identifying	 enriched	 gene	ontology	 (GO)	 terms	 and	biological	
themes,	 which	 it	 clusters	 to	 reduce	 redundancy.	 The	 synapse	 cluster	 was	 heavily	
enriched	with	an	enrichment	score	of	11.48,	as	was	 the	mitochondria	cluster	with	an	







found	more	abundantly	 in	AD	and	81	 found	 to	be	 less	abundant	 (Table	4.4).	Minimal	
	 102	
protein	 changes	 (41	 proteins)	 were	 found	 when	 comparing	 APOE4	 NDC	 with	 APOE3	
NDC	(Table	4.5).	However,	when	comparing	APOE4	AD	cases	with	APOE3	AD	cases	121	





Gene	name	 Protein	name	 Fold	Change	 p-value		
PIP	 prolactin-induced	protein	 8.95	 0.00022	
SBSN	 suprabasin	 6.82	 0.00352	
H1F0	 H1	histone	family,	member	0	 5.97	 0.00004	
AZGP1	 alpha-2-glycoprotein	1,	zinc-binding	 4.97	 0.00488	
IGH	 immunoglobulin	heavy	locus	 3.54	 0.00156	
FLG2	 filaggrin	family	member	2	 3.51	 0.00234	
CALML5	 calmodulin-like	5	 3.31	 0.00278	
HSPB1	 heat	shock	27kDa	protein	1	 2.68	 0.00000	
C4A/C4B	 complement	component	4B	(Chido	blood	group)	 2.57	 0.00003	
APP	 amyloid	beta	(A4)	precursor	protein	 2.37	 0.00004	
IGKC	 immunoglobulin	kappa	constant	 2.36	 0.00733	
dkk3	 dickkopf	WNT	signaling	pathway	inhibitor	3	 2.32	 0.00001	
ADGRG1	 adhesion	G	protein-coupled	receptor	G1	 2.28	 0.00474	
RABGAP1	 RAB	GTPase	activating	protein	1	 2.23	 0.01140	
FABP7	 fatty	acid	binding	protein	7,	brain	 2.13	 0.01610	
RAB27B	 RAB27B,	member	RAS	oncogene	family	 2.04	 0.01690	
IGLC2	 immunoglobulin	lambda	constant	2	(Kern-Oz-	marker)	 2.03	 0.00565	
PAFAH1B3	 platelet-activating	factor	acetylhydrolase	1b,	catalytic	subunit	3	(29kDa)	 1.82	 0.00011	
ANXA2	 annexin	A2	 1.77	 0.00639	
ALDH1L1	 aldehyde	dehydrogenase	1	family,	member	L1	 1.67	 0.00004	
ATP5J	 ATP	synthase,	H+	transporting,	mitochondrial	Fo	complex,	subunit	F6	 1.66	 0.00369	
MACROD1	 MACRO	domain	containing	1	 1.66	 0.00124	
ILF2	 interleukin	enhancer	binding	factor	2	 1.65	 0.00096	
CLU	 clusterin	 1.63	 0.00001	
CA1	 carbonic	anhydrase	I	 1.62	 0.04618	
FLOT2	 flotillin	2	 1.59	 0.00009	
VAT1L	 vesicle	amine	transport	1-like	 1.58	 0.00608	
NPTX1	 neuronal	pentraxin	I	 1.57	 0.00275	
	 104	
CASP14	 caspase	14,	apoptosis-related	cysteine	peptidase	 1.56	 0.03790	
NANS	 N-acetylneuraminic	acid	synthase	 1.55	 0.00007	
PEA15	 phosphoprotein	enriched	in	astrocytes	15	 1.54	 0.00816	
PHPT1	 phosphohistidine	phosphatase	1	 1.53	 0.01768	
PLSCR4	 phospholipid	scramblase	4	 1.50	 0.00003	
CPE	 carboxypeptidase	E	 1.50	 0.00472	
LGI4	 leucine-rich	repeat	LGI	family,	member	4	 1.49	 0.00149	
PCSK1N	 proprotein	convertase	subtilisin/kexin	type	1	inhibitor	 1.49	 0.00294	
ANXA1	 annexin	A1	 1.45	 0.00580	
FLOT1	 flotillin	1	 1.45	 0.00116	
DCLK2	 doublecortin-like	kinase	2	 1.45	 0.00239	
SLC32A1	 solute	carrier	family	32	(GABA	vesicular	transporter),	member	1	 1.43	 0.02741	
CAPG	 capping	protein	(actin	filament),	gelsolin-like	 1.42	 0.01288	
S100A1	 S100	calcium	binding	protein	A1	 1.41	 0.04823	
NCDN	 neurochondrin	 1.41	 0.00071	
CTTN	 cortactin	 1.40	 0.02895	
CTSD	 cathepsin	D	 1.40	 0.00058	
PDE1B	 phosphodiesterase	1B,	calmodulin-dependent	 1.40	 0.00860	
EIF5	 eukaryotic	translation	initiation	factor	5	 1.40	 0.00272	
MLC1	 megalencephalic	leukoencephalopathy	with	subcortical	cysts	1	 1.38	 0.03260	
UBA1	 ubiquitin-like	modifier	activating	enzyme	1	 1.38	 0.01367	
SLC1A3	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	3	 1.37	 0.00591	
OLA1	 Obg-like	ATPase	1	 1.37	 0.02076	
SNTA1	 syntrophin,	alpha	1	 1.37	 0.04158	
PDPK1	 3-phosphoinositide	dependent	protein	kinase	1	 1.35	 0.01878	
HLA-A	 major	histocompatibility	complex,	class	I,	A	 1.34	 0.02596	
PHYHIP	 phytanoyl-CoA	2-hydroxylase	interacting	protein	 1.34	 0.00075	
RAPGEF2	 Rap	guanine	nucleotide	exchange	factor	(GEF)	2	 1.34	 0.04835	
SELENBP1	 selenium	binding	protein	1	 1.33	 0.00091	
PLCD1	 phospholipase	C,	delta	1	 1.32	 0.02837	
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AK1	 adenylate	kinase	1	 1.30	 0.00134	
NAGK	 N-acetylglucosamine	kinase	 1.30	 0.00220	
PSMB4	 proteasome	(prosome,	macropain)	subunit,	beta	type,	4	 1.29	 0.02370	
PDXK	 pyridoxal	(pyridoxine,	vitamin	B6)	kinase	 1.29	 0.00070	
OTUB1	 OTU	deubiquitinase,	ubiquitin	aldehyde	binding	1	 1.29	 0.02064	
GGA3	 golgi-associated,	gamma	adaptin	ear	containing,	ARF	binding	protein	3	 1.29	 0.01195	
NDRG4	 NDRG	family	member	4	 1.29	 0.02482	
GPX1	 glutathione	peroxidase	1	 1.28	 0.04337	
ATP8A1	 ATPase,	aminophospholipid	transporter	(APLT),	class	I,	type	8A,	member	1	 1.28	 0.03207	
RANBP1	 RAN	binding	protein	1	 1.28	 0.03080	
PBXIP1	 pre-B-cell	leukemia	homeobox	interacting	protein	1	 1.27	 0.01359	
FHL1	 four	and	a	half	LIM	domains	1	 1.26	 0.00815	
PYGB	 phosphorylase,	glycogen;	brain	 1.26	 0.00335	
NDUFS6	 NADH	dehydrogenase	(ubiquinone)	Fe-S	protein	6,	13kDa	(NADH-coenzyme	Q	reductase)	 1.26	 0.01220	
L1CAM	 L1	cell	adhesion	molecule	 1.26	 0.04968	
SIRT3	 sirtuin	3	 1.25	 0.04316	
WDR1	 WD	repeat	domain	1	 1.25	 0.02335	
KPNB1	 karyopherin	(importin)	beta	1	 1.25	 0.00024	
PRKAA2	 protein	kinase,	AMP-activated,	alpha	2	catalytic	subunit	 1.25	 0.01254	
MTHFD1	 methylenetetrahydrofolate	dehydrogenase	(NADP+	dependent)	1	 1.24	 0.01311	
PSAP	 prosaposin	 1.24	 0.00110	
ADD3	 adducin	3	(gamma)	 1.24	 0.00443	
ITGAV	 integrin,	alpha	V	 1.24	 0.01427	
PRDX5	 peroxiredoxin	5	 1.23	 0.00256	
PLEC	 plectin	 1.23	 0.00345	
FARSB	 phenylalanyl-tRNA	synthetase,	beta	subunit	 1.23	 0.00360	
UCHL1	 ubiquitin	carboxyl-terminal	esterase	L1	(ubiquitin	thiolesterase)	 1.23	 0.04856	
LRP1	 low	density	lipoprotein	receptor-related	protein	1	 1.23	 0.01797	
FAM213A	 family	with	sequence	similarity	213,	member	A	 1.22	 0.03002	
FASN	 fatty	acid	synthase	 1.21	 0.04989	
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HNRNPK	 heterogeneous	nuclear	ribonucleoprotein	K	 1.21	 0.00247	
PSD3	 pleckstrin	and	Sec7	domain	containing	3	 1.21	 0.01928	
PGM1	 phosphoglucomutase	1	 1.21	 0.02478	
MTX3	 metaxin	3	 1.20	 0.01317	
Sept7	 septin	7	 -1.21	 0.02548	
MCCC2	 methylcrotonoyl-CoA	carboxylase	2	(beta)	 -1.21	 0.04101	
TAGLN3	 transgelin	3	 -1.23	 0.02569	
PALM	 paralemmin	 -1.23	 0.01377	
IARS2	 isoleucyl-tRNA	synthetase	2,	mitochondrial	 -1.23	 0.02219	
CHMP4B	 charged	multivesicular	body	protein	4B	 -1.24	 0.01550	
GSS	 glutathione	synthetase	 -1.24	 0.01008	
NDUFS8	 NADH	dehydrogenase	(ubiquinone)	Fe-S	protein	8,	23kDa	(NADH-coenzyme	Q	reductase)	 -1.25	 0.02927	
STX7	 syntaxin	7	 -1.25	 0.01180	
SNAP25	 synaptosomal-associated	protein,	25kDa	 -1.25	 0.00298	
SEPT2	 septin	2	 -1.26	 0.02808	
NDUFB7	 NADH	dehydrogenase	(ubiquinone)	1	beta	subcomplex,	7,	18kDa	 -1.26	 0.03881	
RAC1	 ras-related	C3	botulinum	toxin	substrate	1	(rho	family,	small	GTP	binding	protein	Rac1)	 -1.27	 0.04528	
RUFY3	 RUN	and	FYVE	domain	containing	3	 -1.28	 0.01262	
CHCHD6	 coiled-coil-helix-coiled-coil-helix	domain	containing	6	 -1.28	 0.01852	
PDHX	 pyruvate	dehydrogenase	complex,	component	X	 -1.29	 0.02459	
GNG12	 guanine	nucleotide	binding	protein	(G	protein),	gamma	12	 -1.29	 0.04449	
LRPPRC	 leucine-rich	pentatricopeptide	repeat	containing	 -1.30	 0.00016	
SLC25A22	 solute	carrier	family	25	(mitochondrial	carrier:	glutamate),	member	22	 -1.30	 0.00014	
ADRM1	 adhesion	regulating	molecule	1	 -1.31	 0.00024	
MAP6	 microtubule-associated	protein	6	 -1.31	 0.01023	
FSCN1	 fascin	actin-bundling	protein	1	 -1.31	 0.03173	
MARCKS	 myristoylated	alanine-rich	protein	kinase	C	substrate	 -1.31	 0.00884	
FIS1	 fission	1	(mitochondrial	outer	membrane)	homolog	(S.	cerevisiae)	 -1.32	 0.00383	
ACADSB	 acyl-CoA	dehydrogenase,	short/branched	chain	 -1.33	 0.04815	
CYCS	 cytochrome	c,	somatic	 -1.33	 0.00507	
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HADHB	 hydroxyacyl-CoA	dehydrogenase/3-ketoacyl-CoA	thiolase/enoyl-CoA	hydratase,	beta	subunit	 -1.33	 0.03733	
DYNLRB1	 dynein,	light	chain,	roadblock-type	1	 -1.33	 0.03712	
LASP1	 LIM	and	SH3	protein	1	 -1.34	 0.04769	
CDC42	 cell	division	cycle	42	 -1.35	 0.04132	
SYNPO	 synaptopodin	 -1.36	 0.00293	
FAM49B	 family	with	sequence	similarity	49,	member	B	 -1.36	 0.01172	
GPM6B	 glycoprotein	M6B	 -1.36	 0.02208	
QDPR	 quinoid	dihydropteridine	reductase	 -1.36	 0.02972	
IDH1	 isocitrate	dehydrogenase	1	(NADP+),	soluble	 -1.38	 0.04546	
CCBL2	 cysteine	conjugate-beta	lyase	2	 -1.38	 0.04868	
NDUFA7	 NADH	dehydrogenase	(ubiquinone)	1	alpha	subcomplex,	7,	14.5kDa	 -1.41	 0.01143	
ADSS	 adenylosuccinate	synthase	 -1.43	 0.04470	
ATP5L	 ATP	synthase,	H+	transporting,	mitochondrial	Fo	complex,	subunit	G	 -1.44	 0.00657	
RPL11	 ribosomal	protein	L11	 -1.46	 0.02048	
TPP2	 tripeptidyl	peptidase	II	 -1.47	 0.01334	
DPYSL5	 dihydropyrimidinase-like	5	 -1.48	 0.02756	
IVD	 isovaleryl-CoA	dehydrogenase	 -1.49	 0.00398	
DYNC1LI2	 dynein,	cytoplasmic	1,	light	intermediate	chain	2	 -1.50	 0.00056	
PLCL1	 phospholipase	C-like	1	 -1.51	 0.04570	
RPL8	 ribosomal	protein	L8	 -1.52	 0.00834	
OMG	 oligodendrocyte	myelin	glycoprotein	 -1.53	 0.04964	
TXNDC5	 thioredoxin	domain	containing	5	(endoplasmic	reticulum)	 -1.57	 0.02718	
DYNC1I2	 dynein,	cytoplasmic	1,	intermediate	chain	2	 -1.60	 0.00269	
MARCKSL1	 MARCKS-like	1	 -1.61	 0.01702	
MYO1D	 myosin	ID	 -1.61	 0.02957	
GNG7	 guanine	nucleotide	binding	protein	(G	protein),	gamma	7	 -1.65	 0.00659	
JAM2	 junctional	adhesion	molecule	2	 -1.67	 0.00000	
MAP4	 microtubule-associated	protein	4	 -1.73	 0.00158	
GLTP	 glycolipid	transfer	protein	 -1.74	 0.02757	
FMNL2	 formin-like	2	 -1.76	 0.01918	
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GPD1	 glycerol-3-phosphate	dehydrogenase	1	(soluble)	 -1.77	 0.04129	
SEPT10	 septin	10	 -1.79	 0.02979	
MYADM	 myeloid-associated	differentiation	marker	 -1.81	 0.04790	
CADM4	 cell	adhesion	molecule	4	 -1.87	 0.01451	
ADAM10	 ADAM	metallopeptidase	domain	10	 -1.94	 0.02719	
SLC12A2	 solute	carrier	family	12	(sodium/potassium/chloride	transporter),	member	2	 -1.96	 0.01194	
OPALIN	 oligodendrocytic	myelin	paranodal	and	inner	loop	protein	 -1.97	 0.00886	
ENPP6	 ectonucleotide	pyrophosphatase/phosphodiesterase	6	 -1.98	 0.04195	
CDC42EP1	 CDC42	effector	protein	(Rho	GTPase	binding)	1	 -2.00	 0.01730	
CNP	 2',3'-cyclic	nucleotide	3'	phosphodiesterase	 -2.01	 0.03573	
PITRM1	 pitrilysin	metallopeptidase	1	 -2.06	 0.02288	
SLC44A1	 solute	carrier	family	44	(choline	transporter),	member	1	 -2.06	 0.04131	
MOG	 myelin	oligodendrocyte	glycoprotein	 -2.10	 0.02783	
ERMN	 ermin,	ERM-like	protein	 -2.19	 0.00477	
JAM3	 junctional	adhesion	molecule	3	 -2.21	 0.01504	
INF2	 inverted	formin,	FH2	and	WH2	domain	containing	 -2.21	 0.01183	
GLIPR2	 GLI	pathogenesis-related	2	 -2.28	 0.01709	
SIRT2	 sirtuin	2	 -2.35	 0.01492	
RHOG	 ras	homolog	family	member	G	 -2.39	 0.00969	
CA14	 carbonic	anhydrase	XIV	 -2.52	 0.01413	
CLDN11	 claudin	11	 -2.52	 0.01552	
PMP2	 peripheral	myelin	protein	2	 -2.52	 0.02069	
MAG	 myelin	associated	glycoprotein	 -2.54	 0.01206	
MVP	 major	vault	protein	 -2.61	 0.00537	





Gene	Name	 Protein	Name	 Fold	Change	 p-value	
C4A/C4B	 complement	component	4B	 2.00	 0.00003		
PITRM1	 pitrilysin	metallopeptidase	1	 1.85	 0.02288		
CASP14	 caspase	14,	apoptosis-related	cysteine	peptidase	 1.76	 0.03790		
PMP2	 peripheral	myelin	protein	2	 1.41	 0.02069		
HLA-A	 major	histocompatibility	complex,	class	I,	A	 1.40	 0.02596		
STOM	 stomatin	 1.39	 0.01512		
PSAP	 prosaposin	 1.38	 0.00110		
FLOT2	 flotillin	2	 1.37	 0.00009		
GPM6B	 glycoprotein	M6B	 1.35	 0.02208		
CPE	 carboxypeptidase	E	 1.35	 0.00472		
RPL8	 ribosomal	protein	L8	 1.32	 0.00834		
GPD2	 glycerol-3-phosphate	dehydrogenase	2	(mitochondrial)	 1.31	 0.02658		
CYB5R1	 cytochrome	b5	reductase	1	 1.28	 0.00392		
DKK3	 dickkopf	WNT	signaling	pathway	inhibitor	3	 1.27	 0.00001		
APOE	 apolipoprotein	E	 1.26	 0.02077		
APP	 amyloid	beta	(A4)	precursor	protein	 1.24	 0.00004		
LGI4	 leucine-rich	repeat	LGI	family,	member	4	 1.23	 0.00149		
IGH	 immunoglobulin	heavy	locus	 1.23	 0.00156		
ERP29	 endoplasmic	reticulum	protein	29	 1.22	 0.02294		
ENPP6	 ectonucleotide	pyrophosphatase/phosphodiesterase	6	 1.21	 0.04195		
MYO1D	 myosin	ID	 -1.20	 0.02957		
CA1	 carbonic	anhydrase	I	 -1.20	 0.04618		
PLCL1	 phospholipase	C-like	1	 -1.21	 0.04570		
ARPC4-TTLL3	 ARPC4-TTLL3	readthrough	 -1.21	 0.04241		
MCCC2	 methylcrotonoyl-CoA	carboxylase	2	(beta)	 -1.22	 0.04101		
AKR1A1	 aldo-keto	reductase	family	1,	member	A1	(aldehyde	reductase)	 -1.22	 0.00204		
ATIC	 5-aminoimidazole-4-carboxamide	ribonucleotide	formyltransferase/IMP	cyclohydrolase	 -1.24	 0.01882		
CA14	 carbonic	anhydrase	XIV	 -1.25	 0.01413		
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LASP1	 LIM	and	SH3	protein	1	 -1.28	 0.04769		
SBSN	 suprabasin	 -1.30	 0.00352		
IPO7	 importin	7	 -1.31	 0.01294		
TPP2	 tripeptidyl	peptidase	II	 -1.31	 0.01334		
ILF2	 interleukin	enhancer	binding	factor	2	 -1.36	 0.00096		
GGA3	 golgi-associated,	gamma	adaptin	ear	containing,	ARF	binding	protein	3	 -1.38	 0.01195		
PYGM	 phosphorylase,	glycogen,	muscle	 -1.40	 0.04450		
GLTP	 glycolipid	transfer	protein	 -1.40	 0.02757		
AZGP1	 alpha-2-glycoprotein	1,	zinc-binding	 -1.40	 0.00488		
PHPT1	 phosphohistidine	phosphatase	1	 -1.52	 0.01768		
H1F0	 H1	histone	family,	member	0	 -1.59	 0.00004		
ITGB1	 integrin,	beta	1	(fibronectin	receptor,	beta	polypeptide,	antigen	CD29	includes	MDF2,	MSK12)	 -1.76	 0.01027		







Gene	Name	 Protein	name	 Fold	change	 p-value	
PIP	 prolactin-induced	protein	 3.77	 0.0002	
PMP2	 peripheral	myelin	protein	2	 3.34	 0.0207	
AZGP1	 alpha-2-glycoprotein	1,	zinc-binding	 3.14	 0.0049	
ITGB1	 integrin,	beta	1	(fibronectin	receptor,	beta	polypeptide,	antigen	CD29	includes	MDF2,	MSK12)	 2.91	 0.0103	
SEPT10	 septin	10	 2.36	 0.0298	
HLA-A	 major	histocompatibility	complex,	class	I,	A	 2.23	 0.0260	
H1F0	 H1	histone	family,	member	0	 2.20	 0.0000	
CALML5	 calmodulin-like	5	 2.10	 0.0028	
RABGAP1	 RAB	GTPase	activating	protein	1	 2.05	 0.0114	
ENPP6	 ectonucleotide	pyrophosphatase/phosphodiesterase	6	 1.98	 0.0419	
GLTP	 glycolipid	transfer	protein	 1.94	 0.0276	
PYGM	 phosphorylase,	glycogen,	muscle	 1.88	 0.0445	
CLDN11	 claudin	11	 1.88	 0.0155	
IVD	 isovaleryl-CoA	dehydrogenase	 1.80	 0.0040	
CA14	 carbonic	anhydrase	XIV	 1.71	 0.0141	
DYNC1I2	 dynein,	cytoplasmic	1,	intermediate	chain	2	 1.70	 0.0027	
PAFAH1B3	 platelet-activating	factor	acetylhydrolase	1b,	catalytic	subunit	3	(29kDa)	 1.70	 0.0001	
GPD1	 glycerol-3-phosphate	dehydrogenase	1	(soluble)	 1.69	 0.0413	
MYO1D	 myosin	ID	 1.66	 0.0296	
JAM3	 junctional	adhesion	molecule	3	 1.66	 0.0150	
PLA2G16	 phospholipase	A2,	group	XVI	 1.66	 0.0282	
PLSCR4	 phospholipid	scramblase	4	 1.64	 0.0000	
SIRT2	 sirtuin	2	 1.64	 0.0149	
MOG	 myelin	oligodendrocyte	glycoprotein	 1.63	 0.0278	
OPALIN	 oligodendrocytic	myelin	paranodal	and	inner	loop	protein	 1.63	 0.0089	
FLG2	 filaggrin	family	member	2	 1.62	 0.0023	
RHOG	 ras	homolog	family	member	G	 1.59	 0.0097	
ADSS	 adenylosuccinate	synthase	 1.58	 0.0447	
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PBXIP1	 pre-B-cell	leukemia	homeobox	interacting	protein	1	 1.58	 0.0136	
SCRN1	 secernin	1	 1.56	 0.0092	
GLIPR2	 GLI	pathogenesis-related	2	 1.56	 0.0171	
AKR1A1	 aldo-keto	reductase	family	1,	member	A1	(aldehyde	reductase)	 1.56	 0.0020	
IDH1	 isocitrate	dehydrogenase	1	(NADP+),	soluble	 1.55	 0.0455	
QDPR	 quinoid	dihydropteridine	reductase	 1.54	 0.0297	
SEPT2	 septin	2	 1.54	 0.0281	
C4A	 complement	component	4B	(Chido	blood	group)	 1.54	 0.0000	
MAG	 myelin	associated	glycoprotein	 1.53	 0.0121	
GNG12	 guanine	nucleotide	binding	protein	(G	protein),	gamma	12	 1.53	 0.0445	
CNP	 2',3'-cyclic	nucleotide	3'	phosphodiesterase	 1.52	 0.0357	
ADAM10	 ADAM	metallopeptidase	domain	10	 1.49	 0.0272	
MARCKSL1	 MARCKS-like	1	 1.48	 0.0170	
INF2	 inverted	formin,	FH2	and	WH2	domain	containing	 1.42	 0.0118	
ERMN	 ermin,	ERM-like	protein	 1.42	 0.0048	
NAGK	 N-acetylglucosamine	kinase	 1.41	 0.0022	
ANXA1	 annexin	A1	 1.41	 0.0058	
SBSN	 suprabasin	 1.41	 0.0035	
ADGRG1	 adhesion	G	protein-coupled	receptor	G1	 1.41	 0.0047	
MTX3	 metaxin	3	 1.41	 0.0132	
FKBP4	 FK506	binding	protein	4,	59kDa	 1.38	 0.0467	
S100A1	 S100	calcium	binding	protein	A1	 1.37	 0.0482	
CRKL	 v-crk	avian	sarcoma	virus	CT10	oncogene	homolog-like	 1.36	 0.0158	
TXNDC5	 thioredoxin	domain	containing	5	(endoplasmic	reticulum)	 1.35	 0.0272	
PLCL1	 phospholipase	C-like	1	 1.35	 0.0457	
GNG7	 guanine	nucleotide	binding	protein	(G	protein),	gamma	7	 1.35	 0.0066	
MARCKS	 myristoylated	alanine-rich	protein	kinase	C	substrate	 1.35	 0.0088	
JAM2	 junctional	adhesion	molecule	2	 1.34	 0.0000	
AKR1C3	 aldo-keto	reductase	family	1,	member	C3	 1.33	 0.0115	
PGM1	 phosphoglucomutase	1	 1.33	 0.0248	
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MVP	 major	vault	protein	 1.32	 0.0054	
SLC44A1	 solute	carrier	family	44	(choline	transporter),	member	1	 1.31	 0.0413	
LASP1	 LIM	and	SH3	protein	1	 1.31	 0.0477	
CASP14	 caspase	14,	apoptosis-related	cysteine	peptidase	 1.29	 0.0379	
PLCD1	 phospholipase	C,	delta	1	 1.28	 0.0284	
HSPB1	 heat	shock	27kDa	protein	1	 1.27	 0.0000	
APOE	 apolipoprotein	E	 1.27	 0.0208	
PRKACB	 protein	kinase,	cAMP-dependent,	catalytic,	beta	 1.27	 0.0026	
SELENBP1	 selenium	binding	protein	1	 1.26	 0.0009	
CLU	 clusterin	 1.26	 0.0000	
RABGGTA	 Rab	geranylgeranyltransferase,	alpha	subunit	 1.25	 0.0197	
FMNL2	 formin-like	2	 1.25	 0.0192	
RPL8	 ribosomal	protein	L8	 1.25	 0.0083	
CTTN	 cortactin	 1.25	 0.0290	
ASRGL1	 asparaginase	like	1	 1.24	 0.0480	
AKR1B1	 aldo-keto	reductase	family	1,	member	B1	(aldose	reductase)	 1.23	 0.0220	
CADM4	 cell	adhesion	molecule	4	 1.23	 0.0145	
APP	 amyloid	beta	(A4)	precursor	protein	 1.22	 0.0000	
PHPT1	 phosphohistidine	phosphatase	1	 1.21	 0.0177	
ALDH1L1	 aldehyde	dehydrogenase	1	family,	member	L1	 1.21	 0.0000	
SLC12A2	 solute	carrier	family	12	(sodium/potassium/chloride	transporter),	member	2	 1.20	 0.0119	
PSMA5	 proteasome	(prosome,	macropain)	subunit,	alpha	type,	5	 1.20	 0.0043	
CAPNS1	 calpain,	small	subunit	1	 1.20	 0.0090	
HINT2	 histidine	triad	nucleotide	binding	protein	2	 -1.20	 0.0240	
ABI1	 abl-interactor	1	 -1.20	 0.0102	
HINT1	 histidine	triad	nucleotide	binding	protein	1	 -1.22	 0.0187	
CYCS	 cytochrome	c,	somatic	 -1.22	 0.0051	
NIPSNAP1	 nipsnap	homolog	1	(C.	elegans)	 -1.23	 0.0489	
NPTX1	 neuronal	pentraxin	I	 -1.23	 0.0028	
PRDX5	 peroxiredoxin	5	 -1.24	 0.0026	
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NCKAP1	 NCK-associated	protein	1	 -1.24	 0.0341	
TSFM	 Ts	translation	elongation	factor,	mitochondrial	 -1.25	 0.0305	
PALM	 paralemmin	 -1.25	 0.0138	
ADRM1	 adhesion	regulating	molecule	1	 -1.26	 0.0002	
DMTN	 dematin	actin	binding	protein	 -1.26	 0.0090	
ERP29	 endoplasmic	reticulum	protein	29	 -1.27	 0.0229	
CAMK4	 calcium/calmodulin-dependent	protein	kinase	IV	 -1.27	 0.0317	
MDH2	 malate	dehydrogenase	2,	NAD	(mitochondrial)	 -1.27	 0.0131	
PACSIN1	 protein	kinase	C	and	casein	kinase	substrate	in	neurons	1	 -1.27	 0.0314	
NDUFS7	 NADH	dehydrogenase	(ubiquinone)	Fe-S	protein	7,	20kDa	(NADH-coenzyme	Q	reductase)	 -1.28	 0.0436	
SOD2	 superoxide	dismutase	2,	mitochondrial	 -1.29	 0.0084	
HAGH	 hydroxyacylglutathione	hydrolase	 -1.30	 0.0210	
ESYT2	 extended	synaptotagmin-like	protein	2	 -1.32	 0.0059	
MAP6	 microtubule-associated	protein	6	 -1.32	 0.0102	
MRPS36	 mitochondrial	ribosomal	protein	S36	 -1.32	 0.0010	
SV2B	 synaptic	vesicle	glycoprotein	2B	 -1.32	 0.0462	
ARPC1A	 actin	related	protein	2/3	complex,	subunit	1A,	41kDa	 -1.33	 0.0461	
NDUFS4	 NADH	dehydrogenase	(ubiquinone)	Fe-S	protein	4,	18kDa	(NADH-coenzyme	Q	reductase)	 -1.33	 0.0293	
SYNPO	 synaptopodin	 -1.34	 0.0029	
NGEF	 neuronal	guanine	nucleotide	exchange	factor	 -1.34	 0.0383	
ATP5H	 ATP	synthase,	H+	transporting,	mitochondrial	Fo	complex,	subunit	d	 -1.35	 0.0360	
FAM213A	 family	with	sequence	similarity	213,	member	A	 -1.36	 0.0300	
FLOT2	 flotillin	2	 -1.38	 0.0001	
RAB27B	 RAB27B,	member	RAS	oncogene	family	 -1.39	 0.0169	
FARSB	 phenylalanyl-tRNA	synthetase,	beta	subunit	 -1.39	 0.0036	
TAGLN3	 transgelin	3	 -1.39	 0.0257	
FARSA	 phenylalanyl-tRNA	synthetase,	alpha	subunit	 -1.39	 0.0246	
IGKC	 immunoglobulin	kappa	constant	 -1.41	 0.0073	
PITRM1	 pitrilysin	metallopeptidase	1	 -1.41	 0.0229	
HAPLN1	 hyaluronan	and	proteoglycan	link	protein	1	 -1.46	 0.0160	
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NDUFS6	 NADH	dehydrogenase	(ubiquinone)	Fe-S	protein	6,	13kDa	(NADH-coenzyme	Q	reductase)	 -1.47	 0.0122	
CYB5R1	 cytochrome	b5	reductase	1	 -1.55	 0.0039	





scoring	 Ingenuity	 pathway	 analysis	 network	 found	 when	 comparing	 proteins	 changing	 in	 AD	
with	 NDC.	Many	 proteins	 in	 this	 network	 are	 involved	 in	 the	 regulation	 of	 cell	 morphology,	
endocytosis	 and	 exocytosis	 and	 maintenance	 of	 the	 lipid	 bilayer.	 Colored	 nodes	 indicate	
proteins	found	to	be	significantly	change	in	the	proteomics	data	set.	Red	nodes	indicate	that	a	
protein’s	expression	has	gone	down	in	AD	and	green	nodes	indicate	the	expression	has	gone	up.	
The	 intensity	 of	 the	 color	 indicates	 the	 size	 of	 the	 fold	 change	where	more	 intense	 coloring	
indicates	a	greater	fold	change.	Uncolored	nodes	are	inserted	by	IPA	to	increase	the	coherence	





Figure	 4.7:	 Changes	 in	 Cell	 Morphology,	 Maintenance	 of	 the	 Lipid	 Bilayer	 and	 Endosome	
Trafficking	 in	 Alzheimer’s	 Disease	 synapse.	 Key	 proteins	 in	 Endosome	 Trafficking	 (SNAP25,	







Figure	4.8:	Western	Blot	 confirmation	of	 selected	proteins	 involved	 in	 the	 regulation	of	 the	
lipid	bilayer.	 (A)	A	Western	Blot	of	some	of	the	synaptoneurosome	preps	sent	for	proteomics	
probed	for	FLOT1	and	GAPDH.	FLOT1	is	up	regulated	by	western	blot	(C)	confirming	the	results	
of	 the	proteomics	 data	 (B)	 by	 another	 technique.	 (D)	 )	 A	Western	Blot	 of	 synaptoneurosome	







Ingenuity	Pathway	Analysis	 (IPA)	allows	 functional	protein-protein	 interactions	
to	be	defined	and	to	be	grouped	into	networks	using	computer	algorithms	with	manual	
curation	of	protein-protein	interactions.	As	IPA	networks	are	generated	from	currently	
existing	 and	 published	 datasets	 the	 strength	 of	 predicted	 interactions	 is	 very	 high	








protein	25	 (SNAP25)	 (Figure	4.7).	DAVID	also	showed	that	21	proteins	 involved	 in	cell	
morphology	 were	 significantly	 different	 in	 AD.	 These	 proteins	 again	 included	 the	




Changes	 in	 proteins	 related	 to	 energy	 production	 and	 small	 molecule	
biochemistry	 were	 also	 highlighted	 by	 both	 IPA	 and	 DAVID	 analysis	 of	 the	 proteins	
significantly	different	in	AD	(Figure	4.9).	32	of	the	proteins	significantly	changed	in	the	
AD	 synapse	 classify	 under	 the	 GO	 term	 Mitochondria	 although	 only	 some	 of	 them	
cluster	into	this	network.	These	proteins	include	many	parts	of	complex	1	the	first	stage	
in	the	energy	production	process	(Figure	4.10A).	All	of	the	mitochondrial	proteins	found	
to	 be	 altered	 in	 this	 proteomics	 data	 set	 are	 chromosomally	 encoded	 although	 no	
proteins	 encoded	 by	 the	mitochondrial	 genome	were	 detected	 by	 the	 LC-MS/MS.	Of	
particular	 interest	 is	 pitrilysin	metallopeptidase	 1	 (PITRM1)	which	 is	 found	 to	 be	 less	
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Figure	 4.9:	 Changes	 in	 Energy	 Production	 and	 Small	 Molecule	 Biochemistry	 Network	 in	
Alzheimer’s	 Disease	 synapse.	 (A)	 A	 high	 scoring	 Ingenuity	 pathway	 analysis	 network	 found	
when	comparing	proteins	changing	the	AD	synapse	and	the	NDC	synapse.	Many	proteins	in	this	
network	 are	 involved	 in	 energy	 production	 or	 are	 APP	 interactors.	 Colored	 nodes	 indicate	
proteins	found	to	be	significantly	change	in	the	proteomics	data	set.	Red	nodes	indicate	that	a	
protein’s	expression	has	gone	down	in	AD	and	green	nodes	indicate	the	expression	has	gone	up.	







NDUFS8	 and	 NDUFA7	 are	 both	 significantly	 down	 regulated	 in	 the	 AD	 synapse.	 Each	 point	
represents	 an	 individual	 sample	 (B)	 PITRM1	 a	 molecule	 involved	 in	 degrading	 Aβ	 in	 the	
mitochondria	 is	 decreased	 in	 AD	 while	 APP	 is	 increased	 in	 the	 AD	 synapse.	 Each	 point	
represents	an	individual	sample.	(***	p<0.001,	**p<0.01,	*p<0.05,	T-test).	
	




inspection	 reveals	 that	 some	 of	 these	 proteins	 are	 involved	 in	 regulation	 of	 the	
immune	 system	 (9	 proteins)	 and	 more	 specifically	 activation	 of	 the	 complement	





Figure	4.11:	Changes	 in	Cellular	Maintenance	Network	 in	Alzheimer’s	Disease	synapse.	 (A)	A	
high	scoring	Ingenuity	pathway	analysis	network	found	when	comparing	proteins	changing	the	
AD	 synapse	and	 the	NDC	 synapse.	Many	proteins	 in	 this	network	are	 involved	 in	maintaining	












regulated	 by	 western	 blot	 when	 comparing	 AD	 to	 NDC	 cases	 confirming	 the	 results	 of	 the	
proteomics	 data	 (B)	 by	 another	 technique.	 (D)	 A	 Western	 Blot	 of	 synaptoneurosome	 preps	
probed	for	Complement	C4	and	GAPDH.	Complement	C4	is	up	regulated	by	western	blot	when	





Figure	 4.13:	 Significant	 changes	 in	 the	 NDC	 APOE4	 proteome	 when	 compared	 to	 the	 NDC	
APOE3	proteome.	(A)	Many	of	the	differences	between	the	NDC	proteomes	are	changed	in	the	
same	direction	when	comparing	the	AD	proteome	with	controls.	Complement	C4,	PSAP,	FLOT2	
and	CASP14	are	all	 increased	 in	NDC	APOE4	cases	 compared	with	NDC	APOE3	cases	and	also	
increased	when	comparing	AD	to	NDC.(B)	Some	proteins	such	as	PITRM1	and	FLG2	however	are	







AD	 APOE3	 synapse.	 The	 highest	 scoring	 Ingenuity	 pathway	 analysis	 network	 found	 when	
comparing	proteins	in	the	AD	APOE4	and	the	AD	APOE3	synapse.	Many	proteins	in	this	network	
are	 involved	 in	 regulation	 of	 cell	 morphology,	 endo-	 and	 exocytosis	 and	 regulation	 of	 the	
immune	 system.	 Colored	 nodes	 indicate	 proteins	 found	 to	 be	 significantly	 change	 in	 the	
proteomics	data	set.	Red	nodes	 indicate	 that	a	protein’s	expression	has	gone	down	 in	APOE4	
AD	and	 green	nodes	 indicate	 the	expression	has	 gone	up	when	 compared	 to	APOE3	AD.	 The	
intensity	of	the	color	indicates	the	size	of	the	fold	change	where	more	intense	coloring	indicates	
a	 greater	 fold	 change.	Uncolored	nodes	are	 inserted	by	 IPA	 to	 increase	 the	 coherence	of	 the	













Only	 41	 proteins	 were	 found	 to	 be	 significantly	 different	 in	 the	 APOE4	 NDC	
synapses	compared	to	the	APOE3	NDC	synapses.	Such	small	datasets	should	be	viewed	
with	caution	as	with	a	total	discovery	rate	of	1043	and	a	significance	cut	off	of	p<0.05	
one	would	 expect	 50	 proteins	 to	 be	 altered	 by	 chance	 alone.	 However,	 after	 careful	




4.3.6 Key	 proteins	 which	 are	 significantly	 changed	 in	 APOE4	




proteins	 significantly	 differed	 in	 their	 abundance	 (p<0.05,	 fold	 change	 >1.2).	 The	
highest	 scoring	 IPA	network	 from	this	analysis	highlights	proteins	 that	are	 involved	 in	
the	 regulation	of	 cell	morphology,	 endocytosis	 and	 regulation	of	 the	 immune	 system	
(Figure	 4.14).	 Many	 of	 the	 proteins	 found	 to	 be	 different	 in	 the	 AD	 APOE4	 synapse	
when	compared	to	the	AD	APOE3	synapse	such	as	Clusterin	(CLU)	and	Apolipoprotein	E	




Of	 the	 120	 proteins	 found	 to	 be	 different	 in	 the	 AD	 APOE4	 synapse	 when	






be	 mainly	 involved	 in	 the	 plasma	 membrane	 (28	 proteins).	 Those	 proteins	 that	 are	
similar	in	their	directional	change	to	AD	compared	to	NPC	appear	to	be	mainly	involved	





This	study	examined	the	difference	 in	proteome	of	synapses	 isolated	 from	AD	
and	NDC	post-mortem	tissue	with	known	APOE	genotypes	using	highly	sensitive	label-





cell	 body	due	not	only	 to	 the	 long	distance	between	 these	 two	 cellular	 locations	but	
also	 due	 to	 the	 break	 down	 in	 protein	 trafficking	 and	 transport	 that	 are	 known	 to	
accompany	AD	(Encalada	and	Goldstein,	2014).	Using	the	highly	sensitive	system,	label	
free	 quantitative	 LC-MS/MS,	 and	 limiting	 the	 samples	 used	 to	 samples	 with	 high	





AD	 causes	 changes	 in	 many	 proteins	 related	 to	 the	 regulation	 of	 cell	
morphology,	endocytosis,	exocytosis	and	maintenance	of	the	lipid	bilayer	(Figure	4.6).	
Endocytosis	 and	 exocytosis	 are	 necessary	 for	 synaptic	 function	 as	 they	 control	 the	
release	and	uptake	of	neurotransmitters	into	the	synaptic	cleft	thus	allowing	signals	to	
propagate	 from	 neuron	 to	 neuron.	 As	 several	 of	 the	 genes	 found	 by	 genome-wide	
association	 studies	 are	 known	 to	 be	 involved	 in	 endosomal	 mechanisms	 (Karch	 and	






the	 synapse	 leading	 to	 a	 decrease	 in	 the	 amount	 of	 neurotransmitter	 release	 or	
reuptake.	As	APP	 is	 cleaved	 to	Ab	 in	 the	 endosome	 changes	 in	 endosomal	 processes	
will	 also	 have	 an	 effect	 on	 the	 rate	 of	 Ab	 production.	 Notably,	 Flotillin	 2	 not	 only	
regulates	 endocytosis	 but	 has	 also	 been	 shown	 to	 facilitate	 the	 endocytosis	 of	 APP.	
Down	regulation	of	Flotillin	2	 	 in	primary	neurons	 impairs	the	endocytosis	of	APP	and	
thus	 reduces	 the	 production	 of	 Ab	 (Schneider	 et	 al.,	 2008).	Western	 blot	 analysis	 of	
FLOT1	 and	 LRP1	 confirmed	 the	 results	 of	 the	 proteomics	 dataset	 by	 an	 independent	
technique	thus	furthering	confidence	in	the	findings.		
	
Also	 crucial	 to	 the	 release	of	 vesicles	 and	 synaptic	 communication	 is	 the	 lipid	
bilayer.	 Proteins	 such	 as	 LDL	 receptor	 related	 protein	 1	 (LRP1),	 Prosaposin	 (PSAP),	
Phospholipase	C	(PLCL1),	and	Phospholipase	A2	group	XVI	(PLA2G16)	are	all	involved	in	
changing	 and	 regulating	 the	 composition	 of	 lipids	 within	 the	 lipid	 bilayer.	 Not	 only	
could	disruption	of	 the	 lipid	bilayer	also	contribute	 to	and	or	 facilitate	a	disruption	 in	
endosome	 release	 but	 the	 composition	 of	 the	 lipid	 bilayer	 particularly	 the	 number,	
composition,	and	size	of	lipid	rafts	of	cholesterol	has	been	shown	to	play	an	important	
part	in	the	pathogenesis	of	AD	(Fabelo	et	al.,	2014).	LRP1	in	particular	has	been	shown	
to	 have	 an	 important	 role	 in	 the	 pathogenesis	 of	 AD	 both	 in	 its	 role	 as	 an	 ApoE	
interactor	 protein	 but	 also	 through	 its	 interactions	 with	 cellular	 prion	 protein	 (PrPc)	
which	allow	for	the	internalization	of	Ab	into	endosomes	(Rushworth	et	al.,	2013).		
	




this	 group	 of	 proteins	 indicates	 a	 loss	 of	 synaptic	 health	 as	 cell	 to	 cell	 adhesion	 is	
particularly	important	in	maintaining	the	function	and	integrity	of	the	synapse	and	the	
synaptic	cleft	(Leshchyns’ka	and	Sytnyk,	2016).	Some	of	these	protein	changes,	such	at	
the	 septins	which	 are	 downregulated	 in	 AD,	 are	 likely	 a	 result	 of	 the	 break	 down	 in	
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synaptic	 membranes	 and	 connections	 that	 occurs	 in	 AD.	 However	 others,	 such	 as	








Synapses	 require	 large	 amounts	 of	 energy	 to	 not	 only	 maintain	 the	 ion	
gradients	 that	 enable	 normal	 function	 of	 neurons	 but	 also	 to	 mobilize,	 release	 and	
recycle	vesicles.	In	many	cases	synapses	are	located	far	away	from	the	cell	bodies	and	
thus	 mitochondria	 localized	 to	 the	 synapse	 are	 a	 key	 part	 of	 this	 structure.	
Mitochondria	 also	 help	 buffer	 Ca2+	 which	 plays	 a	 key	 role	 in	 aiding	 Ca2+	 dependent	
processes	within	 the	 synapse	 such	 as	 the	 regulation	 of	 plasticity	 (Ly	 and	 Verstreken,	
2006).	Neurons	use	specialized	transport	systems	to	move	mitochondria	from	the	cell	
body	 to	 the	 synapse	along	 the	axon	and	mitochondria	 can	be	moved	 throughout	 the	
cell	 to	 respond	 to	 changes	 in	 energy	 demands	 (Cai	 and	 Tammineni,	 2017).	 This	
mitochondrial	transport	is	affected	in	AD	as	the	microtubules	which	make	up	the	main	
traffic	highways	of	 the	cell	begin	 to	break	down	 (Sheng	and	Cai,	2012).	This	prevents	
new	 and	 healthy	mitochondria	 from	 reaching	 the	 synapse	 and	 replacing	 the	 old	 and	
often	highly	stressed	mitochondria.	However	only	one	third	of	axonal	mitochondria	are	
motile	 and	many	mitochondria	 are	 targeted	 to	 the	 synapse	 and	 remain	 there.	 Once	
located	 at	 the	 synapse	 mitochondria	 undergo	 marked	 changes	 in	 protein	 signature	
(Stauch	et	al.,	2014).	They	are	also	longer	lived	and	thus	exposed	to		more	oxidation	in	
ageing	 (Du	et	 al.,	 2012).	Dysfunction	of	mitochondria	 is	 thought	 to	 occur	 early	 in	AD	
and	 multiple	 lines	 of	 evidence	 point	 towards	 mitochondrial	 dysfunction	 being	
important	 in	 disease	 progression	 and	 cognitive	 impairment.	 The	 degree	 of	 cognitive	
impairment	 in	 AD	 correlates	 with	 the	 amount	 of	 Ab	 found	 in	 the	 mitochondria	




Ab	 rather	 than	 the	 effects	 of	 ApoE	 on	 the	 mitochondria	 itself	 (Cai	 and	 Tammineni,	
2017).		
	
The	 synaptoneurosome	 prep	 used	 here	 included	 synaptic	 mitochondria	 and	
thus	 several	 of	 the	 proteins	 altered	 in	 AD	 compared	 with	 NDC	 were	 mitochondrial.	




by	 the	mitochondrial	 genome	 although	 several	 are	 known	 to	 be	 changed	 in	 synaptic	
mitochondria	 compared	 with	 non	 synaptic	 mitochondria	 (Stauch	 et	 al.,	 2014)	 and	




also	 called	 PreP	 (Figure	 4.10).	 PITRM1	 is	 a	 degradation	 enzyme	 localized	 to	 the	
mitochondria	which	 binds	 to	 zinc	 and	 degrades	 small	 peptides	 in	 the	 range	 of	 10-65	
residues.	 Its	degradation	substrates	 include	Ab	and	decreases	 in	PITRM1	activity	have	
been	 found	 in	 AD	 brains	 as	well	 as	 in	 AD	mouse	models	 (Alikhani	 et	 al.,	 2011).	 This	
suggests	 that	decreased	activity	as	well	as	a	decreased	abundance	of	PITRM1	may	be	
responsible	for	some	of	the	mitochondrial	dysfunction	that	occurs	in	AD.	Of	particular	




clinical	 stage	 of	 AD	 and	 thus	 have	 higher	 intracellular	 Ab.	 AD	 has	 a	 long	 pre-clinical	
stage	where	Ab	concentrations	increase	but	no	noticeable	cognitive	decline	occurs.	This	
early	up	 regulation	of	PITRM1	could	be	a	 reaction	 to	an	 increase	 in	mitochondrial	Ab	












been	 found	 to	play	a	 role,	not	only	 in	AD,	but	also	 in	many	other	neurodegenerative	
diseases.	Neuroinflammation,	which	 is	 controlled	mainly	 by	microglia	 and	 astrocytes,	
was	previously	thought	to	be	due	to	the	protein	aggregation	and	neuronal	death	that	
are	 caused	 by	 neurodegenerative	 diseases,	 however	 in	more	 recent	 years	 a	 role	 for	
neuroinflammation	in	disease	initiation	and	progression	has	been	suggested.		
	
The	 role	of	neuroinflammation	and	 the	 innate	 immune	system	 in	contributing	
to	 the	 disease	 pathogenesis	 rather	 than	 being	 a	 product	 of	 disease	 has	 been	 further	





al.,	 2005a),	 inhibiting	 apoptosis	 (Zhang	 et	 al.,	 2005b),	 and	 facilitating	 lipid	 transport	
(Nuutinen	et	 al.,	 2009).	 Crucially	 Clusterin	 has	 been	 shown	 to	 bind	 to	 Ab	 preventing	
aggregation	(Matsubara	et	al.,	1995)	and	promoting	degradation	and	clearance	(Bell	et	
al.,	 2006).	 Previous	 datasets	 have	 shown	 that	 increased	 Clusterin	 plasma	 levels	
correlate	 with	 increased	 progression	 from	 MCI	 to	 AD	 as	 well	 as	 speed	 of	 cognitive	
decline	(Jongbloed	et	al.,	2015).	Clusterin	amount	has	been	shown	to	correlate	with	the	
amount	of	Ab	in	the	AD	human	brain	(Miners	et	al.,	2017)	and	Clusterin	is	increased	in	
the	 entorhinal	 cortex	 of	 elderly	 people	 concomitantly	 with	 Ab	 before	 the	 onset	 of	
dementia	implying	a	possible	early	role	in	disease	(Desikan	et	al.,	2014).	This	is	the	first	
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evidence	 that	Clusterin	 is	 increased	 in	 the	AD	synapse	and	 its	 structural	and	 function	
similarities	to	ApoE	indicate	that	it	may	play	a	role	in	Ab	trafficking	to	the	synapse.	
	
Microglia,	 the	 resident	 immune	 cells	 of	 the	 brain,	 have	 a	 role	 in	 synaptic	
pruning	 in	 development	 using	 the	 complement	 system	of	 the	 innate	 immune	 system	
(Stevens	et	al.,	2007).	Recently	this	process	has	also	been	implicated	in	synaptic	effects	
in	schizophrenia	as	genetic	changes	in	the	major	histocompatibility	complex	locus	cause	
changes	 in	 protein	 levels	 of	 human	 leukocyte	 antigen	 (HLA)	 as	 well	 as	 complement	
component	 4	 (C4)	 (Sekar	et	 al.,	 2016).	 This	 dataset	 shows	 that	 both	 complement	 C4	
and	HLA-1	 are	 altered	 in	 the	AD	 synapse	 and	 this	 data	 fits	 nicely	with	 recent	 papers	
showing	that	other	components	of	 the	complement	cascade,	namely	C1q	and	C3,	are	





but	 ANXA1	 also	 plays	 a	 role	 in	 targeting	 cells	 for	 phagocytosis	 by	 microglia.	 Under	
normal,	 non	 inflammatory,	 conditions	 ANXA1	 is	 involved	 in	 removing	 apoptotic	
neurons	while	preventing	inflammation.	However,	under	inflammatory	conditions,	such	
as	AD,	 this	mechanism	 is	 overwhelmed	and	 is	 likely	 part	 of	 the	 feed	 forward	 loop	of	
neuroinflammation	that	has	been	seen	in	AD	(McArthur	et	al.,	2010).	The	finding	that	





Most	 of	 the	 information	 pertaining	 to	 the	 role	 of	 ApoE	 in	 cognitive	 decline	
focuses	 on	 its	 interaction	 with	 Ab	 or	 occasionally	 tau	 however	 long	 term	 studies	 of	
cognition	have	shown	that	although	APOE	genotype	has	no	effect	on	cognitive	ability	in	
early	 or	 middle	 life,	 presence	 of	 an	APOE	 e4	 allele	 does	 affect	 the	 rate	 of	 cognitive	
decline	in	an	elderly	population	without	AD	(Schiepers	et	al.,	2012).	This	might	be	due	
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to	 preclinical	 AD	 and	 thus	 these	 individuals	 are	 experiencing	 the	 beginnings	 of	 AD	
associated	cognitive	decline.	Alternatively,	ApoE4	itself	may	have	a	impact	on	cognitive	
decline,	which	then	makes	the	brain	more	susceptible	to	AD.	Either	way	the	effects	of	
ApoE	 on	 the	 synaptic	 proteome	 in	 the	 absence	 of	 AD	 diagnosis	 or	 pathology	 is	 an	
interesting	way	of	looking	at	this	all	important	risk	factor	for	disease.		
	
Although	 very	 few	 proteins	 were	 significantly	 different	 between	 APOE3	 NDC	





an	 increase	 in	 APP	 endocytosis	 which	 in	 turn	 cause	 an	 increase	 in	 Ab	 production	
(Schneider	et	al.,	2008).		As	ApoE	has	important	roles	as	a	cholesterol	transporter	and	
the	 different	 ApoE	 isoforms	 transport	 cholesterol	 to	 different	 amounts	 (Dorey	et	 al.,	
2014).	 This	 difference	 in	 cholesterol	 amount	 could	 be	 part	 of	 this	 effect	 on	 APOE	
genotype	 on	 FLOT2	 and	 moderating	 the	 effect	 of	 FLOT2	 with	 APP	 could	 provide	 an	
important	preventative	therapeutic.		
	
Also	 increased	 in	 the	 NDC	 APOE4	 v	 NDC	 APOE3	 synapse	 is	 the	 complement	





accompany	preclinical	AD.	 It	 is	 also	possible	 that	C4	 could	be	 causing	non	Ab	 related	
synaptic	 loss	 causing	 a	 decrease	 in	 the	 amount	 of	 synapse	 and	 thus	 a	 decrease	 in	
cognitive	 ability	 and	 by	 extension	 cognitive	 reserve.	 This	 would	 then	 increase	 the	
chance	 of	 AD	 susceptibility	 because	 less	 synapses	 would	 need	 to	 be	 affected	 by	 AD	





As	discussed	earlier	an	 increase	 in	PITRM	 in	NDC	APOE4	cases	compared	with	











Calpain	activity	 is	known	to	be	 increased	 in	the	AD	brain	due	to	the	 increased	
Ca2+	that	is	known	to	occur	in	AD.	Once	activated	calpain	is	known	to	interact	with	tau	
causing	some	of	the	tau	pathology	seen	in	AD	(Ferreira	and	Bigio,	2011).	In	this	dataset	




have	 increased	 calpain	 1	 and	 2	 and	 that	 this	 increases	 the	 amount	 of	 tau	
phosphorylation	 in	 a	 GSK3b	 independent	manner	 (Zhou	et	 al.,	 2016).	 Also	 of	 note	 is	
that	 calpain	 goes	 on	 to	 activate	 PICALM	which	 is	 another	 genetic	 risk	 factor	 for	 AD	
(Harold	et	al.,	2009).	PICALM	is	known	to	play	a	role	in	endocytosis	which,	as	discussed	
above	has	important	roles	in	the	production	of	Ab,	and	PICALM	also	appears	to	play	a	




discussed	previously	Clusterin,	also	called	apolipoprotein	 J,	 is	an	 important	 risk	 factor	
for	AD	(Harold	et	al.,	2009).	It	is	the	second	most	abundantly	expressed	apolipoprotein	
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in	 the	brain	and	has	crucial	 roles	 in	 trafficking	and	clearance	of	Ab	 similar	 to	 the	role	
played	 by	 ApoE	 (Nuutinen	 et	 al.,	 2009).	 Indeed	 there	 are	 many	 parallels	 between	






experiments	 indicate	 that	 knocking	 out	 Clusterin	 leads	 to	 protection	 from	 Ab	
associated	apoptosis	(Killick	et	al.,	2014).	However	it	remains	to	be	seen	if	an	increase	
in	Clusterin	correlates	with	an	increase	in	Ab	at	the	synapse	and	indeed	if	that	increase	











AD	 cases	 compared	 with	 those	 isolated	 from	 NDC	 and	 the	 effect	 that	 the	 different	
isoforms	 of	 ApoE	 had	 on	 those	 changes	 using	 quantitative	 label-free	 LC-MS/MS.	 A	
major	 finding	 from	 that	 data	 set	 was	 an	 increase	 in	 Clusterin	 in	 the	 AD	 synapse	
compared	with	NDC	synapses	and	also	Clusterin	was	 increased	 in	AD	APOE4	synapses	
compared	 with	 AD	 APOE3	 synapses.	 Clusterin,	 also	 called	 ApoJ,	 is	 the	 second	 most	
abundantly	expressed	apolipoprotein	in	the	CNS	and	a	genetic	risk	factor	for	AD	(Harold	
et	al.,	2009).	There	is	evidence	that	ApoE	and	Clusterin	perform	similar	roles	in	the	CNS	










postsynapse,	 and	 astrocytic	 end	 feet	 using	 array	 tomography	 of	 post	 mortem	 tissue	
from	NDC	and	AD	cases	








Target	 Host	 Concentration	 Catalogue	number	
Clusterin	 Rabbit	 1:500	 sc-8354	
GAPDH	 Mouse	 1:2,000	 ab8245	
	
Table	5.2:	Cases	used	for	western	blotting	in	Chapter	5	
Condition	 Case	number	 Gender		 Age	 APOE	genotype	 MRC	BBN		
NDC	 01/16	 M	 79	 APOE	3/3	 28406	
NDC	 17/16	 F	 79	 APOE	3/3	 28793	
NDC	 24/15	 M	 78	 APOE	3/3	 26495	
NDC	 51/15	 M	 79	 APOE	3/3	 19597	
AD	 14/15	 F	 85	 APOE	3/4	 25739	
AD	 40/15	 M	 78	 APOE	3/4	 26718	
AD	 48/15	 M	 76	 APOE	3/4	 26732	
AD	 49/14	 M	 80	 APOE	3/4	 24322	
AD	 55/14	 M	 79	 APOE	3/4	 24526	
AD	 02/14	 F	 87	 APOE	3/3	 19994	
AD	 56/14	 M	 81	 APOE	3/3	 24527	
AD	 10/16	 M	 85	 APOE	3/3	 28771	
AD	 29/14	 F	 87	 APOE	3/3	 22223	






used	 is	described	 in	Table	5.4	and	ribbons	were	stained	 for	6	markers,	 synaptophysin	
for	presynapses,	PSD95	 for	postsynapses	and	EAAT1	 for	astrocytic	processes	and	end	
feet	 as	 well	 as	 Clusterin,	 ApoE,	 and	 1C22	 (gift	 of	 Dominic	 Walsh)	 which	 detects	
oligomers	of	Aβ	(Mably	et	al.,	2015).	Two	different	tissue	blocks	were	imaged	per	case	








Cases	 Genotype	 Diagnosis	 Age	 Gender	 MRC	BBN	
01/16 APOE3/3	 NDC	 79	 M	 28406	
24/15 APOE3/3	 NDC	 78	 M	 26495	
17/16 APOE3/3	 NDC	 79	 F	 28793	
63/13 APOE3/3	 NDC	 77	 F	 19686	
51/15	 APOE3/3	 NDC	 79	 M	 19597	
1424	 APOE3/3	 AD	Braak	VI	 89	 M	 -	
1456	 APOE3/3	 AD	Braak	VI	 81	 M	 -	
05/16 APOE3/3	 AD	Braak	VI	 62	 F	 28410	
10/16	 APOE3/3	 AD	Braak	VI	 85	 M	 28771	
56/14 APOE3/3	 AD	Braak	V	 81	 M	 24527	
52/16 APOE3/3	 AD	Braak	VI	 78	 F	 29541	
14/15 APOE3/4	 AD	Braak	VI	 85	 F	 25739	
40/15 APOE3/4	 AD	Braak	VI	 78	 M	 26718	
55/14 APOE3/4	 AD	Braak	VI	 79	 M	 24526	
64/13 APOE3/4	 AD	Braak	VI	 57	 M	 19690	





section	 as	 previously	 described.	 The	 astrocytic	 component	 of	 a	 tripartite	 synapses	
(ACTS)	 were	 defined	 in	 matlab	 as	 EAAT1	 positive	 puncta	 that	 were	 within	 0.5μm	 of	
either	 a	 presynapse	 or	 a	 postsynaptic	 terminal	 which	 allowed	 for	 a	 distinction	 from	
astrocytic	processes	which	were	EAAT1	positive.	 Synaptic	puncta	were	defined	as	 co-




tested	 with	 the	 Shapiro-Wilk	 normality	 test.	 Two-way	 ANOVA	 was	 used	 to	 analyse	
density	of	all	three	synaptic	markers	with	condition	(NDC,	AD	ApoE3,	AD	ApoE4)	as	the	
column	 factor	 and	 proximity	 to	 plaque	 as	 the	 row	 factor	 followed	 by	 Bonferroni's	
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AD	 APOE3	 p=0.0492,	 between	 NDC	 and	 AD	 APOE4	 p=0.0134)(Figure	 5.1.C).	 This	 is	
consistent	 with	 previous	 studies,	 however	 a	 recent	 study	 indicated	 that	 Clusterin	 is	
increased	in	AD	due	in	part	to	its	interaction	with	Aβ	plaques	(Miners	et	al.,	2017).	As	
Aβ	 plaques	 are	 more	 prevalent	 in	 individuals	 with	 an	 APOE	 e4	 genotype	 one	 might	




of	 synaptoneurosomes	 (F(2,11)=20.83,	 p=0.0002)(Figure	 5.1B)	 shows	 an	 increase	 in	
Clusterin	in	AD	cases	(NDC	and	AD	APOE3	p=0.0387,	NDC	and	AD	APOE4	p=0.0001)	and	
a	further	increase	in	the	APOE4	cases	compared	with	APOE3	(p=0.0081)	consistent	with	






homogenates.	Western	 blot	 (A)	 analysis	 shows	 that	 AD	 causes	 a	 significant	 increase	 in	 the	







APOE3,	 AD	 APOE3	 and	 AD	 APOE4	 individuals	 were	 stained	 for	 postsynapses	 (PSD95),	


















of	 presynapses,	 and	 PSD95	 as	 a	 marker	 of	 postsynapses,	 and	 EAAT1	 was	 used	 as	 a	
marker	 of	 astrocytic	 end	 feet.	 Consistent	 with	 previous	 studies	 there	 is	 a	 significant	
drop	in	presynaptic	density	near	plaques	when	compared	with	far	from	plaques	(Two-
way	ANOVA	Row	factor,	F(1,25)=16.80,	p=0.0004)	for	both	AD	APOE3	(p=0.0248)	cases	
and	 AD	 APOE4	 cases	 (p=0.0190)	 (Koffie	 et	 al.,	 2012).	 AD	 APOE4	 cases	 have	 a	
significantly	 (Two-way	 ANOVA	 Column	 factor,	 F(1,25)=35.13,	 p<0.0001)	 lower	
presynaptic	 density	 far	 from	 plaques	when	 compared	with	 the	 density	 of	 AD	 APOE3	
(p=0.0056)	cases	and	NDC	(p=0.0085)	meaning	that	APOE4	cases	also	have	significantly	
lower	 presynaptic	 density	 near	 plaques	 compared	 with	 the	 presynaptic	 density	 near	
plaques	in	AD	APOE3	cases	(p=0.0046)	(Figure	5.3A).	
	
Analysis	 of	 postsynaptic	 puncta	 shows	 a	 significant	 (Two-way	 ANOVA	 Row	
factor,	 F(1,25)=6.463,	 p=0.0176,	 Column	 Factor	 F(2,25)=4.62,	 p=0.0196)	 	 decrease	 in	
the	 density	 of	AD	APOE4	 cases	 near	 plaques	 compared	with	NDC	 (p=0.0155)	 and	AD	








Figure	 5.3:	 Density	 of	 Synaptic	 punctate	 by	 Array	 Tomography.	 (A)	 There	 is	 a	 significant	







difference	 in	 either	 genotype	 when	 comparing	 between	 near	 and	 far	 from	 plaques.	 (****	
p<0.0001,	 *** p<0.001, ** p<0.01, * p<0.05, Two-way	 Anova	 with	 Bonferroni's	 multiple	
comparisons	post-hoc	test).	
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EAAT1	 is	 found	 in	 astrocytic	 end	 feet	 near	 synapses	 but	 also	 in	 astrocytic	
processes	 and	 astrocytic	 end	 feet	 around	 blood	 vessels	 therefore	 the	 astrocytic	
component	of	tripartite	synapses	(ACTS)	are	defined	as	EAAT1	positive	puncta	that	are	
within	0.5μm	of	either	a	presynaptic	or	 a	postsynaptic	 terminal.	 This	 is	 likely	a	 lower	
estimate	ACTS	as	 tripartite	 synapses	 in	 the	Z-direction	are	 less	 likely	 to	be	 taken	 into	
account	in	shorter	ribbons.	The	distance	from	a	plaque	does	not	change	the	density	of	
ACTS	for	either	genotype	but	AD	cases	with	an	APOE	e4	genotype	have	a	significantly	
lower	 (Two-way	 ANOVA	 Row	 factor,	 F(1,25)=5.655,	 p=0.0254,	 Column	 Factor	
F(2,25)=27.8,	 p<0.0001)	 end	 foot	 density	 both	 near	 to	 (p=0.0302)	 and	 far	 from	





Previous	 literature	 suggested	 that	 the	 amount	 of	 Aβ	 at	 the	 synapse	 is	
significantly	 increased	 in	 presynapse	 and	 postsynapses	 near	 plaques	 compared	 with	
those	 far	 from	 plaques	 (Koffie	 et	 al.,	 2012).	 1C22,	 an	 antibody	 which	 preferentially	
binds	to	oligomeric	and	aggregated	species	of	Aβ,	was	used	to	assess	the	co-localization	












Figure	5.4:	Percent	of	synaptic	puncta	co-localizing	with	Aβ.	There	 is	a	significant	 increase	 in	
the	percent	of	of	Ab	(1C22)	positive	synapses	near	plaques	compared	with	far	from	plaques	for	
all	 three	 synaptic	 parts.	 There	 is	 a	 further	 significant	 increase	 in	 the	 percent	 of	 Ab	 positive	





Figure	 5.5:	 Percent	 of	 Synaptic	 puncta	 co-localizing	 with	 Clusterin.	 Analysis	 by	 array	
tomography	 shows	 a	 significant	 increase	 in	 the	 amount	 of	 Clusterin	 co-localizing	 with	 both	
presynapses	(A)	and	postsynapses	(B)	in	AD	cases	compared	with	NDC	and	a	significant	increase	
when	comparing	AD	APOE4	cases	with	AD	APOE3	cases.	There	is	no	difference	in	the	amount	of	
Clusterin	 co-localizing	 with	 ACTS	 (C).	 (**p<0.01,	 *p<0.05,	 Kruskal-Wallis	 test	 with	 between	
groups	Mann-Whitney	U	tests)		
		
5.3.4 ApoE4	 is	 associated	 with	 an	 increased	 co-localization	 of	
Clusterin	with	presynapse	and	postsynapse	in	AD	
	
Array	 tomography	 was	 used	 to	 investigate	 whether	 the	 increase	 in	 Clusterin	
seen	 in	 the	 synaptoneurosome	 using	 proteomics	 and	 western	 blot	 was	 due	 to	 an	
increase	 in	Clusterin	 in	 the	presynaptic	compartment,	 the	postsynaptic	compartment,	
and	or	the	ACTS.	Analysis	of	array	tomography	shows	that	there	is	no	difference	in	the	
percent	 of	 synapses	 with	 Clusterin	 when	 synapses	 near	 plaques	 are	 compared	 with	
synapses	far	from	plaques	therefore	all	synapses	for	each	case	were	averaged	together.	




p=0.	 0173)	 and	 APOE4	 cases	 (presynapses	 p=0.0013,	 postsynapses	 p=0.0013)	 and	 a	
further	 increase	 when	 AD	 APOE4	 cases	 were	 compared	 with	 AD	 APOE3	 cases	
(presyanpases	 p=0.0043,	 postsynapses	 p=0.0043)	 (Figure	 5.5).	 However,	 there	 is	 no	




Figure	 5.6:	 Percent	 of	 Synaptic	 puncta	 Co-localizing	 with	 ApoE.	 Array	 tomography	 shows	 a	
significant	increase	in	the	percent	of	postsynapses	colocalizing	with	ApoE	(B)	in	AD	APOE4	cases	














5.3.5 ApoE4	 is	associated	with	an	 increase	 in	 the	amount	of	Aβ	and	
apolipoproteins	at	the	presynapse	and	postsynapse	in	AD	
	
There	 is	 previous	 evidence	 indicating	 that	 ApoE	 is	 in	 part	 responsible	 for	
targeting	Aβ	to	the	synapse	causing	synaptic	shrinkage	and	loss.	It	has	also	been	shown	
that	AD	APOE4	cases	are	more	 likely	to	have	Aβ	at	the	synapse	than	AD	APOE3	cases	
(Figure	5.4).	One	of	 the	benefits	of	array	 tomography	 is	 the	ability	 to	strip	antibodies	
and	 re-probe	 the	 same	 tissue	 ribbon	 with	 different	 antibodies	 thus	 allowing	 the	
analysis	 of	 the	 co-localization	 of	 several	 protein	 markers	 to	 the	 same	 synapse.	 We	
therefore	looked	at	the	co-localization	of	ApoE	and	Aβ	together	at	the	synapse	to	see	if	
AD	APOE4	cases	were	more	 likely	 to	have	synapses	positive	 for	both	markers.	As	 less	
than	1%	of	synapses	far	from	plaques	contain	Aβ,	this	analysis	focuses	on	crops	taken	
near	plaques	only.	There	 is	an	 increase	 in	the	percent	of	synaptic	puncta	co-localizing	
with	 both	 Aβ	 and	 ApoE	 in	 APOE4	 cases	 compared	 with	 APOE3	 cases	 for	 both	
presynapses	 (p=0.0317,	 Figure	 5.7A)	 and	 postsynapses	 (p=0.0159,	 Figure	 5.8A).	 This	
appears	 to	be	due	 to	 an	 increase	 in	 synapses	with	ApoE	 containing	Aβ	 in	 the	APOE4	
cases	compared	with	the	APOE3	cases	(presynapses	p=0.0317,	postsynapses	p=0.0159)	





(p=0.0317,	 Figure	 5.10A)	 and	 postsynapses	 (p=0.0159,	 Figure	 5.11A)	 that	 co-localize	


























Figure	 5.10:	 Co-localization	 of	 Clusterin	 and	 1C22	 with	 presynapses.	 There	 is	 a	 significant	
increase	in	the	amount	of	Clusterin	and	1C22	found	together	at	the	synapse	(A)	in	APOE4	cases	
compared	 with	 APOE3	 cases.	 Synapses	 which	 contain	 Clusterin	 are	 no	 more	 likely	 to	 also	





Figure	 5.11:	 Co-localization	 of	 Clusterin	 and	 1C22	 with	 postsynapses.	 There	 is	 a	 significant	
increase	in	the	amount	of	Clusterin	and	1C22	found	together	at	the	synapse	(A)	in	APOE4	cases	











compared	with	NDC	 and	 a	 further	 increase	 in	 the	 synapse	 of	 AD	 APOE4	 cases	when	





levels	 (Lidström	 et	 al.,	 1998)(Figure	 5.1C).	 Given	 that	 transport	 of	 molecules	 is	
dysregulated	 in	 AD,	 this	 study	 highlights	 a	 need	 to	 look	 at	 specific	 subcellular	
compartments	 when	 investigating	 post-mortem	 tissue.	 Especially	 as	 changes	 at	 the	
synapse	specifically	are	likely	to	have	an	impact	in	AD.	Investigating	the	location	and	co-
localization	of	proteins	of	 interest	 in	AD	with	 synaptic	 elements	will	 provide	 valuable	






To	 further	 investigate	 the	effects	of	ApoE4	 in	AD,	array	 tomography	was	used	
on	 post-mortem	 tissue	 from	 NDC	 APOE3,	 AD	 APOE3,	 and	 AD	 APOE4	 cases.	 Array	
tomography	 allows	 for	 the	 quantification	 and	 characterization	 of	 hundreds	 of	
thousands	of	synapses	and	assesses	the	co-localization	of	multiple	protein	markers	to	a	
single	synapse	(Micheva	and	Smith,	2007;	Kay	et	al.,	2013).	Looking	in	AD	tissue,	Koffie	
et	 al.	 showed	 in	 2012	 that	 synaptic	 density	 is	 decreased	 near	 plaques	 and	 that	 this	
density	returns	to	NDC	levels	greater	than	40μm	from	the	plaque	(Koffie	et	al.,	2012).	
This	 finding	 was	 replicated	 by	 this	 dataset	 examining	 different	 cases,	 which	 showed	
that	crops	near	plaques	have	a	significantly	lower	synaptic	density	compared	with	crops	
taken	far	from	plaques,	or	crops	taken	from	the	NDC	cases	(Figure	5.3).	This	decrease	in	
synaptic	 density	 near	 plaques	 is	 likely	 due	 in	 part	 to	 an	 increase	 in	 toxic	 Aβ	 species	
found	near	plaques	(Figure	5.4).	APOE4	cases	were	found	to	have	a	higher	amount	of	
Aβ	 at	 the	 presynapse	 and	 the	 postsynapse	 as	 well	 as	 a	 lower	 synaptic	 density	 near	
plaques	when	AD	APOE4	and	AD	APOE3	cases	were	compared.	As	Aβ	has	been	shown	
to	be	toxic	to	the	synapse	an	 increase	 in	the	amount	of	synapses	containing	Aβ	could	
help	 to	 explain	 this	 difference	 between	 genotypes	 (Walsh	 et	 al.,	 2002;	 Lacor	 et	 al.,	
2007;	Shankar	et	al.,	2008;	Tomiyama	et	al.,	2010;	Klein,	2013).	However,	this	does	not	
explain	the	decrease	in	synaptic	density	seen	far	from	plaques	in	the	AD	APOE4	cases.	
There	 are	 a	 number	 of	 explanations	 as	 to	why	 this	 could	 be	 and	 it	 is	 likely	 due	 to	 a	
number	of	factors.	One	explanation	is	that	APOE4	cases	often	have	a	more	aggressive	
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disease	 with	 a	 higher	 plaque	 load,	 more	 tau	 pathology,	 and	 higher	 neuron	 loss	
particularly	in	the	temporal	cortex	(Tiraboschi	et	al.,	2004;	Pievani	et	al.,	2011;	Farfel	et	
al.,	2016).	This	increase	in	neuron	death	likely	causes	the	synaptic	loss	far	from	plaques	
as	the	projections	from	those	neurons	are	 lost.	 It	 is	also	possible	that	 independent	of	
AD,	ApoE4	causes	a	global	reduction	in	synapses	even	in	healthy	NDC.	If	this	is	the	case	
then	 the	 density	 far	 from	 plaques	 in	 AD	 APOE4	 cases	 is	 the	 density	 of	 APOE4	 NDC.	
There	are	number	of	studies	which	indicate	that	this	might	be	the	case.	In	a	study	of	a	
healthy	aging	cohort,	Deary	et	al.	showed	that	APOE	e4	carriers	have	reduced	cognitive	
performance	even	 in	 the	 absence	of	AD	which	 could	be	due	 to	 a	 loss	 of	 synapses	or	




reduced	branching	and	 less	spines	 than	ApoE3	knock	 in	mice	 (Wang	et	al.,	2005).	 	All	
this	indicates	that	ApoE4	has	an	effect	on	the	brain	in	healthy	aging	that	might	cause	a	
reduction	 in	 synapse	 number	 however	 in	 order	 to	 confirm	 this	 hypothesis	 array	





Astrocytic	 end	 feet	 are	 found	 at	 tripartite	 synapses	 and	 perform	 a	myriad	 of	
important	functions	for	synaptic	development	and	maintenance.	Among	these	roles	are	
the	provision	of	proteins	and	nutrients	needed	 for	 the	synapse	 to	 function	as	well	as	
clearing	 away	 excess	 neurotransmitter	 from	 the	 synaptic	 cleft	 (Bernardinelli	 et	 al.,	
2014;	Chung	et	al.,	2015).	This	dataset	found	that	although	there	is	no	significant	loss	of	
ACTS	 near	 plaques	 compared	 with	 far	 from	 plaques,	 APOE4	 cases	 do	 have	 a	
significantly	 lower	 density	 of	 ACTS	 (Figure	 5.3C).	 This	 is	 likely	 detrimental	 to	 the	
synapses	 in	 APOE4	 cases	 as	 they	will	 have	 lost	 the	 protective	 effects	 of	 those	 ACTS.	




in	 AD.	 For	 example	 a	 major	 role	 of	 the	 astrocyte	 at	 the	 synapse	 is	 in	 regulation	 of	











Array	 tomography	 shows	 an	 increase	 in	 the	number	of	 both	presynapses	 and	
postsynapses	co-localizing	with	Clusterin	 in	AD	cases	and	a	 further	 increase	 in	 the	AD	
APOE4	 cases	 compared	 with	 with	 APOE3	 cases.	 As	 the	 second	 most	 abundantly	
expressed	 apolipoprotein	 in	 the	 brain	 Clusterin	 performs	many	 of	 the	 same	 roles	 as	
ApoE	 including	 the	 transport	 of	 cholesterol	 and	 other	 necessary	 lipids	 to	 the	 neuron	
(Dong	et	 al.,	 2017).	 An	APOE	 e4	 genotype	 has	 been	 shown	 to	 have	 an	 effect	 on	 the	
amount	of	ApoE	 in	 the	brain	due	 in	part	 to	 the	 increased	speed	with	which	ApoE4	 is	
degraded	 (Riddell	et	al.,	2008).	Here	array	 tomography	has	 shown	that	 there	are	 less	
synapses	with	ApoE	in	APOE4	cases	and	it	 is	possible,	that	the	 increase	 in	Clusterin	 in	
the	APOE4	cases	is	due	to	compensation	for	less	ApoE.	Indeed,	when	Apoe	is	knocked	
out	 of	 a	mouse	 line	 there	 is	 an	 increase	 in	 the	 amount	 of	 Clusterin	mRNA	 indicating	
that	 Clusterin	 can	 and	 does	 compensate	 for	 the	 loss	 of	 ApoE	 (Stone	 et	 al.,	 1998).	
However,	 an	 increase	 in	 Clusterin	 at	 the	 synapse	 could	 also	 be	 due	 to	 a	 number	 of	
other	 reasons	 including	 neuron	 stress.	 It	 is	 known	 that	 stress,	 and	 specifically	 Aβ	
induced	 stress,	 results	 in	 an	 increase	 in	 intracellular	 Clusterin	 and	 a	 decrease	 in	










Both	 Clusterin	 and	 ApoE	 are	 known	 to	 interact	 with	 plaques	 and	 bind	 to	 Aβ	
species	 in	 the	 brain,	 so	 to	 assess	 the	 interactions	 of	 these	 proteins	 with	 Aβ	 at	 the	
synapse	we	analysed	the	number	of	synapses	that	co-localize	with	both	ApoE	and	Aβ	as	
well	 as	 both	 Clusterin	 and	 Aβ.	 AD	 APOE4	 cases	 have	 an	 increased	 number	 of	
presynapses	 and	 postsynapses	 which	 co-localize	 with	 both	 ApoE	 and	 Aβ	 and	 both	
Clusterin	and	Aβ	(Figures	5.7A,	5.8A,	5.10A,	5.11A).	However,	the	effect	of	APOE	e4	on	
these	 protein	 combinations	 is	 different.	 Analysis	 of	 the	 number	 of	 ApoE	 positive	
synapses	 containing	Aβ	 shows	 that	 in	APOE4	 cases	 synapses	which	 contain	ApoE	 are	
more	 likely	 to	 also	 contain	 Aβ	 (Figure	 5.7B,	 5.8B).	 This	 indicates	 that	 ApoE4	 is	more	
likely	to	bind	Aβ	and	deliver	 it	to	the	synapse	a	finding	confirmed	by	the	experiments	
performed	 by	 Koffie	 et	 al.	 (Koffie	 et	 al.,	 2012).	 In	 contrast	 synapses	 which	 contain	
Clusterin	 are	 no	more	 likely	 to	 also	 contain	 Aβ	 in	 the	 APOE4	 cases	 although	 APOE4	
cases	 are	 more	 likely	 to	 contain	 both	 Clusterin	 and	 Aβ	 at	 the	 synapse	 (Figure	 5.10,	
5.11).	 This	 indicates	 that	 an	 APOE	 e4	 genotype	 does	 not	 change	 the	 likelihood	 of	
Clusterin	 binding	 Aβ	 in	 the	 way	 that	 it	 affects	 in	 the	 interaction	 of	 ApoE	 with	 Aβ.	
Figures	 5.13-5.15	 graphically	 show	 the	 extent	 of	 co-localization	 of	 each	 pathogenic	













feedback	 loop.	 Another	 question	 raised	 by	 this	 dataset	 is	 whether	 an	 increase	 in	
Clusterin	has	a	protective	or	a	detrimental	effect	on	the	synapse.	As	mentioned	before	
Clusterin	has	been	 shown	 to	bind	 to	Aβ,	prevent	 fibrillization	of	Aβ	and	prevents	 the	
loss	of	LTP	and	memory	when	injected	into	a	rat	which	points	towards	Clusterin	having	
a	protective	role	in	AD	(Cascella	et	al.	2013).	On	the	other	hand,	knockout	of	Clusterin	
in	 rat	 primary	 neurons	 prevented	 Aβ	 induced	 neuronal	 death	 which	 indicates	 that	
Clusterin	has	detrimental	roles	in	the	neuron	(Killick	et	al.,	2014).	It	is	entirely	likely	that	
Clusterin	 has	 multiple	 roles	 in	 the	 brain	 and	 that	 these	 jobs	 depend	 in	 part	 upon	
subcellular	localization	of	the	protein.	To	fully	understand	the	implications	of	this	study,	






boxes	 represent	 100%	 of	 the	 presynapses	 for	 that	 condition	 and	 area	 of	 overlap	 with	 other	
colored	 boxes	 (green	 for	 ApoE,	 purple	 for	 Clusterin,	 and	 red	 for	 Ab	 stained	 using	 1C22)	





Figure	 5.14:	 Euler	 diagram	 of	 Postsynaptic	 Co-localization	 with	 ApoE,	 Clusterin,	 and	 1C22.	
Blue	boxes	represent	100%	of	the	postsynapses	for	that	condition	and	area	of	overlap	
with	other	colored	boxes	(green	for	ApoE,	purple	for	Clusterin,	and	red	for	Ab	stained	
using	1C22)	 represent	 the	percent	of	postsynapses	 that	co-localize	with	 that	or	 those	






boxes	 (green	 for	 ApoE,	 purple	 for	 Clusterin,	 and	 red	 for	 Ab	 stained	 using	 1C22)	










Model	 systems	 provide	 an	 excellent	 opportunity	 to	 discover	 the	 effects	 of	
proteins	as	they	allow	for	manipulation	of	targets	under	controlled	conditions.	Human	
induced	pluripotent	stem	cells	 (iPSC)	allow	for	 the	reprogramming	of	cells	 to	neurons	
from	 both	 patients	 and	 healthy	 controls	 (Takahashi	et	 al.,	 2007).	 These	 cells	 provide	
scientists	 with	 a	 human	 system	 that	 can	 easily	 be	 manipulated	 and	 iPSC-derived	
neurons	 particularly	 from	 familial	 AD	 cases	 are	 used	 widely	 to	 study	 pathological	
processes	 in	AD	(Arber	et	al.,	2017).	This	 is	beneficial	as,	as	seen	 in	chapter	3,	mouse	
models	 of	 AD	 do	 not	 replicate	many	 aspects	 of	 the	 disease	 and	 studying	 humanized	
proteins	in	a	murine	system	can	be	complicated	by	the	presence	of	endogenous	murine	
proteins.	However,	neurons	derived	from	iPSCs	have	a	developmental	phenotype	and	




synaptic	 loss.	Other	 studies	 have	 shown	 that	when	oligomeric	Ab	 (oAb)	 is	 applied	 to	
rodent	 primary	 culture,	 oAb	 is	 synaptotoxic	 in	 low	 concentrations	 and	 neurotoxic	 in	




















Cortical	 neurons	 derived	 from	 human	 iPSCs	 from	 an	 individual	 with	 an	APOE	
e3/4	 genotype	 and	 no	 known	 cognitive	 or	 neurological	 disorders	 were	 grown	 to	 8	
weeks	as	described	in	2.7.3.	Human	brain	extract,	experimental	control	or	aCSF	(media	
control)	 was	 added	 to	 the	 cells	 and	 well	 volume	 was	 brought	 up	 to	 500µl	 with	
+BDNF/GDNF	media.	 After	 48	 hours	 cells	were	 fixed	 using	 4%	PFA	 for	 20	minutes	 at	
room	temperature.	Cells	were	stained	as	described	 in	2.7.6	using	the	antibodies	table	
6.1.	 Images	(Figure	6.1)	were	taken	on	a	Leica	DM6	CS	upright	microscope	with	a	TCS	
SP8	 confocal	 platform	 and	 5-10	 images	 per	 well	 were	 analysed	 using	 custom	 cell	
profiler	pipelines	 (appendix	3).	Synaptic	puncta	were	only	counted	 if	 they	overlapped	
with	MAP2	and	the	number	of	synaptic	puncta	per	µm	of	MAP2	positive	dendrites	was	
calculated	for	each	well.	An	average	synaptic	density	was	generated	for	all	aCSF	control	







Map2	 Guinea	Pig	 0.001	 -	 188	004	
Synaptophysin	 Mouse	 0.002	 -	 ab8049	
PSD95	 Rabbit	 0.001	 -	 D27E11	
Guinea-pig	IgG	 Goat	 0.0014	 488	 706-545-148	
Mouse	IgG	 Goat	 0.0007	 Cy3	 ab97035	




Target	 Host	 Dilution	 Catalogue	number	
Beta-actin	 Mouse	 1:1000	 ab8226	
Clusterin	 Rabbit	 1:1000	 Sc-8354	
	
Linear	regression	analysis	was	used	to	analyse	the	effect	of	Ab	concentration	on	





lysed	 with	 lysis	 buffer	 (50	 mmol/L	 Tris	 [pH	 7.5],	 1.5%	 SDS,	 and	 2	 mmol/L	 DTT)	 and	
protein	assayed.	Western	blotting	was	performed	on	cell	 lysates	as	described	 in	2.2.2	





6.3.1 Aβ	 derived	 from	 AD	 human	 brain	 but	 not	 NDC	 human	 brain	
causes	synapse	loss		
	
8	week	 old	 cortical	 neurons	 derived	 from	 human	 iPSCs	were	 challenged	with	
brain	extract	derived	from	AD	or	NDC	post-mortem	tissue.	Analysis	of	confocal	images	
(Figure	 6.1)	 of	 these	 cells	 show	 when	 AD	 brain	 extract	 is	 added	 there	 is	 strong	
correlation	between	the	concentration	of	Ab	and	the	amount	of	synapse	loss	for	both	
presynapses	 (R2=0.5796,	 F(1,24)	 =	 33.09,	 p<0.0001)	 and	 postsynapses	 (R2=0.7767,	
F(1,24)	 =	 83.46,	 p<0.0001)	 (Figure	 6.2).	 The	 highest	 concentration	 of	 Ab	 tested	 here	
was	 0.651ng/ml	 which	 caused	 ~30%	 loss	 of	 synaptic	 puncta.	 However,	 NDC	 brain	
extract	 treated	 in	 the	 same	 way	 does	 not	 show	 any	 correlation	 between	 Ab	










Figure	 6.2:	 Synaptic	 loss	 with	 Aβ	 addition	 is	 concentration	 dependent.	 Linear	 regression	






Figure	 6.3:	 Immunodepletion	 of	 Aβ	 ameliorates	 the	 effects	 of	 AD	 brain	 extract	 on	 synapse	
loss.		
There	is	a	significant	loss	of	synapses	in	wells	treated	with	mock	immunodepleted	(MID)	brain	
extract	but	not	 in	wells	 treated	with	 immunodepleted	 (ID)	brain	extract	 for	both	presynapses	
(A)	 and	 postsynapses	 (B).	 Colors	 indicate	 wells	 from	 the	 same	 plate	 down.	 (**	 p<0.01,	 ***	
p<0.001,	****	p<0.0001).	
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6.3.2 Aβ	 is	necessary	 for	 the	 synaptotoxic	effect	of	AD	human	brain	
extract	in	iPSCs		
	
To	ensure	that	 it	 is	the	Ab	content	of	AD	brain	extract	that	 is	causing	synaptic	
loss,	brain	extract	was	immune	depleted	(ID)	of	Ab.	Brain	extract	treated	with	4G8,	an	
anti-Ab	antibody,	and	protein	A	agarose	beads	was	prepared	alongside	mock	immune	
depleted	 (MID)	 brain	 extract	 which	 was	 treated	 with	 pre-immune	 sera	 and	 beads.	
Incubation	 of	 MID	 extract	 with	 cells	 showed	 a	 significant	 loss	 of	 synaptic	 puncta	
compared	with	 controls	 for	 presynapses	 (one-way	ANOVA	 (F(4,30)=	 9.776,	 p<0.0001)	
Tukeys	post-hoc	 for	100µl	MID	p=0.0076	and	200µl	MID	p=0.0003)	and	postsynapses	
(one-way	ANOVA	(F(4,30)=	47.91,	p<0.0001)	Tukeys	post-hoc	 for	100µl	MID	p<0.0001	










Figure	 6.5:	 Knock	 down	of	 Clusterin	 expression	 by	 siRNA	does	 not	 change	 the	 effect	 of	 AD	
human	brain	extract	on	synapse	loss.	Human	brain	extract	causes	a	significant	loss	of	both	pre-
synapse	(A)	and	postsynapses	(B)	but	knock	down	of	Clusterin	with	siRNA	does	not	change	the	












p<0.0001)	Tukeys	post-hoc	Clu	 siRNA	v	Clu	 siRNA+AD	p=0.0005	and	Con	 siRNA	v	Con	
siRNA+AD	 p=0.0009)	 and	 postsynapse	 (one-way	 ANOVA	 (F(3,19)=	 28.83,	 p<0.0001)	









This	 chapter	 presents	 a	 new	 model	 of	 oAb	 induced	 synaptotoxicity	 using	
cortical	neurons	derived	 from	human	 iPSCs	and	oAb	 extracted	 from	AD	post-mortem	
tissue.	The	cortical	neurons	used	here	are	derived	 from	control	human	 iPSCs	with	no	
known	 neurological	 defects.	 Neurons	 grown	 using	 the	 protocol	 used	 show	 synaptic	
puncta	 (Figure	 6.1)	 and	 functional	 synaptic	 connections	 (Bilican	et	 al.,	 2014)	 5	weeks	
after	 differentiation	 from	 neural	 precursor	 cells	 negating	 the	 need	 for	 complicated	
immunopanning	techniques	(Nieweg	et	al.,	2015)	.	Using	these	cells	as	a	model	allows	
for	the	development	of	an	entirely	human	based	model	of	the	early	stages	of	synaptic	




understanding	 the	 role	 of	 various	 proteins	 in	 pathology	 especially	 in	 a	 disease	 as	
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complex	as	AD.	Studies	in	rodent	primary	culture	have	been	very	valuable	in	revealing	a	
multitude	 of	 diverse	 and	 occasionally	 contradictory	 downstream	 effects	 of	 oAb	 on	
neurons	(Hiruma	2003,	Shankar	2007).	However,	which	of	these	effects	is	applicable	to	
humans	 is	still	an	 important	question	and	neurons	derived	from	human	 iPSCs	provide	
an	 in	 vitro	 approach	 to	 study	 these	 effects.	 iPSCs	 are	 also	 particularly	 important	 for	
diseases	in	which	no	causal	genetic	link	is	established	but	many	risk	factors	are	involved	
such	 as	 sAD.	 The	 generation	 of	 iPSC	 lines	 from	 individuals	 with	 high	 risk	 genetic	
polymorphisms	 such	 as	APOE	 e4/4	 could	 aid	 in	 our	 understanding	 of	 how	 these	 risk	
factors	 increase	 risk	 of	 disease	 both	 individually	 and	 in	 concert	with	 each	 other.	 The	
power	 of	 iPSC	 technology	 has	 recently	 increased	 due	 to	 	 the	 discovery	 of	 the	




The	 use	 of	 oAb	 derived	 from	 human	 post-mortem	 brain	 also	 provides	 this	
model	with	an	increased	relevance	to	disease.	The	exact	species	of	oAb	that	is	toxic	in	
AD	 is	 unknown	 and	 different	 species	 and	 sizes	 of	 oAb	 are	 known	 to	 have	 different	
levels	of	toxicity	at	the	synapse	(Ono	et	al.,	2009;	Roychaudhuri	et	al.,	2009).	By	using	
oAb	 found	 in	post-mortem	AD	cases	 in	 the	model	 it	can	be	assumed	that	 the	disease	
relevant	 species	 are	 present.	 This	 is	 important	 for	 a	 number	 of	 reasons	 not	 least	 of	
which	is	that	oAb	from	human	brain	appears	to	be	more	neurotoxic	than	synthetic	oAb.	
Others	have	shown	that	oAb	derived	 from	the	human	brain	 is	 in	a	conformation	 that	
makes	it	highly	potent	in	inducing	neuronal	changes	in	a	way	that	synthetic	oligomers	
are	 not	 (Jin	et	 al.,	 2011).	 In	 this	model	 the	 concentrations	 used	 are	 in	 the	 pM	 range	
which	 is	much	closer	to	the	pathological	concentration	found	in	AD	(Lue	et	al.,	1999).	
Studies	using	synthetic	oAb	often	use	in	excess	of	10nM	to	achieve	synaptotoxic	effects	
(Deleglise	 et	 al.,	 2014).	 This	 has	 important	 implications	 for	 therapeutics	 directed	




Finally,	 this	 model	 reduces	 the	 impact	 on	 animals	 and	 animal	 welfare	 of	
scientific	 research.	 Although	 there	 are	 many	 questions	 that	 can	 be	 answered	 only	
through	 animal	 research,	 scientists	 have	 an	 ethical	 responsibility	 to	 ensure	 that	 the	





There	are	also	many	 limitations	of	 this	model	although	 it	 is	worth	mentioning	
that	 many	 of	 these	 are	 limitations	 of	 cell	 culture	 in	 general	 and	 thus	 also	 apply	 to	
rodent	primary	culture.	These	of	course	 include	that	cells	 in	a	dish	are	not	cognitively	
aware	 and	 thus	 the	 cognitive	 effects	 of	 AD	 can	 not	 be	 tested	 using	 in	 vitro	models.	
However,	a	major	limitation	of	this	model	compared	with	other	in	vitro	systems	is	that	
iPSCs	are	inherently	developmental	in	nature	(Patani	et	al.,	2012;	Camp	et	al.,	2015).	In	
a	 disease	 primarily	 of	 aging,	 cells	 expressing	 proteins	 mainly	 associated	 with	 early	
development	do	not	express	many	of	 the	proteins	associated	with	AD	 (Sposito	et	al.,	
2015).	Rodent	neurons	reach	a	 level	of	maturity	quicker	 in	a	culture	dish	and	thus	do	
not	 require	 as	 long	 an	 incubation	 period	 to	 become	 functionally	 mature.	 The	 cells	
studied	 in	 this	 chapter	 do	 have	 all	 the	 synaptic	 machinery	 required	 for	 functionally	
active	 synapses	 after	 5	weeks	 in	 culture	 and	 to	 the	 best	 our	 knowledge	 the	 synaptic	
machinery	needed	for	synapse	denegation	 is	 in	place	by	8	weeks	 in	culture	(Bilican	et	
al.,	 2014;	 Livesey	 et	 al.,	 2014).	 However	 new	 protocols	 are	 being	 developed	 which	




Neuronal	 cultures	 also	 intentionally	 contain	 low	 concentrations	 of	 glial	 cells.	
Glial	 cells	 have	 been	 shown	 to	 play	 an	 important	 role	 in	 the	 pathology	 and	
synaptotoxicity	 of	 AD	 (Garwood	 et	 al.,	 2011).	 Glia	 are	 also	 important	 for	 cell	
development	 and	 studies	 have	 shown	 that	 co-culturing	 iPSC	 derived	 neurons	 with	
astrocytes	 or	 even	 conditioned	 media	 from	 astrocytes	 increases	 the	 speed	 of	
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development	of	 functional	 synapses	 (Tang	et	al.,	 2013;	Odawara	et	al.,	 2014).	 Future	
experiments	 using	 this	model	 could	 investigate	 the	 effects	 of	 co-culturing	 these	 cells	
with	human	astrocytes	 to	see	what	effect	 that	might	have.	This	would	be	particularly	
interesting	 in	 regards	 to	 ApoE	 and	 Clusterin	 as	 there	 is	 some	 evidence	 that	 the	 cell	
these	proteins	are	derived	from	makes	a	difference	to	their	physiology.		
	





high-resolution	 imaging	 technique,	 array	 tomography,	 in	 chapter	 5	 confirmed	 this	
increase	 in	 Clusterin	 in	 both	 presynapses	 and	 postsynapses.	 Further-more,	 array	
tomography	found	that	15%	of	the	synapses	near	plaques	that	contained	Clusterin	also	
contained	oAb	 indicating	a	link	between	these	two	proteins	that	might	mirror	the	link	
between	ApoE	and	oAb.	However	 further	 investigation	of	 the	role	of	Clusterin	on	the	





















of	Clusterin	 in	oAb	 induced	 synaptotoxicity,	 as	would	 increasing	 the	 concentration	of	
Clusterin.	Cascella	et	al.	showed	that	incubating	oAb	with	Clusterin	prior	to	incubating	
it	 with	 cells	 reduced	 the	 amount	 of	 fibrillisation	 of	 Ab	 and	 thus	 the	 toxic	 effect	 on	
neurons	(Cascella	et	al.,	2013).	However,	this	experiment	did	not	 look	at	the	effect	of	
an	 increase	 in	 intracellular	 Clusterin	 or	 the	 downstream	 signalling	 cascades	 such	 an	
increase	 might	 cause.	 Killick	 et	 al.	 showed	 that	 an	 increase	 in	 intracellular	 Clusterin	
causes	an	increase	in	Dkk1	and	Wnt	which	then	causes	neuron	death.	Interrupting	this	
cascade	both	at	Clusterin	and	at	Dkk1	prevented	neuron	death	implicating	this	pathway	









In	 this	 thesis,	 synapse	 degeneration	 and	 dysfunction	 in	 AD	were	 investigated	
using	multiple	methods	and	models	 as	well	 as	post	mortem	 tissue	 from	AD	and	NDC	
cases.	In	particular	the	following	research	questions	were	addressed.		
	










Chapter	 4	 shows	 that	AD	has	 a	 profound	 effect	 on	 the	 synaptic	 proteome	by	
comparing	 AD	 and	NDC	 post	mortem	 cases	 using	 unbiased	 label-free	 LC/MS-MS.	 IPA	
analysis	 indicated	 that	 the	 protein	 networks	 that	 were	 most	 affected	 in	 AD	 were	
endocytosis,	 exocytosis,	 cell	 morphology,	 and	 mitochondrial	 function.	 Further-more	




postsynapses,	 and	 astrocytic	 end	 feet	 in	 AD,	 and	 what	 effect	 does	 it	
have	on	the	synaptic	co-localization	of	Clusterin,	Aβ,	and	ApoE?	










Chapter	 6	 shows	 a	 clear	 loss	 of	 synapses	 in	 cortical	 neurons	 derived	 from	






Synapses	 are	 incredibly	 complicated	 and	 diverse	 structures	 crucial	 to	 the	
creation	and	maintenance	of	memory	and	loss	of	these	structures	is	though	to	underlie	
the	 symptoms	 in	 several	 neurodegenerative	 disease	 including	 AD	 (Moreno	 and	
Mallucci,	2010).	In	fact,	in	AD	the	greatest	correlate	of	the	cognitive	decline	seen	in	the	
disease	 is	 synaptic	 loss	 placing	 synaptic	 loss	 at	 the	 centre	 of	 disease	 pathogenesis	
(Selkoe	et	 al.,	 2012).	 Preventing	 the	 loss	 of	 synapses,	which	 in	 AD	 is	 associated	with	
oligomeric	 species	of	Ab	 and	 tau,	 is	 likely	of	 therapeutic	benefit(Shankar	et	al.,	2008;	
Guerrero-Muñoz	 et	 al.,	 2015).	 Indeed,	 studies	 in	 the	 related	 field	 of	 prion	 diseases	
show	that	preventing	synaptic	loss	in	mouse	models	of	scrapie	prevents	clinical	disease	
even	 in	 the	presence	of	 toxic	protein	 accumulation	 (Moreno	et	al.,	 2013).	 This	 thesis	
therefore	focuses	on	uncovering	the	effect	of	AD	and	the	toxic	proteins	associated	with	






Ab	 mediated	 synapses	 loss.	 Previous	 studies	 in	 this	 area	 have	 shown	 that	 tau	 is	
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necessary	 for	 the	effects	of	Ab	 induced	memory	 loss,	LTP	deficits,	and	synaptic	death	
and	 therefore	 it	 was	 surprising	 that	 increasing	 the	 level	 of	 non-mutant	 tau	 had	 no	
effect	on	synaptic	loss	(Roberson	et	al.,	2007,	2011;	Shipton	et	al.,	2011).	This	indicates	
that	 endogenous	 mouse	 tau	 is	 necessary	 and	 sufficient	 to	 cause	 the	 synaptic	 loss	
associated	 with	 Ab.	 These	 studies	 together	 would	 indicate	 that	 this	 places	 tau	
dysfunction	downstream	of	Ab	accumulation	at	the	synapse	but	upstream	of	synaptic	
death.	 However	 other	 studies	 have	 shown	 that	 pathological	 species	 of	 tau	 are	




further	 investigation.	An	 interesting	 line	of	 further	 study	would	be	 to	express	Ab	 and	






phosphorylation	of	tau	 is	an	early	feature	 in	AD	and	a	recent	study	has	 indicated	that	
phospho-tau	is	increased	in	Ab	positive	synapses	in	AD	(Bilousova	et	al.,	2016).	Gotz	et	




Another	 potential	 follow	 up	 study	 would	 be	 to	 investigate	 the	 interaction	
between	Ab	and	tau	using	an	human	iPSC	culture	based	model	similar	to	that	described	
in	 chapter	 6.	A	benefit	 of	 this	 system	would	be	 that	 all	 proteins	 expressed	would	be	
human	in	nature	and	and	yet	a	major	 limitation	of	this	model	 is	that	all	6	 isoforms	of	
tau	 are	 not	 expressed	 until	 late	 in	 development	 necessitating	 long	 culture	 times	
(Sposito	 et	 al.,	 2015).	 New	 protocols	 might	 make	 this	 approach	 more	 possible	 by	
reducing	 the	 amount	 of	 time	 required	 for	 neurons	 to	 reach	 a	more	 developmentally	
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To	 further	understand	 the	 synaptic	dysfunction	 that	occurs	 in	AD,	proteomics	
was	used	on	post	mortem	tissue	from	AD	and	NDC	cases.	By	isolating	the	synapse	this	
study	 increased	 our	 understanding	 of	 which	 proteins	 and	 pathways	 are	 involved	 in	
synaptic	 dysfunction	 while	 minimising	 the	 effect	 of	 other	 subcellular	 compartments	
and	cell	types.	As	trafficking	is	known	to	be	disrupted	in	AD	it	is	important	to	consider	
the	 effects	 of	 protein	 location	 as	 well	 abundance	 (Encalada	 and	 Goldstein,	 2014).	
Mitochondrial	transport	in	particular	is	known	to	be	affected	in	AD	and	this	study	adds	
to	 that	 knowledge	 by	 indicating	 that	 many	 of	 the	 proteins	 involved	 in	 energy	
production	 in	 the	mitochondria	are	affected	 in	 the	AD	synapse	 (Sheng	and	Cai,	2012;	
Cai	and	Tammineni,	2017).	Dysfunction	of	the	mitochondria	is	known	to	occur	early	in	
AD	 pathogenesis	 and	 represents	 an	 area	 of	 potential	 therapeutic	 development.	 In	
particular	PITRM1,	an	enzyme	found	in	the	mitochondria	and	known	to	degrade	Ab	 is	
shown	 to	 be	 reduced	 in	 AD	 cases	 (Alikhani	 et	 al.,	 2011).	 It	 is	 possible	 that	 reduced	
PITRM1	 lessens	 the	 ability	 of	 mitochondria	 in	 AD	 to	 degrade	 Ab	 leading	 to	





This	 study	 also	 found	 that	 proteins	 involved	 in	 the	 immune	 system	 and	
neuroinflammation	 are	 dysregulated	 in	 the	 AD	 synapse.	Microglia	 and	 astrocytes	 are	
known	 to	 play	 a	 large	 role	 in	 synaptic	 function	 both	 in	 health	 and	 disease.	 Indeed,	
recent	 evidence	 has	 indicated	 that	 the	 complement	 system	 of	 innate	 immunity,	
particularly	complement	components	C1q	and	C3,	are	involved	in	synaptic	death	in	AD	
(Hong	et	al.,	2016;	Shi	et	al.,	2017).	This	study	shows	that	other	proteins	in	this	cascade	
including	 complement	 component	 C4,	 HLA-1,	 and	 Clusterin	 are	 all	 increased	 at	 the	
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synapse	 in	AD	presenting	 innate	 immunity	as	an	attractive	area	 for	 further	 study	and	











the	 risk	 of	 AD	 but	 also	 the	 rate	 of	 cognitive	 decline.	APOE	 genotype	 also	 affects	 the	
cognitive	 ability	 of	 elderly	 people	 in	 the	 absence	 of	 AD	 indicating	 that	 APOE	 might	
affect	 synaptic	 protein	 composition	 in	 the	 absence	 and	presence	of	AD	 (Deary	et	 al.,	
2004).	The	effects	of	APOE	 genotype	on	 the	 synaptic	proteome	 in	 the	absence	of	AD	
are	 relatively	 small	 and	 highlights	 proteins	 involved	 in	 endocytosis	 and	 exocytosis	
indicating	that	differences	in	the	lipid	binding	properties	of	the	different	ApoE	isoforms	




of	 AD	 are	 more	 numerous	 and	 could	 indicate	 proteins	 which	 contribute	 to	 that	
increased	risk	or	rate	of	cognitive	decline	seen	in	APOE4	cases.	Here	Clusterin	is	found	
to	be	increased	in	the	presence	of	ApoE4	and	AD,	a	relationship	that	is	confirmed	using	
array	 tomography.	 Array	 tomography	 also	 showed	 that	 Clusterin	 and	 Ab	 were	more	
likely	 to	 be	 found	 together	 in	 the	 synapse	 of	APOE	 e4	 carriers	 compared	with	APOE	






Array	 tomography	 also	 revealed	 that	 an	APOE	 e4	 allele	 in	 AD	was	 associated	
with	 a	 decrease	 in	 synaptic	 density	 not	 only	 near	 plaques	 but	 also	 far	 from	 plaques	
when	 compared	with	AD	APOE3	 cases.	 The	 synaptic	density	of	APOE3	 cases	 far	 from	




in	 understanding	 the	mechanisms	by	which	 an	APOE	e4	 allele	 affects	 synaptic	 health	
and	 loss.	 Interestingly	 this	 study	 also	 found	 that	 the	 astrocytic	 component	 of	 the	
tripartite	synapse	(ACTS)	was	reduced	in	AD	cases	with	an	APOE	e4	allele	and	again	it	is	











disease	 which	 allow	 for	 manipulation	 of	 one	 or	 more	 proteins	 under	 controlled	
conditions.	 The	 results	 described	 in	 this	 thesis	 demonstrate	 that	 AD	 has	 a	 profound	
impact	 on	 the	 protein	 content	 of	 the	 synapse	 and	 that	 further	 understanding	 of	 the	
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